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Bovine tuberculosis is of huge animal health and economic concern in the UK. Current ‘test 
and slaughter’ control measures are not sufficient at controlling the disease, with evidence 
suggesting the introduction of an efficacious cattle vaccine being a viable alternative to 
reduce annual herd incidence. Approaches using the human tuberculosis vaccine, the live 
attenuated Mycobacterium bovis strain Bacillus Calmette–Guérin (BCG) Danish, as part of a 
prime/boost strategy have been shown to be effective at inducing immunity in cattle. One of 
the most effective vaccination strategies involves the development of a subunit vaccine for 
use alongside BCG. To this end, identification of protective antigens for use in a subunit 
vaccine is key.  
Here we describe a BCG transposon library mutant selection in cattle to identify the 
protective antigens of BCG. Prior to the cattle screen, the ‘selectability’ of the transposon 
library was validated using the mycobacterial heat-shock response and isoniazid resistance 
mechanisms. The preliminary screens identified essential genes in the respective pathways, 
such as hspR and katG, validating the use of the library to select for genes relevant to a 
selection pressure. Following validation, BCG vaccinated and immunologically naïve cattle 
were intranodally challenged with the transposon library and transposon mutants with 
comparatively better survival in BCG vaccinated animals were identified using TnSeq.   
The screen identified Mb0025, Mb0086, YrbE1B, PPE20 and Mb2235 as potential antigenic 
proteins of BCG.  Mb0025 and Mb2235 were recombinantly expressed using an E. coli 
expression system. Mb0086, YrbE1B and PPE20 were purchased as peptides. The 
immunogenicity of the selected proteins was assessed in PBMCs harvested from 
immunologically naïve and BCG vaccinated cattle. IFN-γ, IP10, IL-β, IL-17a, IL-10 and IL-
12 release from simulated PBMCs was quantified. IP10 production significantly increased 
upon stimulation with Mb0086, YrbE1B and PPE20 in vaccinated animals, with a trend of 
increased IL-17a and IL-10. Mb0086 and YrbE1B stimulated an increase in IL-1β 
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production. Although protection has not been proven, this study has acted as a gate to select 
the best possible candidates for further experimentation in small animal studies.  
The transposon library screen also identified genes encoding enzymes involved in the 
synthesis of glycolipid antigens, such as ppm1 and ltp2, suggesting the inclusion of 
immunogenic glycolipids in a subunit vaccine along with protein antigens as an area for 
further study.  
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1.1 Bovine Tuberculosis 
Bovine tuberculosis (bTB) is a chronic infectious disease of cattle caused by pathogens from 
the Mycobacterium tuberculosis complex group of organisms, with Mycobacterium bovis 
being the most common causative agent.  M. bovis primarily infects cattle but is also known 
to infect other species including humans, white-tailed deer, domesticated cats and dogs, and 
European badgers  (Cosivi et al.,1998). It is a chronic granulomatous caseous-necrotising 
inflammatory disease that mainly affects the respiratory tract and associated lymphatic 
systems of infected cattle (Domingo, Vidal and Marco, 2014). Similar to human tuberculosis, 
disease pathology is associated with interplay between the virulence mechanisms of the 
pathogen and the host immune and inflammatory processes generated to eliminate the 
infection (Smith, 2003). bTB is of huge economic importance in both developing and 
developed countries. Globally, the disease costs US$3 billion annually (Waters et al., 2012). 
The cost is incurred due to many factors, including; compensatory payments to farmers, loss 
in productivity in severely infected animals, movement controls, trade restrictions and annual 
herd testing. bTB is endemic in parts of the UK such as South West and Central England and 
in South West Wales, with these areas being considered high risk for transmission and herd 
breakdown (Gilbert et al., 2005). Counties in England are divided into three categories: high 
risk, edge and low risk. In 2016, 3,229 herd breakdowns were recorded in high risk areas, 
attributing to 86 % of all bTB cases in England. Comparing this to breakdowns in the edge 
(387-10 %) and low risk (137-4 %) areas, it is clear that the current test and slaughter control 
strategy in high risk areas is not sufficient at controlling the disease where it is most 
prevalent. This has become more apparent since an increase in cases in edge areas was seen 
in 2016. This breakdown distribution between areas remains relatively stable when compared 
to previous years (Figure 1.1), but there is no significant decrease in the total number of herd 
breakdowns, further validating the need for new control measures (Animal & Plant Health 
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Agency, 2017). A rise in the edge area cases since 2013 has been attributed to the 
implementation of annual testing in these areas. The bTB problem was worsened due to the 
reduction of herd testing and atypical cattle movement following the 2001 foot and mouth 
disease outbreak (Gopal et al., 2006). Recently, a model of bTB transmission suggests 
multiple routes of transmission need to be controlled to prevent the further spread of the 
disease, with vaccination being a viable option (Brooks-Pollock, Roberts and Keeling, 2014).  
The model also predicted whole herd culling upon identification of one infected animal and 
an increase in frequency of national testing resulting in a quicker diagnosis upon 
transmission. Whole herd culling would increase the number of animals culled in the first 
year of implementation by approximately 20 fold (Brooks-Pollock, Roberts and Keeling, 
2014).  
In the UK, compensatory payments ranging from £82-£4,770 per animal (species and age 
dependant) is paid to farmers losing animals as a result of the controlled culling of M. bovis 
infected animals (Department for Environment Food & Rural Affairs, 2017). During the 
2013-2014 financial year, bTB expenditure was just over £99 million. Of this, £66 million 
covered operational, policy and laboratory work, including private vets for herd bTB testing. 
£23.5 million covered the compensatory payments to farmers (Department for Environment 
Food & Rural Affairs, 2014b). In Britain the associated cost of slaughtering infected cattle 
alongside compensation to farmers between 2008 and 2013 was £193million (DEFRA, 
2013.) 
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Figure 1.1 Total number of bTB cases recorded in the UK between 2006-2016. An increase 
in herd breakdowns since 2006 reinforces the need for new control strategies. An increase in 
edge area cases is attributed to the implementation of annual herd testing in these areas.  
The public health consequences of the disease are more prevalent in developing countries in 
which preventative measures such as milk pasteurisation are not prominent,  HIV incidence 
rates  are higher and human-animal interactions with herds in endemic areas are more 
prevalent (Cosivi et al., 1998; Ayele et al., 2004; Thoen, LoBue and de Kantor, 2006; Olea-
Popelka et al., 2017).  The zoonotic risk of M. bovis transmission to humans in the UK is 
minimal, although from 1999-2015 468 M. bovis cultures have been isolated from humans 
(Public Health England, 2016). Prior to milk pasteurisation, it is thought that M. bovis was 
responsible for 6 % of the total human deaths attributed to tuberculosis during the 1930’s and 
1940’s (Hardie and Watson, 1992; Davies, 2006). 
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1.2 Wildlife Reservoirs of M. bovis in the UK 
M. bovis is able to persist in wildlife populations, making the disease difficult to control. 
Meles meles (European Badger) are thought to be a major contributor to M. bovis spread in 
the UK (Krebs, 1997; Donnelly and Hone, 2010; Godfray et al., 2013; Brooks-Pollock, 
Roberts and Keeling, 2014). Whilst also contributing to the M. bovis endemic status, badgers 
have the ability to transmit the disease to cattle (Donnelly et al., 2003). The wildlife reservoir 
is thought to be one of the reasons the number of bovine tuberculosis cases has been 
increasing in recent years (Krebs, 1997). Badger culling is a controversial method of bovine 
tuberculosis control, particularly as the animals in question are a protected species. Previous 
badger culls have had varying levels of success, leaving many people sceptical at the 
effectiveness of badger culling (Donnelly et al., 2003; Griffin et al., 2005). There are many 
issues, not all ethical, associated with culling badgers. Once a badger cull has started, any 
remaining badgers have been shown to roam an increased distance away from their set 
compared to those in an area where no culling has taken place. The increase in roaming range 
is thought to be down to the territorial behaviour badgers exhibit  (Woodroffe et al., 2005). 
Wild deer and rodents are another possible wildlife source (Mathews et al., 2006); wild deer 
have been shown to be a wildlife source of M. bovis  in other parts of the world, making them 
a higher risk factor than previously thought (Nishi, Shury and Elkin, 2006; Delahay et al., 
2007). Preventing bovine tuberculosis from spreading to dense, susceptible communities that 
currently do not harbour the disease is a priority. Surveillance of wildlife host communities in 
high risk areas is required to prevent the disease becoming established in these areas, along 
with controlled culling or vaccination, thus reducing the chance of a herd-breakdown in these 
areas.  
The culling of wildlife reservoirs which are known to be carriers of the disease has been 
successfully implemented in New Zealand. Through the strict implementation of test and 
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slaughter strategies, alongside the culling of possums in at-risk areas, New Zealand achieved 
a 95 % reduction in the annual incidence of M. bovis infected herds over a 20 year period 
(Livingstone et al., 2015).  
Vaccination of cattle with BCG based vaccines has been predicted to be one of the long-term 
solutions available to reduce the incidence and risk of bovine tuberculosis in the UK (Brooks-
Pollock, Roberts and Keeling, 2014). These strategies are described in more detail in Section 
1.7. Alongside cattle vaccination, badger vaccination strategies are being developed to aid in 
reducing disease incidence. The aim of badger vaccination is to eliminate badger to cattle M. 
bovis transmission in areas that have a natural reservoir of infection in badgers, either by 
preventing badger infection completely or by reducing the infectiousness of badgers carrying 
M. bovis. Vaccination could also prevent the spread of the disease within the badger 
population, potentially preventing further disease advancement in edge areas (Chambers et 
al., 2014). The currently licensed vaccine for use in badgers is the injectable vaccine- 
BadgerBCG. BadgerBCG is identical to BCG Danish, the vaccine strain used in humans, 
with 1ml dose being administered in badgers compared to the 0.1ml dose in humans. 
Laboratory and field studies have been completed to assess the efficacy of this vaccine in 
badgers and have shown reduced severity and progression of disease in these settings 
(Chambers et al., 2011; Carter et al., 2012). Wild badgers are difficult to vaccinate with an 
injectable dose, therefore other routes of administration have been investigated. Oral BCG 
vaccination has been shown to confer protection (Corner et al., 2010; Murphy et al., 2014), 
however there are disadvantages with this route of vaccination. The choice of bait and 
vaccine carrier can impact vaccine uptake and it is difficult to ensure even distribution of the 
baits within badger sets (Palphramand et al., 2017). Further work is needed on this topic and 
the effectiveness of such a strategy has been questioned, with models suggesting control of 
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the environmental reservoir may have minimal impact on bTB incidence (Brooks-Pollock, 
Roberts and Keeling, 2014).  
1.3 Transmission of M. bovis between Cattle 
It is accepted that the main route of transmission of M. bovis between cows is through 
inhalation of bacilli. Lesions are commonly seen in the upper and lower respiratory tract as 
well as the associated lymph nodes (Crews, 1991). Experimental models involving the 
inoculation of cattle through the nasal and tracheal routes support the importance of this route 
of transmission (Cassidy et al. 1998; Buddle et al. 1994). Ingestion of contaminated 
substances, such as milk, is a secondary route of transmission (Menzies & Neill 2000). 
Tuberculosis mastitis (tuberculosis of the udder) is rare, but can be an important route of 
transmission to calves (Goodchild and Clifton-Hadley, 2001). Interestingly, Ameni et al 
showed that lesions may predominantly be found in the head and thoracic lymph nodes of 
animals found in areas of intensive cattle husbandry , rather than directly in the lung which is 
often seen in grazing cattle (Ameni et al., 2006, 2007) . Once infected and after a brief lag 
period, cattle may intermittently shed M. bovis from nasal mucus (McCorry et al., 2005).   M. 
bovis  found in faeces is thought to originate from the animal swallowing infected fluids from 
the respiratory tract (Cassidy et al. 1998).  
1.4 Pathology of Bovine Tuberculosis 
Bovine tuberculosis is a chronic granulomatous caseous necrotising infection that 
predominantly affects the lungs and the associated lymph nodes. The process is driven by the 
host’s inflammatory response. The initial infection occurs when the mycobacteria enter the 
alveolar spaces. Phagocytosis of the mycobacteria by macrophages occurs and neutrophils 
accumulate at the site of the initial infection. The bacterial cells are transported in phagocytes 
to the draining lymph node in which they establish another site of infection due to their 
ability to persist within macrophages. The combination of these two sites of infection is 
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known as the primary complex. In cattle the primary complex is predominantly found in the 
lower respiratory tract (Domingo, Vidal and Marco, 2014). The gross lesion formed by this 
process is known as a tubercle. A tubercle is a granulomatous nodule with central necrosis 
and mineralisation.  Granulomas are formed when neutrophils, epithelioid macrophages, 
Langhans-type giant cells, T cells, B cells and fibroblasts accumulate around the sites of 
infection. This cell mediated immune response (CMI) contains the intracellular mycobacteria 
and limits the progression of the disease in most cases - Figure 1.2 (Ulrichs and Kaufmann, 
2006).  Fibroblast proliferation occurs as the granuloma develops and results in a connective-
tissue ‘capsule’ surrounding the central zone of necrosis (Domingo, Vidal and Marco, 2014). 
Chronic tuberculosis occurs when the infection is not completely stopped by the CMI and the 
bacilli spread between anatomical channels in the organs which leads to the development and 
growth of chronic lesions.  A chronic lesion in the lung is characterised by extension through 
lung tissues with multifocal caseous necrosis, which eventually leads to cavernous lesions 
(Domingo, Vidal and Marco, 2014).  
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Figure 1.2 Initial stage of a tuberculosis granuloma within a cow lymph-node prior to 
development of caseous necrosis. Large quantities of neutrophils can be seen at the centre of 
the granuloma (A). Macrophages (B), Langhans-type giant cells (C) and lymphocytes (D) are 
also seen. Image from (Domingo, Vidal and Marco, 2014). License to use image obtained 
from Elsevier.  
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1.5 Cattle Immune Response to M. bovis Infection 
Mycobacteria are facultative intracellular pathogens that use macrophages as a host cell. The 
relationship between mycobacteria and macrophages is complex, as the macrophage is also 
involved in containing infection. Upon initial infection, the mycobacterial cells are 
phagocytosed by antigen presenting cells such as macrophages and dendritic cells. The initial 
interaction leading to phagocytosis occurs due to the recognition of mycobacterial surface 
lipids by the receptors found on these phagocytic cells, such as the mannose receptor, toll-like 
receptors, scavenger receptors, complement receptors and CD14 (Schlesinger, 1993; Pugin et 
al., 1994; Underhill et al., 1999; Pieters, 2001). Nitric oxide (NO) and reactive oxygen 
species produced in bovine macrophages play a major role in the killing of intracellular 
mycobacteria as part of the innate immune response (Widdison et al., 2007). The ability of 
mycobacteria to survive within macrophages is reliant on a range of strategies. Glycolipids in 
the mycobacterial cell wall are able to modulate host cell signalling pathways whilst secreted 
protein kinases (PknG) and phosphatases, with the ability to interfere with host cell 
trafficking, are also produced (Scherr et al., 2009). Genes leading to resistance to oxidative 
and nitrosative stress are also present in the mycobacterial genome (Voskuil et al., 2011). 
Mycobacteria possess several tools to prevent phagosome-lysosome fusion. The cell-wall 
glycolipid lipoarabinomannan (LAM) as well as several lipid (SapM) and protein 
phosphatases (PtpA and B) are thought to be involved in this process (Pieters, 2008). 
However, upon macrophage activation, phagosome-lysosome fusion will occur and the 
mycobacteria will be killed (Pieters, 2008). Macrophage activation with IFN-γ and TNF-α is 
characterised by induction of nitric oxide synthase (NOS) (Berrington and Hawn, 2007). 
Recently, macrophages from healthy and infected cows have been shown to have distinctly 
different gene expression profiles upon exposure to the pathogen  (Lin et al., 2015; Alcaraz-
López et al., 2017). A large difference in bacterial uptake by phagocytosis between cattle in-
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contact with infected animals and infected animals was reported, providing evidence that 
bovine macrophages are the first line of defence against M. bovis infection (Alcaraz-López et 
al., 2017). Further, expression of NOS mRNA was similar in both in-contact and infected 
animals, suggesting full macrophage activation, whilst levels of NO in infected animals were 
lower, suggesting more efficient killing in the healthy animals (Alcaraz-López et al., 2017). 
Antigen presenting cells, such as macrophages and dendritic cells, express major 
histocompatibility complex (MHC) class II which activate CD4+ T cells by presenting 
mycobacterial antigens processed by the antigen presenting cells. This process is vital in 
containing mycobacterial infections. CD8+ T cells recognise antigens present on the surface 
of host cells presented by MHC class I molecules, resulting in cytotoxic activity.  
Innate killing of intracellular mycobacteria is also dependant on invariant natural killer T 
(iNKT) cells, whose activation is dependent on CD1d expression of infected macrophages as 
well as IL-12 (Sada-Ovalle et al., 2008). iNKT have a direct bactericidal effect and protect 
mice against aerosol M. tuberculosis infection (Sada-Ovalle et al., 2008). iNKT cell 
antimicrobial activity is mediated by CD1d-dependant granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Rothchild et al., 2014).  GM-CSF activates macrophages and 
increases dendritic cell maturation (Shi et al., 2006). CD1 proteins enable T cells to recognise 
mycobacterial lipid, glycolipid, phospholipid, sulfolipid and lipopeptide antigens, resulting in 
T cell activation (Van Rhijn and Moody, 2015). CD1 have a similar function to MHC 
molecules, presenting lipid based molecules opposed to proteins.  
The CMI is a key part of the body's defence against M. bovis and is key in granuloma 
formation (Pollock et al., 2001). A study comparing the CMI response to the antibody 
response in M. bovis challenged cattle demonstrated that a CMI response was observed 
within 8 weeks in test animals, whereas an antibody response was only observed in one 
animal and at a much later stage (Pollock et al., 2001). T-cells are one of the first responses 
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to an M. bovis infection (Cassidy et al., 2001). All of the main T-cell subsets have been 
shown to be involved in the anti-mycobacterial immune response, 70 % of which produce 
IFN-γ, a cytokine that activates macrophages, which then produce an array of 
proinflammatory cytokines such as TNF-α and IL-1β (Rhodes et al., 2000; Maggioli et al., 
2014). Initially circulating γδ T cell levels in M. bovis infected cattle were shown to decrease 
and then increase, suggesting localisation to developing tuberculosis lesions and clonal 
expansion.  γδ T cells  release low levels of IFN-γ  and may link the innate and adaptive 
immune response (Smyth et al., 2001; Kennedy et al., 2002; McGill et al., 2014). Following 
the γδ T cell response, CD4+ T cell levels increase followed by an increase in CD8+ T cell 
levels (Pollock et al., 1996; Brosch et al., 2000). γδ T cells are a cellular source of IL-17 , an 
important cytokine involved in the induction of an optimal Th1 response (Umemura et al., 
2007). In calves, γδ T cells constitute up to 70 %  of peripheral blood lymphocytes, indicating 
a critical role of these cells in the young animal’s immune response (Waters et al., 2014). The 
establishment of a Type 1 T helper (Th1) (expressing CD4 surface protein and therefore 
CD4+ T cells) immune response to mycobacterial infection is vital in the development of 
protective immunity (Mogues et al., 2001), this response is characterised by the production of 
IFN-γ and TNF-α.  CD4 T-cells are the largest cell population in infected cattle, leading to 
the production of an antigen-specific IFN-γ response. The release of IFN-γ is essential in the 
activation of macrophage antimycobacterial pathways.  IFN-γ production strongly induces 
interferon gamma-induced protein 10 (IP10). IP10 is a chemoattractant for activated T-cells, 
resulting in migration from regional lymph nodes to the sites of infection, which is a critical 
step in granuloma formation (Bai et al., 2011).  
CD8+ T-cells (cytotoxic T-cells) are involved in the lysis of infected macrophages and have a 
greater involvement in the later stages of infection, whilst also contributing to the IFN-γ 
response (Skinner, Parlane, et al., 2003; Villarreal-Ramos et al., 2003). CD8+ T cells 
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produce perforin and granulysin which are essential for pathogen killing via pore formation 
and induction of apoptosis in target cells (Waters and Palmer, 2015). A study assessing the 
role of CD8+ T-cells in a nonhuman primate model of tuberculosis suggest these cells have a 
major role in vaccine-induced tuberculosis immunity (Chen et al., 2009). The importance of 
CD8+ mediated protection in cattle against M. bovis requires further study.  
 IL-12 is a pro-inflammatory cytokine released from antigen presenting cells, such as 
macrophages and leads to the induction of IFN-γ via promoting the differentiation of T cells 
to Th1 cells (Cooper et al., 1995). Phagocytic cells produce IL-12 in response to pathogens 
during infection (Trinchieri, 2003). IL-12 production in vaccinated and unvaccinated cattle 
challenged with M. bovis remained stable between the two groups, suggesting its importance 
in both the innate and adaptive immune response to mycobacterial infection in cattle 
(Widdison et al., 2006).  IL-23 and IL-17 are also involved in some degree in the 
antimycobacterial host defence.  IL-17 production is seen during the early innate and later 
adaptive immunity phases and leads to acute neutrophil-mediated inflammation and 
granuloma formation  (Umemura et al., 2007). The increase in IL-17 within early stage 
tuberculous lesions corresponds with the localisation of γδ T cells to early tuberculosis 
lesions (McGill et al., 2014).  Alongside this, an IL-17 response drives a Th1-cell response 
by down-regulating IL-10, an anti-inflammatory cytokine evolved to prevent collateral 
damage to the host tissue during the immune response to pathogens (Gopal et al., 2012; Ng et 
al., 2013). IL-10 downregulates M. tuberculosis-induced Th1 responses, therefore for a Th1 
response-leading to protective immunity- to be established this inhibitory effect must be 
overcome (Gong et al., 1996). IL-10 has been reported as having an essential role in an 
immunoregulation phenotype in B-cells, resulting in the development of a substantial anti-
inflammatory and immunosuppressive reaction (Stanic et al., 2015). Phagocytosis inhibition 
and prevention of microbial killing through suppressing the production of reactive oxygen 
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species and NO in response to IFN-γ has also been attributed to IL-10 (Redford and Murray, 
2011). Exposure to BCG induces IL-10 production, which limits Th1 cell responses whilst 
simultaneously promoting IL-23 and Th17 cell differentiation (Gopal et al., 2012).   
Th17 cells are the main producers of IL-17 and this explains why the IL-17 response is 
dependent on IL-23 production in mice (Khader and Cooper, 2008). With IL-17 down 
regulating IL-10 and inducing IL-12 production, it is a key cytokine in the host response to 
mycobacterial infection. IL-10 production is lower in macrophages in cattle in-contact with 
M. bovis infected cattle compared to the production in already infected cattle (Alcaraz-López 
et al., 2017). The decreased IL-10 expression in these circumstances is thought to correspond 
to permanent modulation of the inflammatory response, avoiding the negative consequences 
of extensive inflammation-which lead to increased pathology-whilst allowing control of the 
pathogen (Welsh et al., 2005; Alcaraz-López et al., 2017).  
The development of a Th2 response in mycobacterial infection facilitates the progression of 
the disease by inhibiting the host protective Th1 response. M. tuberculosis RD1-ESAT6 
specific IL-1β production in dendritic cells causes the differentiation of CD4+ T cells into 
Th2 cells (Dwivedi et al., 2012) . M. tuberculosis infected macrophages produce large 
amounts of IL-1β, playing an important role in Th2 cell differentiation (Juffermans et al., 
2000). Th2 differentiation is not seen upon exposure to the attenuated M. bovis strain, BCG, 
due to it lacking the RD1 region (Dwivedi et al., 2012). BCG redirects dendritic cells from 
inducing an inflammatory Th2 response, instead promoting the development of a regulatory 
Th1 response (Yokoi et al., 2008). IL-1β is not required for the control of acute BCG 
infection, but allows for some control of M. tuberculosis, further supporting the role of the 
RD1 region in the response (Bourigault et al., 2013). Increased IL-1β production has been 
associated with M. bovis infection in cattle (Jones et al., 2010). 
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Cattle exposed to M. bovis could resist infection through their innate immune response, most 
of these animals would be tuberculin skin test negative due to the lack of development of a 
cellular response, resulting in the lack of recognition of M. bovis antigens upon re-exposure. 
Heritable variation in bTB resistance in dairy herds has been established, with evidence that 
the effect is a complex polygenic phenomenon (Bishop and Woolliams, 2014). Animals with 
previous exposure to M. bovis are less likely to control the disease via macrophage killing 
compared to healthy animals (Alcaraz-López et al., 2017).  The effectiveness of macrophage 
killing is also strain dependent, with some M. bovis isolates being able to modulate the host 
macrophage response (Andrade et al., 2012). Animals that kill the infection via the innate 
response may react positively  to the M. bovis diagnostic skin test due to a T-cell response 
occurring (Pollock and Neill, 2002). Alternatively, cattle become infected and show signs of 
disease or a latent infection occurs. There is limited research investigating latency within 
herds, although it is a potential issue, with 38 % of herds that clear movement restrictions 
experiencing a recurrent breakdown within 24 months (Karolemeas et al., 2011). It has been 
estimated that up to 21 % of herds may be harbouring infection after clearing movement 
restrictions (Conlan et al., 2012). Alternatively, environmental survival of M. bovis may be 
responsible for recurrent herd breakdown (Courtenay et al., 2006). Cattle have been found to 
react to mycobacterial antigens in the absence of tuberculosis lesions that are usually 
associated with the disease, suggesting innate clearance of infection. This may also arise due 
to previous sensitisation via contact with environmental mycobacteria (Lauzi et al., 2000; 
Pollock and Neill, 2002). 
1.6 Diagnosis of Bovine Tuberculosis in Cattle 
Control programs for bovine tuberculosis are based on tuberculin skin test and slaughter 
strategies. The primary ante-mortem screening test for bovine tuberculosis in the UK is the 
single intradermal comparative cervical tuberculin (SICCT) test (de la Rua-Domenech et al., 
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2006). Tuberculin is the name given to mycobacterium extracts used to diagnose infection. 
The comparative skin test involves the injection of both bovine and avian tuberculin. The use 
of both types of tuberculin enables a comparison to be made between the reactions. M. bovis 
infected cattle show a greater response to bovine tuberculin than to avian tuberculin, whilst 
previous sensitisation with other species of mycobacteria, such as Mycobacterium avium, 
have a greater response to the avian tuberculin (de la Rua-Domenech et al., 2006). The single 
intradermal comparative cervical tuberculin test therefore allows discrimination between 
those animals infected with M. bovis and those that have been exposed to non-pathogenic, 
environmental mycobacteria (de la Rua-Domenech et al., 2006). The type of tuberculin most 
commonly used for diagnosing bovine tuberculosis is bovine purified protein derivative 
(PPDB). PPDB is a poorly defined mixture of antigens made from M. bovis, whereas avian 
PPD is produced from M. avium. Due to the poorly defined nature of the PPD, the potency of 
the PPD varies between batches of the product (Haagsma et al., 1982).  If an animal tests 
positive for the presence of M. bovis antigens via the tuberculin skin test, it is slaughtered. 
The major advantages of skin testing are that it is highly specific (>90 %), resulting in few 
false positive reactions and therefore no unnecessary culling, and highly sensitive (up to 85 
%) (Karolemeas et al., 2012; Goodchild et al., 2015). The process is also relatively cheap, 
minimal training is required and the test can be completed at the point of care, foregoing the 
need for a laboratory. The test isn’t perfect however, not all infected animals are diagnosed 
and therefore additional diagnostic tests are required (Monaghan et al., 1994). Due to the 
dynamics of M. bovis infection and transmission, no single diagnostic test can be expected to 
detect every infected animal. Many factors have been shown to affect the reliability of the 
tuberculin skin test, such as the stage and severity of the disease, the presence of 
immunosuppressive agents and desensitisation to bovine tuberculin due to the test being 
administered too soon after previous exposure to bovine tuberculin (Snider, 1982). Sensitivity 
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of skin tests increases when two or more gross lesions are present (Norby et al., 2004). 
Diagnosis via the tuberculin skin test also identifies BCG vaccinated animals as being skin 
test positive. This is a central reason as to why BCG vaccination of cattle in the UK has not 
been carried out. A way to differentiate between animals that are diseased and those that are 
vaccinated is required. Such a test is known as a DIVA test (Differentiating Infected from 
Vaccinated Animals).  
 An advancement in the diagnosis of bovine tuberculosis has been the development of the 
interferon-γ (IFN-γ) release assay (IGRA).  IGRA is an in vitro blood test used to diagnose 
tuberculosis in cattle (Wood et al., 1991). The IFN-γ assay is performed in two stages. The 
first step involves incubating a blood sample with test antigens, such as bovine PPD and 
avian PPD tuberculin. The second step quantifies the amount of IFN-γ in the sample via an 
enzyme-linked immunosorbent assay (ELISA). IFN-γ is an important cytokine released by T 
lymphocytes in response to mycobacterial infection, as described in Section 1.5.  Once T 
lymphocytes have been stimulated by antigens, IFN-γ is released.  Similarly, to the tuberculin 
skin test, the test compares the host response to a variety of antigens. It also relies on the 
hosts cell mediated immune response against the antigens-which mimic infection, which is a 
similar principle to that of the tuberculin skin test (Pollock, Welsh and McNair, 2005). The 
diagnostic performance of the IFN-γ test has been assessed in many countries. In these trials 
an average sensitivity of 87.6 % and specificity of 96.6 % was observed (Wood and Jones, 
2001). As can be expected with an alternative diagnostic technique, there are advantages and 
disadvantages associated with the IFN-γ test. The IFN-γ test is able to be repeated in an 
animal with no delay. As the animal’s immune system has not had to previously respond to 
injected antigens, desensitisation does not occur. However, if a previous skin test has been 
carried out, this may interfere with the IFN-γ test (Wood and Rothel, 1994). The time taken 
to develop a response to the test is less than that of a skin test, allowing for more rapid 
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diagnosis. All measurements are laboratory based, allowing for result interpretation to be 
standardised (Wood and Jones, 2001).  Although the sensitivity of the IFN-γ test is higher 
than that of the SICCT, the specificity appears to be lower (Wood and Jones, 2001).  A small 
number of skin test positive M. bovis infected cattle are not detected by the  IFN-γ test 
(Pollock, Welsh and McNair, 2005). This would suggest the use of both the tuberculin skin 
test and the IFN-γ test  in tandem is the most effective way of diagnosing bovine tuberculosis 
(Pollock, Welsh and McNair, 2005). Cattle with a latent infection can be skin test positive, 
although some cattle may be unresponsive to skin testing. In this case the IFN-γ release assay 
should detect these animals (Neill et al., 1994). The significant levels of skin test positive 
cattle that show no evidence of M. bovis infection post-mortem could support the idea that 
latency in cattle can occur (Alvarez, Estrada-Chávez and Flores-Valdez, 2009).  
As well as being a vital chemokine in the response to mycobacterial infection, antigen-
specific IP10 release has the potential to be a used as a biomarker of M. bovis infection in 
cattle (Parsons et al., 2016). With a sensitivity of 100 % and specificity of 97 %, antigen 
specific IP10 release to PPDB may prove to be a valuable diagnostic marker for use 
alongside the conventional assays. Recent findings also suggest IL-17a may be used as a 
biomarker for infection and protection in the cattle immune response (Waters et al., 2015; 
Parsons et al., 2016). Recent research completed by Elnaggar and colleagues suggests IL-1β 
may also be a biomarker to detect M. bovis infected cattle, with the ability to differentiate 
between cattle previously exposed to NTM and those exposed to M. bovis (Elnaggar et al., 
2017).  
The frequency with which cattle herds are tested for the presence of bTB is dependent on the 
area in which the herds are found. Counties are given a risk status: High risk area, edge area 
or low risk area. Areas of high risk such as the West and South West of England, as indicated 
by the high frequency of herd breakdowns in Figure 1.3, perform annual herd testing to 
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monitor M. bovis levels. Upon herd-breakdown, skin testing is completed in neighbouring 
herds. Edge areas border high risk areas, and herds found in these areas undergo the most 
rigorous testing to ensure any disease transmission is caught as early as possible to prevent 
further spread. Annual herd testing, or more frequent, is completed in areas at particularly 
high risk such as Cheshire completing testing every 6 months. Upon herd break-down in edge 
areas, skin testing is completed in neighbouring herds as well as additional skin testing in all 
herds within 3km of the original breakdown in areas such as Derbyshire, which has herds in 
both high-risk and edge areas. Herds found in low risk areas complete skin testing every 4 
years and upon break down all herds within 3km radius are skin tested to ensure any further 
transmission is caught.  
The current ‘test and slaughter’ and movement restriction strategy is not sufficient at 
controlling bTB in the UK. Alternative control methods need to be implemented in order to 
reverse the current trend of annual increase in the number of herd breakdowns. Possible 
strategies include the introduction of a vaccine that prevents the transmission of M. bovis via 
multiple channels, whole herd culling upon a single positive diagnosis within a herd or an 
increase in the frequency of national herd testing resulting in quicker diagnosis (Brooks-
Pollock, Roberts and Keeling, 2014).  
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Figure 1.3 The total number of herd breakdowns between 2013-2017 in England and Wales 
(A) (Department for Environment Food & Rural Affairs et al., 2017). High-risk areas are 
found in the west and south-west of England and the south-west of Wales. Edge areas border 
high-risk areas with low risk areas found in the east and south-east and north of England (B) 
(Department for Environment Food & Rural Affairs, 2014a). 
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1.7 Vaccination of Cattle against Bovine Tuberculosis 
1.7.1 BCG Vaccination 
The production and the wide spread introduction of a vaccine that induces immunity to M. 
bovis would greatly decrease the impact of the disease.  The vaccination of cattle in the field 
is currently prohibited under National and EU legislation, therefore studies testing the 
efficacy of BCG vaccines are completed in experimentally infected cattle in controlled 
conditions within the EU. Tuberculosis vaccine development is greatly hindered by the lack 
of immune correlates of protection. The human tuberculosis vaccine (BCG) has been shown 
to induce significant levels of protection against bovine tuberculosis in cattle. This ability of 
BCG to confer protection in cattle against M. bovis infection was first discovered by Calmette 
and Guérin in 1911 (Calmette and Guérin, 1911). Vaccination strategies including 
commercially available BCG are advantageous compared to developing a new vaccine due to 
the current infrastructure allowing its inexpensive production.  Two BCG strains Pasteur and 
Danish have been shown to induce similar levels of protection (Wedlock et al., 2007). When 
young calves were vaccinated with BCG a rapid rise in IFN-γ was seen when tested against 
bovine PPD, demonstrating that an immune response was developed with exposure to BCG 
(Buddle, 1995). It has been previously reported that vaccination at a young age (<one month) 
induces high vaccine efficacy in calves when compared to vaccination at 6 months (Buddle et 
al., 2003; Hope et al., 2005b). New born calves vaccinated at 8 hours after birth or at 6 weeks 
of age with BCG produced IFN-γ responses to bovine PPD. When challenged with M. bovis, 
tuberculosis lesions were seen in only 1 out of 19 calves, compared to lesions being seen in 
100 % of the unvaccinated animals (Buddle et al., 2003). Calves that were initially 
vaccinated within 8 hours of birth and revaccinated at 6 weeks had less protection than those 
calves that only received the single dose of BCG at 8 hours after birth, suggesting early 
revaccination may be detrimental. However, revaccination 2 years post initial vaccination has 
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been shown to boost protection (Parlane et al., 2014).   Response to repeat vaccination varied 
between younger and older calves, this may be due to the prevalence of natural killer cells in 
younger animals leading to the rapid innate clearance of mycobacterial cells (Buddle et al., 
2005).  When neonatal calves were vaccinated with BCG Danish, significant protection was 
seen against infection at 12 months. At 24 months post vaccination a reduction in lung and 
lymph node pathology was observed. However, when vaccinated and unvaccinated control 
groups were compared no statistical difference in pathology was seen at the 24 month period 
(Thom et al., 2012). Field studies testing the efficacy of BCG in livestock have been 
completed, for example,  in Ethiopia (Ameni et al., 2010) and Mexico (Lopez-Valencia et al., 
2010). Ameni et al studied the efficacy of BCG for protection against M. bovis. Neonatally 
vaccinated calves and control calves were exposed to skin test positive cows. BCG efficacy 
was assessed using the IFN- γ assay, the tuberculin skin test, post-mortem examination and 
bacteriological culture.  The overall pathology score in control calves was significantly 
higher than observed in vaccinated calves. The protective efficacy of BCG was between 58 % 
and 68 % (Ameni et al., 2010). A field study completed in Mexico showed the efficacy of 
BCG to be 59.4 %, with non-vaccinated calves being 2.4 times more likely at becoming 
infected than vaccinated animals (Lopez-Valencia et al., 2010). To assess the efficacy of 
potential vaccines in the natural route of transmission, field trials need to be completed. 
Under current legislation, this is not possible in the UK.  
The route of vaccination is an important factor which could affect vaccine efficacy. When 
cattle were given an oral dose of BCG, the levels of colony forming units (CFU) present had 
an effect on the efficacy of the vaccine. Positive tuberculin skin test results were observed 
when given an oral dose of 108 CFU. Significant reduction in lesions and bacterial counts 
post M. bovis challenge was seen at 108 CFU. Counts lower than 108 CFU did not induce 
protection or a positive tuberculin skin test result (Buddle et al. 2011). Compare this result to 
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vaccination via a 106 CFU subcutaneous vaccination, which successfully induced an immune 
response when challenged with M. bovis at 18 weeks post vaccination, it is clear that the 
subcutaneous route is a more efficient method of vaccination (Buddle et al. 2011).  
Pre-exposure to environmental mycobacteria or non-tuberculosis mycobacteria (NTM), such 
as M. avium, has a variable effect on BCG efficacy. Buddle et al (2002) demonstrated pre-
sensitisation with NTM prevented the induction of BCG protection, leading in minimal 
protection to virulent M. bovis when intratracheally challenged (Buddle et al., 2002). 
Contrary to this, Hope et al describe a degree of protection is garnered from pre-exposure to 
M. avium (Hope et al., 2005a). The definitive effect of pre-sensitisation with NTM on BCG 
protection is unknown and needs further study. 
Due to the low/moderate efficacy of cattle BCG vaccination, many strategies are currently 
being developed to increase the protection conferred by BCG, including prime-boost 
strategies involving initial immune system priming with BCG, followed by boosting with 
viral or subunit vaccines with selected antigens. It has been predicted that vaccination 
strategies with the currently available vaccine would not suffice, and the introduction of a 
vaccine with increased efficacy would aid in the control of the disease (Brooks-Pollock, 
Roberts and Keeling, 2014). Alternative vaccines are also in development with the aim to 
replace BCG as the vaccine of choice (Buddle et al., 2002).  
1.7.2 Viral Vectored Booster Vaccines  
Viral vectored booster vaccines have been shown to increase BCG-induced protection against 
bovine tuberculosis (Vordermeier et al., 2009). M. bovis BCG is used to prime the immune 
response and modified vaccinia virus Ankara strain or recombinant attenuated adenoviruses 
expressing mycobacterial antigens, specifically Ag85A, can be used to boost protective 
efficacy. Ag85A is a M. tuberculosis mycolytransferase involved in lipid body formation and 
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has been shown to be abundantly secreted in this organism (Wiker and Harboe, 1992; Elamin 
et al., 2011). Ag85A is an ideal antigen to use in a vaccination strategy due to its involvement 
in the final stages of cell wall assembly and cell envelope integrity (Belisle et al., 1997). 
Ag85A induces a strong T-cell proliferation and IFN-γ response, making it a promising 
candidate as a protective antigen in a prime-boost strategy (Tanghe et al. 2000). Boosting 
with adenovirus vaccine expressing Ag85a after a BCG priming improves BCG efficacy in 
cattle, demonstrated by reduced lesions and gross pathology compared to lone BCG 
vaccination (Vordermeier, Villarreal-Ramos, et al., 2009; Dean et al., 2014). Cattle 
vaccinated via the intradermal and endobronchial route demonstrated similar levels of 
antigen-specific IFN-γ production post-Ag85a boosting (Whelan et al., 2012). Both routes of 
vaccination induced peripheral blood antigen specific responses and later pulmonary specific 
responses, however the level of protection afforded is unknown (Whelan et al., 2012). 
Animals simultaneously vaccinated locally and systemically with subcutaneous BCG and 
endobronchial Ag85a exhibited reduced pathology when compared to simultaneous 
vaccination with BCG (Dean et al., 2015). This highlights the improved protection conferred 
when using specific mycobacterial antigens alongside conventional BCG, as well as the 
potential of combining immunisation routes to improve vaccine efficacy.   
A phase 2b clinical trial investigating the efficacy of a modified Vaccinia Ankara virus 
expressing antigen 85A (MVA85A) in humans was recently completed. MVA85A was 
shown to be well tolerated and induced a cell-mediated immune response, however there was 
an absence of efficacy in infants against M. tuberculosis (Tameris et al. 2013) even though a 
durable T cell response is seen in immunocompetent persons (Tameris et al. 2014). 
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1.7.3 Subunit Vaccines 
Subunit vaccines have been in development for prevention of M. tuberculosis infection in 
humans; the effectiveness of these vaccines gives insight into the potential of a subunit 
vaccine for bovine tuberculosis. A subunit vaccine contains selected protective antigens 
present in mycobacteria within a carrier adjuvant.  
A subunit vaccine based on the fusion proteins of ESAT-6 and antigen 85b induced a strong 
dose dependant immune response in mice, accompanied by high levels of protective 
immunity which were comparable to that which BCG induces. Immunological memory 
remained stable 30 weeks post vaccination (Weinrich Olsen et al. 2001).  A subunit vaccine 
comprising of the M. tuberculosis antigens Rv2875, Rv3478 and Rv1886 (ID87) exhibited 
promising results in mice (Windish et al., 2011). Bacterial burden in the lungs was reduced 
and significant leukocyte infiltration into the lung was seen (Windish et al. 2011). The choice 
of adjuvant used with subunit vaccines is also an important factor that can increase the 
immunogenicity of the proteins present within the vaccine (Wedlock et al., 2008; 
Vordermeier, Dean, et al., 2009).  
Vaccination of cattle with a variety of tuberculosis antigens can improve BCG protective 
efficacy and allow a more detailed evaluation of immune response correlates of protection.  
M. bovis culture filtrate protein (CFP) was used alongside BCG and levels of protection 
against M. bovis were assessed (Buddle et al., 2005). Groups of calves were vaccinated with 
either CFP, BCG or both CFP and BCG vaccines. IFN-γ levels were assessed throughout the 
study. Mean levels of IFN-γ produced in the CFP/BCG group were significantly higher than 
that of the individual vaccines, with IFN-γ levels in the BCG and CFP groups having similar 
means at the 13-21 week point (Buddle et al., 2005). Calves were later challenged with 103 
CFU of M. bovis (21 weeks after initial vaccination).  The BCG/CFP group had a significant 
reduction in the number of animals with lung or lymph node lesions, a lower number of 
26 
 
lesions per animal and a lower mean number of M. bovis cultured from thoracic lymph nodes, 
compared to the non-vaccinated group. CFP vaccination alone showed no decrease in these 
parameters compared to non-vaccinated calves, and BCG showed a significant decrease in 
only one parameter-lower mean lymph node legion number (Buddle et al., 2005). Thus the 
efficacy of BCG can be improved by use in a regimen combining other novel vaccine 
candidates, in this case CFP, which act in a synergistic way with a BCG (Wedlock et al., 
2008).  
Many studies aiming to develop a subunit vaccine for human M. tuberculosis control have 
been completed. Vaccination with fusion proteins of known mycobacterial antigens, such as 
ESAT-6 and CFP10 is a popular strategy (Brodin et al., 2004). A vaccine compromised of a 
fusion protein consisting of 5 known immunodominant mycobacterial peptides: CFP10, 
TB10.4, TB8.4, Rv3615c, and HBHA induces an antigen specific CD4+ Th1 response in 
mice (Teng et al., 2015). The adjuvant used in the study stimulated a CD8+ T-cell response 
which may be key in the generation of protective immunity (Behar, 2013). An ESAT-6-
Ag85B-Rv2660 fusion protein subunit vaccine generated a durable CD4 T-cell protective 
response that trafficked into M. tuberculosis infected lungs in mice (Woodworth et al., 2017). 
Rv3131, an antigen from the dormancy survival regulator regulon (DosR) which is key for 
mycobacterial latency was recently assessed as a vaccine antigen (Kwon et al., 2017). 
Rv3131-specific multifunctional CD4+ T-cells producing TNF-α, IFN-γ and IL-2 were 
generated post vaccination and a significant reduction in bacterial burden and lung 
inflammation was seen following M. tuberculosis challenge compared to immunisation with 
BCG (Kwon et al., 2017). Importantly, a protein does not have to be excreted or cell surface 
expressed to be immunogenic. Rv0733, an adenylate kinase, is essential in intracellular 
nucleotide metabolism. Rv0733 was identified to possess T-cell epitopes and vaccination 
with Rv0733 provided protection against M. tuberculosis in mice via the generation of a 
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strong antigen-specific T and B cell response (Devasundaram, Deenadayalan and Raja, 2014; 
Xiao et al., 2016). An increase in T-cell response with antigen specific IFN-γ, TNF-α and IL-
2 production was exhibited in whole blood samples obtained from M. tuberculosis infected 
individuals upon stimulation with the hypothetical proteins Rv2251 and Rv2721c, unveiling 
the potential of these novel antigens for use in a subunit vaccine (Santhi and Raja, 2016). 
PE/PPE family proteins have also been assessed for use in subunit vaccines, with a recent 
review by Brennan highlighting the role of these proteins in tuberculosis vaccination 
(Brennan, 2017). Specific examples include PE3, which stimulated TNF, IL-6 and IL-2 
secretion in mice immunisation experiments as well as protective immunity against 
mycobacterial challenge (Singh et al., 2013).  There is also evidence of protection in non-
human primates and humans upon vaccination with Mtb72F (PPE18) (Reed et al., 2009; Von 
Eschen et al., 2009).  Protein antigens are not the only option for subunit vaccination, lipid 
and glycolipid antigens can also induce protective immunity in models of tuberculosis 
(Dascher et al., 2003; García et al., 2014; Larrouy-Maumus et al., 2017; Wang et al., 2017).  
Strategies combining antigens expressed throughout different stages of tuberculosis infection 
have also been investigated  (Xin et al., 2013; Wang et al., 2015; Li et al., 2017; Ma et al., 
2017). Specific M. tuberculosis antigens are known to be expressed during different stages of 
M. tuberculosis growth. Inclusion of antigens from different stages of growth could protect 
against different stages of mycobacterial infection, such as: primary, latency and reactivation. 
Fusion proteins have been produced combining differentially expressed antigens in varying 
adjuvants and the protective effects were evaluated in mice.  The study identified the fusion 
proteins: ESAT6-Ag85B-MPT64190-198-Mtb8.4 and Mtb10.4-HspX as promising candidates 
for subunit vaccines due to the robust antigen-specific T-cell response developed in mice 
post-vaccination with both fusion proteins. Boosting with ESAT6-Ag85B-MPT64190-198-
Mtb8.4 after initial priming with BCG also induced a higher protective effect compared to 
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BCG vaccination alone (Xin et al., 2013). A fusion protein combining ESAT6-Ag85B-
MPT64190-198-Mtb8.4 and Mtb10.4-HspX to create a ESAT6-Ag85B-MPT64(190-198)-
Mtb8.4-HspX fusion protein induces long-term protection against M. tuberculosis in mice 
(Niu et al., 2015). A fusion protein consisting of four antigens related to the latency phase 
and one related to the primary phase of infection: Rv1813-Rv2660c-Ag85B-Rv2623-HspX, 
induced antigen specific polyfunctional CD4+ T-cells in BCG vaccinated mice, highlighting 
its potential as part of a prime/boost strategy alongside BCG (Wang et al., 2015).  A 
multistage fusion protein sub unit comprising of Rv2875-Rv3044-Rv2073c-Rv0577 antigenic 
proteins protects mice against primary tuberculosis, latency and reactivation via promoting 
IFN-γ and IL-2 producing T-cell migration from the spleen to the lung (Ma et al., 2017). 
Subunit vaccines comprised of antigens differentially expressed throughout the stages of cell 
growth and infection have the potential to prevent tuberculosis development at multiple 
stages of disease progression, however further study is required to assess whether protection 
is generated in humans or cattle. 
The search for novel antigenic peptides for use in a subunit vaccine requires an initial screen 
to identify potential targets. One such screen completed by Jones et al used an unbiased 
procedure utilising a broad range of proteins not pre-selected based on their function. Proteins 
were used to stimulate bTB reactor and BCG vaccinated bovine whole-blood samples and 
IFN-γ levels were quantified. Immunogenic proteins were taken forward for small animal 
studies and significant differences in mycobacterial cell burden post exposure to the selected 
antigens was assessed. This approach identified Rv3329 as a potential antigen for use in a 
subunit vaccine (Jones et al., 2013). Interestingly, Rv3329 is a probable aminotransferase 
likely to be involved in cellular metabolism and there is no previous evidence that this protein 
may be secreted or cell surface exposed-key properties of some antigenic proteins (Wiker and 
Harboe, 1992; Cole et al., 1998; Wiker, 2009).  A genome-wide screen identifying in vivo 
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expressed M. tuberculosis antigens inducing T-cell responses in human lungs has recently 
been completed, identifying several antigens that stimulate a multi-cytokine response 
(Coppola et al., 2016). The protection conferred by these identified antigens was not 
described. 
This is far from an exhaustive review of all the current literature surrounding subunit 
vaccines for the control of mycobacterial species. It is clear however, that a one-health 
approach is aiding both the bTB and human tuberculosis subunit development pipeline and 
breakthroughs regarding the protective immunity and potential antigens of either organism 
are highly relevant to both species.    
The present study aims to identify novel protective antigens for use in a subunit vaccine 
through a parallel genetic screen within the target species. We aim to identify the proteins of 
BCG that act as protective antigens once processed and recognised by the bovine adaptive 
immune response. The selection process utilised a recently developed cattle lymph-node 
challenge model (Villarreal-Ramos et al., 2014). As the screen was completed in the model 
animal, the antigen selection process was robust and novel. Further adding to the selectivity 
of the screen, both BCG vaccinated and immunologically naïve cattle were used to assess 
survival. Immunogenicity was compared in bovine PBMCs harvested pre and post-BCG 
vaccination. An increased cytokine response indicates the recognition of the proteins due to 
the previous exposure to BCG due to the original vaccination. Proteins stimulating a greater 
immune response post-BCG vaccination were seen as potential antigens for further study due 
to host immune response ‘boosting’ exhibited after the initial BCG ‘priming’. Unbiased 
antigen selection within cattle to identify protective antigens has not previously been 
completed. Comparing survival in BCG vaccinated animals and immunologically naïve 
animals further adds novelty to the study.  
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1.8 Differentiating Infected from Vaccinated Animals (DIVA) 
The development of a DIVA strategy for bovine tuberculosis vaccination is required for 
significant progress in vaccine development to take place. Alongside this study, colleagues at 
the University of Surrey are identifying and validating the use of novel proteins for use as in 
a DIVA reagent.  
Significant progress has been made in the development of a DIVA.  The complete genomes 
of multiple M. bovis  BCG strains (Seki et al., 2009; Pan et al., 2011) as well as M. bovis 
(Garnier et al., 2003)  and M. tuberculosis (Cole et al., 1998) have been sequenced. This 
information greatly facilitates the discovery of specific antigens present in M. bovis and M. 
tuberculosis but absent from BCG -such as ESAT-6 and CFP-10-that can be used to 
differentiate between BCG-vaccinated animals and those which are actually infected 
(Vordermeier, Jones and Whelan, 2011). The M. bovis antigens ESAT-6 and CFP-10 are 
encoded on the RD1 region of the M. bovis genome (Pollock and Andersen, 1997), whose 
genes are not present in BCG due to the RD1 locus being lost through the attenuation process. 
Peptides derived from ESAT-6 and CFP-10 were formulated into peptide cocktails, similar to 
the PPD cocktails previously mentioned.  BCG vaccinated cattle did not produce an immune 
response to this cocktail, whereas the traditional bovine PPD mix did elicit an immune 
response in 70 % of the cattle. The DIVA potential of this novel cocktail is clear, however the 
sensitivity for the detection of M. bovis infected cattle provided by these two antigens (77.9 
%) was below that of the traditional tuberculin mix. As such, further antigens need to be 
identified to increase the sensitivity of the assay (Vordermeier et al., 2001; Vordermeier, 
Jones and Whelan, 2011). The specificity of the cocktail however was 100 %. Cattle that 
were Mycobacterium avium-sensitized did not respond to the cocktail, meaning animals that 
are naturally sensitized due to environmental mycobacteria would not respond to the test 
(Vordermeier et al. 2001).  
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Stimulation with ESAT-6 and CFP10 does not generate a strong proliferative T-cell or IFN-γ 
response in vaccinated cattle, though a strong immune response was generated towards other 
antigens present in the BCG vaccine (Vordermeier, 2002). M. bovis diagnostic reagents based 
on the antigens missing in BCG, such as ESAT-6, were still able to distinguish between 
vaccinated animals not showing disease and vaccinated animals showing disease. Therefore, 
if ESAT-6 specific interferon can be detected the animal is currently diseased, even if 
vaccinated. If the ESAT-6 specific interferon is not detected, the animal is vaccinated and not 
diseased. The determination of the levels of ESAT-6 specific interferon or any interferon 
associated with genes absent in BCG could lead to new ways to predict vaccine efficacy and 
disease severity (Vordermeier, 2002). Diagnostic tools for M. bovis based on the principle of 
missing genes in the BCG genome could also remove the dependency on the current 
tuberculin skin tests, which cannot distinguish the difference between vaccinated and infected 
animals.  A field study completed in Ethiopia showed that by assessing the IFN-γ response to 
ESAT-6 and CFP-10, vaccinated calves could be distinguished from infected animals (Ameni 
et al., 2010). A cocktail of the recombinant protein antigens ESAT-6, CFP-10, MPB70 and 
MPB83 was shown to elicit a skin test response in naturally infected tuberculin-positive cattle 
whilst not reacting to BCG-vaccinated cattle (Whelan et al., 2010). Other mycobacterial 
proteins such as Rv3020c and Rv3615c have also been identified as allowing a differentiation 
between infected and vaccinated animals to be made (Sidders et al., 2008; Whelan et al., 
2010; Jones et al., 2012). 
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Chapter 2  
Aims, Objectives and Hypotheses 
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Bovine TB (bTB) is the single most important animal health problem in the UK; developing 
cattle (and wildlife) vaccines is a research priority. BCG, the only potentially available 
vaccine, displays mediocre efficacy to protect cattle against bTB. Promising strategies to 
improve BCG protection are based on heterologous BCG prime/subunit vaccine boosting 
strategy. The successful development and optimisation of this approach will depend on a 
rational and comprehensive screen for protective subunit antigens, an activity hitherto mainly 
based on serendipity rather than comprehensive antigen mining approaches. This study 
aimed to undertake a comprehensive genetic screen to identify the mycobacterial 
antigens that are targeted by the protective arm of the bovine immune response 
following vaccination with BCG. Importantly, the screen was to be undertaken in the target 
species, cattle. The approach merged next generation sequence-based BCG transposon library 
screening with a novel BCG cattle challenge model recently developed at the APHA 
(Villarreal-Ramos et al., 2014). It was hypothesised that mutants deficient in protective 
antigens will have increased survival in vaccinated cattle compared to unvaccinated cattle- 
relative to wild-type BCG. These potential antigens thereby will be potential subunit vaccine 
candidates. Alternatively, these mutants may be deficient in enzymes involved in the 
synthesis of non-protein antigens such as glycolipids which results in a mutant deficient in a 
protective antigen. A selection of these putative subunit candidates would then be tested for 
immunogenicity in bovine PBMCs harvested from animals pre and post BCG vaccination 
with IFN-γ, IP-10, TNF-α, IL-1β, IL-10, IL-12 and IL-17a cytokine profiles assessed. 
Knowledge of the immune response elicited by these antigens during BCG vaccination would 
be used to facilitate decisions regarding the likelihood that they are involved in protective 
immune responses against M. bovis. 
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The specific objectives of this study and the rationale are as follows: 
1. Genetic screening for protective antigens of BCG using a bovine BCG challenge model 
1a. Generate a transposon (Tn) mutant library in the BCG Denmark vaccine strain using the 
MycoMar transposon. 
BCG Denmark is the standard strain for vaccination of humans in the UK and it is 
also licensed for use in Badgers and a license for cattle is being assessed. A large 
body of immunological data now exists on experiments/vaccination with BCG 
Denmark and therefore the study will be performed using BCG Denmark. BCG will 
be grown to late log phase and then transfected with the φMycoMarT7 phage carrying 
the MycoMar transposon. Transposon mutants will be selected on 7H11 media 
containing kanamycin and harvested for resuspension, washing and aliquoting for use 
in challenge experiments. A transposon library of approximately 1x105 mutants is 
necessary to avoid a bottle neck effect during the mutant selection process. 
1b. Validate the use of the transposon library in cattle experiments using in vitro assays to 
identify essential genes in the mycobacterial heat-shock and isoniazid resistance pathways. 
It is essential to characterise the library in terms of coverage and ‘selectability’ so that 
it can be used in animal experiments with confidence. To this end, the library will be 
exposed to stress conditions in vitro to ensure essential genes relevant to the stress 
conditions are identified. The well-studied mycobacterial heat-shock response will be 
used, with hspR mutants aiming to be identified as having a heat-shock resistance 
phenotype. The library will also be exposed to the antimycobacterial drug, isoniazid, 
with the aim of identifying an abundance of katG mutants in the isoniazid selected 
library due to the resistance generated by the loss of katG.  
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1c. Challenge immunised and non-immunised calves with the BCG Tn mutant library. 
Three calves will be immunised with 106 CFU of wild-type BCG Denmark SSI. Each 
cow will be challenged 6 weeks post-vaccination with 108 CFU of the BCG Tn 
mutant library in each pre-scapular lymph node. Three-to-four weeks post-challenge, 
calves will be euthanised and the pre-scapular lymph nodes removed, homogenised 
and plated on Middlebrook 7H11 media containing kanamycin. Recovery of at least 
106 CFU of the BCG mutant library from unvaccinated calf lymph-nodes and 104-105 
from vaccinated calf lymph nodes is expected. These will be harvested and stored at -
80oC. This process will be repeated using age matched unvaccinated calves. 
1d. Genomic sequencing of BCG mutant library composition following intra-lymph node 
selection in vaccinated and unvaccinated calves (identify mutants with immune phenotype). 
To identify bacterial mutants that were cleared from lymph nodes to a lesser relative 
extent in vaccinated compared to unvaccinated calves, this study will identify and 
quantitate the abundance of mutants in the BCG mutant pools recovered from the 
lymph nodes using the TnSeq technique with Illumina sequencing of transposon 
insertion sites. DNA will be extracted from the mutant pools, digested, ligated to 
adapters, and PCR amplified with transposon/adapter specific primers incorporating 
Illumina attachment and sequencing sites. Amplified fragments will be purified and 
sequenced on an Illumina HiSeq2500. Sequence reads containing the transposon 
inverted repeat sequence are sorted and then genomic TA transposon insertion sites 
identified and the coordinates related to gene identities. The normalised number of 
reads per insertion TA site will be compared between mutant libraries from 
vaccinated and non-vaccinated lymph nodes (3 cattle, 6 lymph nodes per group) and 
mutants with statistically different survival, relative to the wild-type/bulk mutant 
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population, in immunised versus non-immunised calves will be identified using Rank 
Product analysis 
2. Protective efficacy of subunit vaccines 
2a. Expression of candidate protective antigens as recombinant proteins. 
Mutant BCG with increased survival (relative to wild-type /bulk mutant population) 
in BCG immunised calves compared to non-immunised calves may represent bacteria 
lacking molecules to which the protective BCG immune response. Mutants with an 
immune-related phenotype, will be selected for further study, with priority given to 
those with the most pronounced phenotype and those that encode secreted or surface 
exposed proteins. The genes mutated in these immune-related phenotype strains will 
be cloned and the proteins overexpressed using the pet15b E. coli expression system, 
producing His-tagged proteins. 
2b. Assess the immunogenicity of recombinant proteins 
Bovine PBMCs harvested from animals pre and post BCG vaccination will be 
stimulated with the recombinant proteins. IFN-γ, IP10, IL-17A, IL-10, IL-12, IL-1β 
and TNF-α production will be quantified using immunoassays. Proteins that generate 
a multi-cytokine response post-BCG vaccination may confer protection immunity as 
part of a prime/boost strategy alongside BCG and are the best candidates for further 
study.  
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Chapter 3 
Methods 
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3.1 Bacterial Strains, Cell Culture and Growth Conditions 
BCG Vaccine Danish Strain 1331 (Statens Serum Institut-SSI) was used throughout all 
experiments. The lyophilised BCG vaccine was reconstituted using Middlebrook 7H9 (Difco) 
with 10 % added albumin dextrose catalase (ADC) supplement. The reconstituted bacteria 
were streak plated on Middlebrook 7H11 (Difco) agar with added 10 % oleic acid albumin 
dextrose catalase (OADC) agar plates incubated at 37oC for 3-4 weeks at 37oC in 5 % CO2. 
Mycobacterium smegmatis mc2 155 was used to amplify and titre the MycoMarT7 phage 
(Section 3.2) (Rubin et al. 1999). M. smegmatis mc2 155 was cultured in Nutrient Broth 2 
(NB2 (Oxoid)) as a liquid media, or on NB2 with 1.5 % Bacteriological Agar 1 (Oxoid).  
Cultures prior to phage infection were incubated at 37oC for 48 hours. Cultures infected with 
phage to assess the titre of the phage stock were incubated at 30oC. The lower temperature 
allowed the heat sensitive phage to lyse the M. smegmatis mc2 155 cells, enabling plaque 
formation and quantification. 50mg/ml kanamycin concentration used for selection.  
PBMC’s (Peripheral Blood Mononuclear Cell) from 10 BCG vaccinated cattle and 10 control 
animals were used for ELISA determination of cytokine production in response to 
mycobacterial antigens (Section 3.6). The control PBMCs were harvested from the 
vaccinated animals prior to vaccination. Peptide stock solutions were created using RPMI 
1640 + GlutaMAX (1x (Gibco Life Technologies)). Working solutions were created using 
complete media, this contained 500 ml RPMI 1640 + GlutaMAX (1x), 50 ml FCS (Foetal 
Calf Serum), 5 ml penicillin/streptomycin (10,000 U/ml, ThermoFisher Scientific), 5ml 
MEM NEAA (100x (Minimum Essential Medium Non-Essential Amino Acids) and 0.5 ml β-
mecaptoethanol (Gibco Life Technologies).  
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3.2 Amplification and Quantification of MycoMarT7 phage in Mycobacterium 
smegmatis mc2 155 
A high concentration of phage was required to increase the probability of generating a 
saturated BCG transposon library. The amplification step ensured a high quantity of phage 
was present to enable this. M. smegamtis mc2 155 cells and serial diluted MycoMarT7 phage 
were added to 0.7 % molten NB2 agar. The 0.7 % agar was poured onto warm NB2 agar 
plates and incubated for 48 hours. After 48 hours, the number of plaques was assessed. The 
dilution with which ‘lacy’ lysis was seen was the dilution used for the amplification stage. 
Lacy growth is present when the number of phage was not too small-leading to very few 
plaques-and not too large as to lyse all of the bacteria present before exponential growth can 
occur.  
To amplify the phage the above method was used with slight deviations; the phage was not 
serially diluted. 10-6 of the initial stock is used throughout, creating 10 plates exhibiting lacy 
growth. The top layer of agar was removed and the phage was extracted via centrifugation 
and filtration. Phage were stored at 4oC in mycobacteriophage buffer (Tris 50 mM, NaCl 150 
mM, MgCl2 10 mM, CaCl2 2 mM (MP buffer)). The titre of the phage stock was determined 
by plaque assay with M. smegmatis to be 2.7 x 1010 plaque forming units/ml (PFU/ml). 
3.3 Construction of a MycoMarT7 Transposon Library in BCG Vaccine Danish strain 
1331 using MycoMarT7 phage 
100 ml of BCG was cultured until an OD600 1 was achieved. The bacterial cells were then 
washed (4000 rpm for 10 min) in 40 ml MP buffer and resuspended in 9 ml MP buffer. 1 ml 
phage solution was added and the solution incubated at 37oC for 4 hours. The bacteria-phage 
solution was centrifuged and resuspended in 10 ml 7H9. 500 µl of the culture was dispensed 
onto twenty large 7H11 agar plates (150 mm x 15 mm) with kanamycin and incubated at 
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37oC for 2-3 weeks. Alongside this the culture was serially diluted and plated in triplicate 
using the Miles and Misra method to obtain a viable count (Miles et al. 1938).  Once small 
colonies had formed cultures were removed, aliquoted and stored at -80oC in a 50/50 mix of 
15 % glycerol and 7H9. Prior to all colonies being harvested, 40 single colonies were 
harvested and cultured. It was expected that each mutant within a colony would have the 
same transposon insertion site as all other mutants within that colony. Genomic DNA 
analysis was completed on these isolates (see Section 4.4).  
3.4 Heat Shock Selection of BCG Danish Transposon Mutants 
A heat shock selection of the BCG mutant library was performed to validate the selection 
screen and also to identify mutants that might overexpress important stress proteins which are 
commonly immunodominant antigens. To achieve an appropriate heat kill percentage of 99-
99.99 %, bacteria need to be incubated for a specific amount of time at a specific 
temperature.  To establish the incubation time, 1ml of wild type BCG was incubated in a 
53oC (Group et al., 2001) water bath for up to 90 minutes. After each 30-minute time points a 
100 µL sample was taken, serially diluted and plated on 7H11 media. A room temperature 
control was used. 
A 1.5 ml frozen aliquot of BCG Danish transposon mutant library was cultured in 50ml 7H9 
with added kanamycin for 2 days to stimulate growth. 1 ml of the culture was then aliquoted 
into 1.5ml reaction tubes in preparation for heat shock selection.  As the ideal conditions for 
heat shock selection were previously investigated (see above), these 1 ml cultures were 
incubated using those conditions (53oC for 30 minutes). This was completed in triplicate with 
a room temperature control. Post incubation, the 1 ml cultures were transferred to 7H11 agar 
and grown for 2-4 weeks at 37oC. Once colonies had formed the cultures were removed, 
aliquoted and stored at -80oC in a 1:1 mixture of 30 % glycerol and 7H9.  
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3.5 Selection of Isoniazid Sensitive BCG Danish Transposon Mutants 
3.5.1 Confirmation of BCG Danish MIC 
The antibiotic resistance profile of BCG Danish is known, however the isoniazid (INH) MIC 
was confirmed prior to mutant selection (Statens Serum Institut, 2011). INH concentrations 
ranged between 8-0.015 µg/ml (10 dilutions in total). A 12.8 mg/ml (INH) stock was made. 
INH was dissolved in Ultrapure (Milli-Q) water and filter sterilised using a 0.22 µm filter. 
The stock was diluted 1:100 with 7H9 to create a 128 µg/ml working solution, with which the 
other dilutions were made (following the dilution scheme in Table 3.1). Each well in a 96-
well plate contained 100 µl of antibiotic solution and 100 µl of a 1 McFarland Standard BCG 
Danish culture diluted 1 in 25 in 7H9 broth (Franzblau et al. 1998).  
The 96-well plates were incubated for 3 weeks. To ensure the liquid in the wells did not 
evaporate, all spare wells on the plate were filled with PBS and the plates were incubated in a 
humid environment. The experiment was completed in triplicate with a growth control on 
each plate. The absence or presence of growth was recorded and this gave the MIC. 
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Table 3.1 INH dilution scheme used to create all INH concentrations required to determine 
the MIC of transposon mutants. The range used allowed both resistant and susceptible 
mutants to be identified.  
 
 
 
 
 
Tube  Final Concentration 
µg/ml 
INH solution 
used 
Volume INH solution 
/µL 
Volume 
7H9/µL 
A 8 working 
solution 
1000 7000 
B 4 A 2000 2000 
C 2 A 1000 3000 
D 1 A 1000 7000 
E 0.5 D 2000 2000 
F 0.25 D 1000 3000 
G 0.12 D 1000 7000 
H 0.06 G 2000 2000 
I 0.03 G 1000 3000 
J 0.015 G 1000 7000 
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3.5.2 Selection of INH Susceptible Transposon Mutants 
The optimal INH concertation to select for transposon mutants hyper-susceptible to INH had 
to first be determined. 100 µL OD1 BCG Danish culture was Miles and Misra plated, in 
triplicate, on modified 7H11 containing 0.12, 0.06 or 0.03 mg/L INH. Cultures were 
incubated for 2-3 weeks and colonies counted to ascertain the level of killing exhibited by the 
different INH concentrations. 0.06 mg/L was selected to produce the wanted level of 
mycobacterial cell killing.  
1ml of harvested transposon library was spread plated onto a large modified 7H11 agar plate 
containing 0.06 mg/L INH in triplicate and cultured at 37oC for 2-3 weeks. Surviving 
colonies were harvested and stored in 15 % glycerol at -80oC.  
3.6 Transposon Mutant Genomic DNA Extraction, Amplification and Analysis 
3.6.1 Genomic DNA Extraction 
Genomic DNA (gDNA) was analysed from single isolates to begin to determine the 
'randomness' of transposon insertion into the BCG Danish genome and to verify the 
occurrence of genuine mariner transposition into TA sequences. An enzymatic reaction was 
used to extract gDNA from the BCG Danish transposon mutants. Transposon mutant cultures 
were centrifuged at 2000 x g for 20 minutes. The pellet was resuspended in glucose-tris-
EDTA (Ethylenediaminetetraacetic acid (GTE)) and 10 mg/ml lysozyme (Sigma) was added. 
GTE maintains osmotic pressure, whilst also buffering the cells to a pH 8 and binding 
covalent cations in the lipid bilayer, weakening the cell envelope. Lysozyme damages the 
bacterial cell wall by hydrolysing links between residues which make up peptidoglycan. The 
solution was incubated over-night at 37oC in a shaking incubator. Sodium dodecyl sulphate 
(SDS-a detergent that dissolves the lipid components the cellular envelope) and proteinase k 
(Sigma) were added and the solution incubated at 55oC, followed by the addition of 
cetrimonium bromide (CTAB) and further incubation at 65oC. Proteinase k is a serine 
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protease that cleaves peptide bonds. CTAB is a surfactant that produces micelles and acts as a 
buffer solution.  
The next stage involved the repeated process of the addition of chloroform-isoamyl alcohol, 
centrifugation and the removal of the aqueous layer. The resulting aqueous solution should be 
free of cellular proteins and lipids. Isopropanol was used to precipitate the gDNA and 70 % 
ethanol wash was used to remove any remaining salt or SDS, which if not removed cause 
problems during gel electrophoresis or subsequent enzymatic reactions.  Nuclease free water 
was the solvent in which the preparation was dissolved and stored.  
3.6.2 Genomic DNA Amplification 
Polymerase chain reaction (PCR) was used to amplify the transposon insertion site of BCG 
Danish transposon mutants. The gDNA was extracted as described above and a hemi-nested 
PCR used to obtain the desired quantity of DNA at the transposon insertion to be sequenced 
via Sanger sequencing. The first round of PCR was run at a low annealing temperature. Due 
to the randomness of the transposon insertion it is unknown where exactly the transposon is 
located in the genome, a low annealing temperature allows one partially redundant primer to 
bind relatively freely to the regions of the genome either side of the transposon.  The second 
primer is specific to the transposon. The first round of PCR had the following parameters: 
activation- 95oC 5 minutes, denaturation- 95oC 1 minute, annealing- 38oC 1 minute, 
extension- 72oC 4 minutes. A negative control of master mix without DNA was used 
alongside each reaction set. The primers used for the initial PCR were HiMar_Right_1 
(CCTCGTGCTTTACGGTATCG) and Arb_primer_1c 
(GGCCAGCGAGCTAACGAGACNNNNNNAGTAC). A 5 0µL reaction consisted of; 10 
µL of gDNA diluted 1 in 10 in nuclease free water, 2.5 µL of 10 µM HiMar_Right_1, 2.5 µL 
of 10 µM Arb_primer_1c, 25 µL 2xHotStarTaq Master Mix (Qiagen), 5 % total volume 
dimethyl sulfoxide (DMSO) and 17.5 µL nuclease free water.  10 µl of the completed PCR 
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product was run on a 0.8 % agarose gel. Each reaction was analysed on a Nanodrop 2000 
UV-Vis Spectrophotometer, to allow the quantity of DNA to be assessed.  A QIAquick PCR 
Purification Kit (Qiagen) was used to clean up the amplified DNA in preparation for the 
second PCR reaction.  
The second round of PCR was completed using the above method, however to increase the 
level of primer binding specificity, the annealing temperature was raised to 55oC for 2 
minutes. The primers Himar_Tn_Junct_PCR (ACTATAGGGGTCTAGAGACCGGG) and 
Arb_primer_1 (GGCCAGCGAGCTAACGAGC) were used at this stage.  Again, the PCR 
product was cleaned up using the Qiagen kit and visualised on an agarose gel and Nanodrop 
2000 UV-Vis Spectrophotometer for quantification. 
 Sanger sequencing (Source BioScience LifeSciences) was completed on all samples using 
the Himar_Tn_Jnct_Seq (CGGGGACTTATCAGCCAACCTG) as the sequencing primer. A 
quality value limit of 10 was requested and the software used to call the bases was 
PeakTrace™ Basecaller. Sequence data was analysed using Basic Local Alignment Search 
Tool (BLAST). 
3.7 Cattle Challenge and Growth of Surviving Mutants 
Six Holsten-Friesian cattle of 4-6 months of age were sourced from farms known to be free 
from bTB. Six weeks prior to transposon library challenge on the 3 animals (C14-8772, C14-
8774, and C14-8777) were inoculated subcutaneously in the right prescapular area with 1-
2x106 BCG SSI Lot 113032B. Control animals (C14-8773, C14-8778 and C14-8780) and 
vaccinated animals were bled at this time. The animals were bled 4 more times throughout 
the experiment to monitor IFN-Ƴ production. The second bleed occurred 3 weeks after 
vaccination, the third at the same time as the library challenge, the fourth 2 weeks after 
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challenge and the final bleed occurred on the day of the cull. BOVIGAM™ tests were 
completed to determine blood IFN- γ levels over the course of the challenge. 
Prior to challenge, 1 frozen vial of library was cultured in 100 ml 7H9+OADC for 2 days at 
80rpm shaking to achieve approximately 1x108 CFU/ml. On the day of challenge (6 weeks 
post vaccination) 1.5ml of 1x108 CFU/ml library was injected into the left and right 
prescapular lymph node of each animal, as described previously (Villarreal-Ramos et al., 
2014).  
Four weeks post challenge, animals were culled and prescapular lymph nodes removed. 
Lymph nodes were trimmed of fat and submerged briefly in 70 % ethanol prior to weighing 
and slicing for processing in a stomacher (Seward) for 2 minutes with 7ml PBS. Macerate 
was serial diluted in PBS and plated to calculate the number of surviving mutants. 4mls of the 
macerate was diluted 1:10 in PBS, with 500 µL of this dilution being plated onto large 7H11+ 
Kan agar plates. Plates were incubated at 37˚C in ambient air for 4 weeks. Tween80 was 
absent from all media.  
3.8 Isolation and Preparation of population gDNA from Transposon Libraries for 
TnSeq 
Surviving mutants were harvested by scraping from agar plates into 50ml conical tubes. The 
pellet was resuspended in 10ml TE. An equal volume of Chloroform:Methanol (2:1) was 
added and tubes were then rocked for 5 mins at room temperature. To separate the organic 
solvent and aqueous layers from the pellet, tubes were centrifuged at 4000 rpm for 10 
minutes at room temperature.  Aqueous and organic solvent layers were removed and the 
pellet was dried in a biosafety cabinet for 3 hours. 5 ml of TE was added and then vortexed to 
resuspend the pellet. Lysozyme was added to achieve a final concentration of 100 µg/ml. 
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This reaction was incubated overnight at 37˚C. The following day 0.1 volumes of 100 µg/ml 
Proteinase K prepared in 10 % SDS was added and incubated at 50˚C for 3 hours. 
Solutions were transferred to clean 50 ml conical tubes, an equal volume of 
Phenol:Chloroform:Isoamyl alcohol (25:24:1) was added and stood and rocked for 30 
minutes each at room temperature. Tubes were centrifuged at 4000 x g for 15 minutes, the 
aqueous layer was removed into a clean tube, extracted again using an equal volume of 
chloroform and centrifuged. The aqueous layer was removed into a clean 1.5ml Eppendorf 
tube and DNA precipitated using 1/10th volume 3M sodium acetate and one volume 
isopropanol. Tubes were gently rocked until the solutions were fully mixed and DNA strands 
visible.  Tubes were centrifuged at 13000 x g for 10 minutes to pellet the DNA. The pellet 
was washed using 70 % ethanol and dried at room temperature for 1 hour. Each pellet was 
resuspended in 1ml TE. DNA was quantified using a Nanodrop 2000 UV-Vis 
Spectrophotometer.  
Following extraction, 5 µg of DNA from each sample was combined with TE buffer to 
produce a total volume of 150 µL.  DNA was sheared to approximately 500 bp using a 
Covaris Sono 7 machine with following parameters: Incident Power - 105, Duty Factor – 5 
%, 200 cycles/burst for 80 seconds. The size of the sheared DNA was checked on a 0.8 % 
agarose gel and the product was cleaned using the QIAquick PCR purification kit. 
The sheared DNA was blunt ended using the NEBNext® End Repair Module (New England 
Biolabs).  85 µL of sheared DNA was mixed with 10 µL 10xNEBNext end repair reaction 
buffer and 5 µL NEBNext end repair enzyme mix, to create a total volume of 100 µL. This 
mix was incubated for 30 minutes at 20˚C and purified using the QIAquick PCR purification 
kit. A 3’ A was added to the blunt-ended DNA using the NEBNext dA-tailing module. 42 µL 
of end repaired DNA was mixed with 5 µL 10xNEBNext dA-Tailing reaction buffer and 3 
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µL Klenow fragment. The mix was incubated at 37˚C for 30minutes and purified using the 
QIAquick PCR purification kit. 
The blunt ending and A-tailing of the sheared DNA was required to allow adapters to link 
with the 3’ ‘T’ overhang that is generated. Two adapters were used which contain elements 
which allowed the DNA to be sequenced on the Illumina platform and allow a level of quality 
control post-sequencing.  
Adap1(caagcAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTTCAGACG
TGTGCTCTTCCgatct) contains the 5’ Illumina binding region 
(caagcAGAAGACGGCATACGAGAT) and a barcode sequence (NNNNNNNN) which 
allows the removal of PCR amplification artefacts. N’s represent random nucleotides 
introduced during oligonucleotide synthesis. Products with an identical position and index to 
an already identified product are discarded during analysis. The final segment of adap1 
(GTGACTGGAGTTCAGACGTGTGCTCTTCCgatct) is the Illumina read sequence. Lower 
case letters indicate phosphorothioate (PTO) bonds, which prevent endonuclease degradation; 
this is essential as the 3’ T nucleotide must be present to allow the adapter to bond with the 3’ 
A overhang which was introduced onto the sheared DNA. PTO bonds substitute a sulfur atom 
for a non-bridging oxygen in the phosphate backbone of the DNA, which renders the 
internucleotide linkage resistant to degradation. Adap2 (gatcgGAAgagca-PHO) is 3’ 
phosphorylated to prevent extension of the adapter by polymerases.  
Adap1 and Adap2 were prepared by mixing equal volumes of 100 µM of each adapter in 2 
mM MgCl2. This gives a final concentration of 50 µM of each adapter. The mix was heated at 
95˚C for 5 minutes in a thermocycler then cooled slowly to room temperature. Adapters were 
ligated onto the prepared DNA by adding 4 µL T4 DNA ligase, 6 µL 10x ligase buffer and 4 
µL adapter mix for 2 hours and room temperature. The initial ligation was supplemented with 
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a second overnight ligation with an additional 4 µL T4 DNA ligase, 4 µL 10x ligase buffer 
and 32 µL nuclease free water being added. Ligation reactions were purified using a 
QIAquick PCR purification kit. The columns were washed 4 times with PE buffer, with 2 of 
the washes being left on the column for 5 minutes each. Samples were eluted in 50 µL water, 
with the water being left in the column for 2 minutes before centrifugation.  
3.9 Amplification of Loci Adjacent to Transposon Insertions 
The loci adjacent to the transposon insertions were selectively amplified using one PCR 
amplification. The primers used in this amplification contained the index sequence required 
to multiplex-sequence the libraries. This allows multiple libraries to be sequenced in the same 
lane on the Illumina chip as libraries can be sorted using the index sequence introduced. The 
process was completed for all generated libraries, including the heat shock and isoniazid 
susceptibility experiments. 
Two types of primers were used for the amplification: IS6 
(CAAGCAGAAGACGGCATACGA) is homologous with the 5’ Illumina binding region of 
the final product; MarX 
(AATGATACGGCGACCACCGAGATCTACACNNNNNNNNACACTCTTTCCCTACAC
GACGCTCTTCCGATCTTCGGGGACTTATCAGCCAACC) contain the Illumina binding 
region (AATGATACGGCGACCACCGAGATCTACAC), an index (NNNNNNNN) to 
identify the sample, a spacer (T) and the transposon specific sequence 
(CGGGGACTTATCAGCCAACC). MarA, MarB, MarC, MarD, MarE, MarF, MarG and 
MarH were designed to each have a different index and spacer, with as little base overlap as 
possible between each index (Table 3.2). As there are eight different indices it is possible to 
sequence eight different indexed libraries on one sequence run.  
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Prior to amplifying the whole library preparation, a real-time optimisation for cycle number 
was completed using 5 µL Phusion® High-Fidelity PCR master mix with GC buffer (NEB) 
and 0.5 µL EvaGreen Dye (x20) and a Stratagene Mx3005P™ qPCR System. A 10 µL 
reaction consisted of 1 µL MarX/IS6 mix and 1 µL template DNA. The MarX/IS6 mix 
contained 2 pmol/µL of each primer. The initial denaturation was 95˚C for 2minutes, 
followed by 45 cycles of 95˚C 10seconds, 58˚C 10seconds, 72˚C 30seconds.  The product 
was visualised on a 1 % agarose gel to confirm the presence of smears of <1kb.  
Following this, preparative PCR amplifications were completed on larger library volumes 
using the optimised cycle number. Four 50 µL PCR reactions were set up for each sample: 25 
µL Phusion® High-Fidelity PCR master mix with GC buffer, 5 µL MarX/IS6 primer mix and 
5 µL template. Control reactions of 10 µL with IS6 primer/template only and IS6/MarX 
primer mix with no template were used.  
Amplification products were pooled to give 200 µL total volume, mixed with 34 µL 6x 
Blue/Orange loading dye and run on a 2 % agarose gel. DNA fragments between 
approximately 400 and 600 bp were gel extracted using a QIAquick Gel Extraction Kit with 
an additional 5 washes (6 total), 2 of which were left on the column for 5 minutes. The DNA 
was eluted in 50 µL water. Sample fragment distribution and quality was checked using a 
2100 BioAnalyzer with a DNA100 chip. DNA concentration was determined using a 
Quantus® Fluorometer (Promega). 
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MarA AATGATACGGCGACCACCGAGATCTACACTGTTCCGAACACTCTTTCC
CTACACGACGCTCTTCCGATCTCGGGGACTTATCAGCCAACC 
MarB AATGATACGGCGACCACCGAGATCTACACTTCCGGAGACACTCTTTCC
CTACACGACGCTCTTCCGATCTTCGGGGACTTATCAGCCAACC 
MarC AATGATACGGCGACCACCGAGATCTACACGCCGATGTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGATACGGGGACTTATCAGCCAACC 
MarD AATGATACGGCGACCACCGAGATCTACACCATGATCGACACTCTTTCC
CTACACGACGCTCTTCCGATCTTATCTACGGGGACTTATCAGCCAACC 
MarE AATGATACGGCGACCACCGAGATCTACACCGCGCGGTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCGGGGACTTATCAGCCAACC 
MarF AATGATACGGCGACCACCGAGATCTACACACACGATCACACTCTTTCC
CTACACGACGCTCTTCCGATCTTCGGGGACTTATCAGCCAACC 
MarG AATGATACGGCGACCACCGAGATCTACACAAGTAGAGACACTCTTTCC
CTACACGACGCTCTTCCGATCTGATACGGGGACTTATCAGCCAACC 
MarH AATGATACGGCGACCACCGAGATCTACACGAGATCTTACACTCTTTCC
CTACACGACGCTCTTCCGATCTTATCTACGGGGACTTATCAGCCAACC 
 
Table 3.2 MarA-H primers containing the Illumina binding region, an index, spacers and the 
transposon specific sequence. The primers were used to multiplex a number of libraries, 
enabling each data set to be distinguished and separated for analysis 
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3.10 Data Analysis 
Libraries were sequenced on the Illumina HiSeq 2500 platform with v3 chemistry, with 8 
libraries multiplexed per HiSeq lane. The specifications for the sequencing runs were as 
follows: single read of at least 100bp and double index, delivering between 120 million and 
180 million reads per channel. Sequence handling and initial data analysis was completed by 
Dr Huihau Wu from the University of Surrey, FHMS, Bioinformatics core facility. Data was 
demultiplexed to separate reads from each library and the raw fastq output files were filtered 
and sequences trimmed before alignment. The number of reads was calculated for each 
library, with parameters set to allow 2 mismatches for the index. The data was further filtered 
by read quality, with a cut-off of Q=50 (1:100,000 chance a base was incorrectly called) and 
whether the transposon site TGTTA was present in the first 32bp of the read. Reads are 
mapped onto the reference genome (Mycobacterium bovis BCG Pasteur 1173P2) and any 
reads with identical barcodes mapping to the same TA site and DNA sequence are assumed 
to be PCR duplicates and were only counted once. In addition, only reads with map quality 
>30 were kept.  
Once the reads had been filtered a list of surviving transposon mutants was generated. The 
list showed every TA site in the genome with how many times a mutant of that TA site was 
seen. This data was normalised by dividing the number of each insertion by the total number 
of insertions seen in lymph node as a whole. This allowed the lymph node data to be 
compared without the bias that would be generated by the variable number of reads between 
each lymph node. Any TA sites located within the first 5 % and last 20 % of a given gene 
were also removed from this analysis. It is predicted that insertions within these areas were 
less likely to result in loss of gene function (Griffin et al., 2011). 
Ranked Product analysis was completed on the data, comparing the control group normalised 
transposon insertion rate to that of the vaccinated animals. The reads for each TA site within 
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a gene were combined (per lymph node). This gave the number of reads per gene for each 
lymph node, and made the use of Rank Products possible. Following this, if half of the 
control group lacked reads in a gene, that data set was removed from the analysis.  The Rank 
Products analysis was completed using the RankProdIt online tool found at http://strep-
microarray.sbs.surrey.ac.uk/RankProducts/  (Laing and Smith, 2010). Rank Products is a non-
parametric test that enables the identification of transposon mutants that are significantly 
over-represented in each group, even amongst noisy data. Rank Products assumes that 1) 
expression changes only affect a minority of genes, or in this study only a minority of gene 
knock-outs will lead to increased survival, 2) measurements are independent between 
replicates, 3) changes in survival are independent of each other and 4) measurement variance 
is about equal for all genes (Breitling et al., 2004). The online tool generates a ranked list of 
all genes, each with an associated fold-change and pfp value. Genes were selected for 
recombinant protein expression and immunogenicity assessment based off the data using a 
pfp cut-off of 0.1 whilst also taking into account the fold change between the reads, and the 
functions of the genes that were high on the list after filtering for these parameters.  
3.11 Cloning Selected Genes into pet15B Vector 
3.11.1 Preparation of Mycobacterial Genes using PCR Amplification  
From the Ranked Products analysis 5 genes were selected for cloning and protein expression: 
mb0024, mb0025, yrbE1B, mb2235, PPE20 and mb0086. Forward and reverse PCR primers 
were designed to incorporate the XhoI (5' CTCGAG) or Nde1 (5' CATATG) restriction site 
(table 3.3). DNA Oligonucleotides were purchased from Sigma Aldrich. The selected genes 
were PCR amplified using the corresponding primers in table 3.11.1. A 50 µL reaction was 
set up, containing; 25 µL Phusion® High-Fidelity PCR master mix with GC buffer (NEB), 
2.5 µL of 10 µM forward and reverse primers, 4 µL glycerol (8 % final concentration), 10ng 
BCG Danish gDNA and 15 µL nuclease free water. Thirty cycles of the following PCR 
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conditions were used: 95°C 2 minutes, 95°C 1 minute, 62°C 1 minute, 72°C 1 minute, 72°C 7 
minutes. Following amplification, products were visualised on a 0.8 % agarose gel. Products 
of expected size (mb0024-834 bp, mb0025-270 bp, yrbE1B- 870 bp, mb2235- 1134 bp, 
PPE20- 1620 bp and mb0086- 1929 bp) were cleaned using the Qiagen PCR purification kit 
and eluted into 50 µL elution buffer. Products were digested using the XhoI restriction 
enzyme; 44 µL of product, 5 µL 10x buffer D and 1 µL XhoI /NdeI were mixed and 
incubated at 4°C overnight or at 37°C for 3 hours.  
Following digestion, samples were visualised on a 1 % agarose gel and bands of the predicted 
sizes were cut out of the gel using a Qiagen Gel Extraction kit.  
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Table 3.3 Oligonucleotide sequences with specific restriction enzyme digestion (bold) sites 
used for the amplification of genes located in the M. bovis BCG bacterial chromosome. Each 
gene has a forward and reverse primer, both with the restriction enzyme site incorporated at 
the 5’ end of the oligonucleotide. 
3.11.2 Preparation of pet15b Vector 
The pet15b vector (Novagen) was amplified in Library Efficient® DH5ɑ™ Competent Cells 
(Thermofisher Scientific). Following the manufacturer’s transformation protocol; cells were 
thawed on ice and 50 µL of cell suspension was aliquoted into chilled 1.5 ml tubes. 5 µL 
pet15b stock was added to the cells and gently mixed with stirring. Cells were incubated on 
ice for 30 minutes, followed by heat-shock for 45 seconds in a 42°C water bath. Tubes were 
Primer  Oligonucleotide Primer Sequence 5’-3’ 
 yrbE1Bf  CGACCTCGAGATGTCGACCGCTGTGC 
 yrbE1Br  CAGCCTCGAGTACACCGTGAGATTGAA 
 PPE20f  CGACCATATGACCGAGCCGTGGATAGCC 
 PPE20r  CAGCCATATGTCAGCGATGCTGCTCGTCG 
Mb0086f  CGACCTCGAGATGACCGCTGCACCGACGGCC 
Mb0086r  CAGCCTCGAGTCACGTACACCTCGCGACC 
Mb2235f CGACCATATGTACGATTCCTTGGACTTC 
Mb2235r CAGCCTCGAGTCAGCGGTCGCCGAATCTG 
Mb0024f CGAACCTCGAGGTGAATTACAGCGAGGTCGAG 
Mb0024r CAGCCTCGAGTCAGCGGTCGCCGAATCTG 
Mb0025f CGACCTCGAGAACCAGTTCGACTGTTCCG 
Mb0025r CAGCCTCGAGTTATCTGCCACTCAGCGGTC 
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placed on ice for 2 minutes, 450 µL of room temperature S.O.C Medium was added, followed 
by incubation at 225 rpm for 1 hour. Reactions were diluted 1:10 with S.O.C Medium and 
100 µL of the dilution was spread on LB agar with 100 µg/ml ampicillin added to select for 
successful transformations. Agar plates were incubated overnight at 37°C. A single colony 
was picked into 5ml LB broth with 100 µg/ml ampicillin and incubated overnight at 37°C at 
225 rpm. Following incubation, pet15b plasmid was extracted and purified using the Qiagen 
Spin Miniprep Kit, with elution into 50 µL elution buffer. 
As above in 3.11.1, pet15b was linearised using the XhoI/NdeI restriction enzymes and 
purified using the Qiagen Gel Extraction kit. 1 µL Calf Intestinal Alkaline Phosphatase 
(CIAP (Thermofisher)) was added to de-phosphorylate the cut plasmid and prevent re-
ligation.  
3.11.3 Creation of pet15b Constructs 
Linearised pet15b and digested PCR products were ligated to produce plasmids which allow 
the over-expression of N-terminus 6xHistidine tagged proteins. The amount of plasmid DNA 
and PCR product present was estimated by running a known quantity of DNA marker and 1 
µL of the sample on an agarose gel. Fluorescence was compared and the molecular weight of 
the samples was taken into account. Ligation was completed in 10 µL reactions using T4 
DNA Ligase, the manufacturer’s protocol was followed. Into a 1.5 ml tube 4 µL of linearised 
plasmid, 0.5 µL T4 DNA Ligase, 1 µL 10x buffer, PCR product and water was added. The 
volume of PCR product added was dependant on the concentration of said product, the final 
vector:insert ratio required was 1:3. Nuclease free water was added to bring the total reaction 
volume to 10 µL. The ligation reactions were incubated overnight at 4°C.  
Library Efficient® DH5ɑ™ Competent Cells were thawed on ice. 3 µL of each ligation 
reaction was mixed with 50 µL of DH5ɑ cells and chilled on ice for 30 minutes. 
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Transformation reactions were completed as previously described in 3.11.2. A pUC19 control 
to test the transformation efficiency was set up, following the manufacturer’s protocol. The 
negative control used was a pet15b plasmid that lacked an insert. Single colonies were picked 
into 5 ml LB broth and screened for the presence of insert using a PCR based method. A 
small quantity of each colony was picked into the bottom of a 0.1 ml PCR tube 10 µL 
GoTaq® Green Master Mix was added to each tube, with 1 µL of 10 µM reverse and forward 
primer (table3.11.1), 1.6 µL glycerol and 6.4 µL nuclease free water, giving a final volume of 
20 µL. A 27 cycle PCR amplification was completed with the conditions described in 3.11.1, 
however the extension time was increased to 2 minutes.  PCR products were visualised on a 
0.8 % agarose gel.  
Colonies that tested positive for the presence of insert had plasmids extracted using a Qiagen 
spin miniprep kit. Final elution was in 50 µL of elution buffer. A restriction digest was 
completed on the plasmids that tested positive for insert, this was to ensure the insert was in 
the correct orientation. Restriction enzymes were chosen that cut once in the insert and once 
in the plasmid (Table 3.4). Plasmid maps can be seen in Appendix 3.2.  
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Table 3.4 Restriction enzymes used and predicted digestion sites of plasmid and insert. 
Enzymes were selected so that they cut at one end of the insert to allow insert orientation to 
be assessed. There are two expected fragments for each digest due to enzymes cutting once in 
the insert and once in the plasmid 
One Shot® Bl21 (DE3) Chemically Competent E. coli (ThermoFisher Scientific) were 
transformed with pet15b vector containing insert in the correct orientation. One vial (50 µL) 
of BL21 cells was thawed per plasmid. 1 µL of plasmid was added to the cells and the tube 
was incubated on ice for 30 minutes. Cells were heat-shocked at 42°C for 30 seconds, 250 µL 
of S.O.C broth was added and cultures were incubated for 30 minutes at 37°C shaking at 225 
rpm. Cultures were plated on LB agar with 100 µg/ml ampicillin. pUC19 controls were used 
to calculate the transformation efficiency, a negative control of plasmid without insert was 
used and an acr2::pet15b plasmid was used as a positive control (a gift from Dr Salim Al-
Hashmi).  
Gene Restriction 
Enzyme  
Insert digestion 
site 
Plasmid digestion 
site 
Expected fragment 
sizes 
mb0024 BamHI 993 319 674/5871 
mb0025 BamHI 418 319 99/5882 
yrbE1B BssHII 363 2516 2153/4444 
mb2235 SphI 1068 1831 763/6085 
mb0086 NruI 2241 4251 2010/5630 
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3.12 Recombinant Protein Expression, Purification and Visualisation  
A single colony of BL21 E. coli containing the pet15b plasmid with insert was picked from 
fresh overnight cultures grown an LB+Amp and inoculated into 50mls of MagicMedia™ E. 
coli Expression Medium (prepared according to manufacturer’s instructions (ThermoFisher 
Scientific) containing 100 µg/ml ampicillin. Cultures were incubated at 37˚C for 24 hours 
with shaking at 240rpm. Bacterial cells were pelleted via centrifugation at 4k x g for 20 
minutes at 4˚C. The supernatant was discarded and the pellet resuspended in 1ml denaturing 
binding buffer (20 mM Tris+HCl, 8 M urea, 500 mM NaCl, 5 mM imidazole, pH 8.0 + 1 mM 
β-mercaptoethanol). Cells were lysed enzymatically using 0.2mg/ml lysozyme and 20µg/ml 
DNAse for 1 hour at room temperature. The lysate was then clarified by spinning in a bench 
top centrifuge at 13k x g for 10 minutes. The supernatant was collected for purification using 
a His SpinTrap column (GE Life Sciences). The manufacturers provided protocol was used to 
complete the purification. His SpinTrap columns were equilibrated using denaturing binding 
buffer, the sample was washed 3 times and all centrifugation steps were 90 seconds. 
Denaturing elution buffer (20 mM Tris-HCl, 8 M urea, 50 mM NaCl, 500 mM imidazole, pH 
8.0 +1 mM β-mercaptoethanol) was used to elute the protein. The first time each protein was 
purified a native condition purification was also completed with binding buffer (20 mM 
sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH7.4) and elution buffer (20 mM 
sodium phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4) replacing the denaturing 
buffers. 
Proteins were visualised on a NuPAGE™ Novex™ 10 % Bis-Tris Protein Gel 
(ThermoFischer Scientific) with 1x NuPAGE® MES SDS Running Buffer (ThermoFischer 
Scientific). 7.5 µL of the protein elution was mixed with 2.5 µL NuPAGE® LDS Sample 
buffer (4x) (ThermoFischer Scientific) and incubated at 37˚C for 5 minutes. 10 µL 
PageRuler™ Plus Prestained Protein ladder 10 to 250 kDa was used as a molecular weight 
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marker. An XCell SureLock® Mini-Cell gel tank was used and gels were run for 1 hour at 
150V. The gel was removed from the casing and washed 3 times for 5 minutes in 25 ml 
ultrapure water and stained for 1 hour at room temperature with 20 ml SimplyBlue™ 
SafeStain (ThermoFischer Scientific) with gentle shaking. The gel was then washed for a 
further 2 hours with ultrapure water (gentle shaking) with a change of water after 1 hour.  
3.13 Western Blot 
For Western blotting, the gel was washed in 1x transfer buffer (25mM Tris, 190mM glycine, 
20 % methanol, pH 8.3). Polyvinylidene Difluoride (PVDF) membrane was cut to size and 
soaked in methanol for 5 minutes. Filter paper cut to size, the membrane and the gel were 
then soaked in transfer buffer and transferred to a Bio-Rad Trans-Blot® SD Semi-Dry 
Transfer Cell, with the filter paper sandwiching the membrane and gel (gel closer to anode). 
The transfer was completed at 22 V for 30 minutes.  
The membrane was blocked in Tris-buffered saline with Tween 20 (TBST) buffer (20 mM 
Tris pH 7.5, 150 mM NaCl, 0.1 % Tween 20) with 5 % skimmed milk for 1 hour. The 
primary antibody (6x-His tag mouse monoclonal antibody) was diluted 1:1000 in 10 ml 
TBST with 3 % skimmed milk and incubated with the membrane at 4˚C rolling overnight. 
Next, the membrane was rinsed 5 times for 5 minutes in 30 ml TBST. The secondary 
antibody (anti-mouse IgG-peroxidase antibody produced in rabbit) was diluted 1:100,000 in 
TBST with 3 % skimmed milk and incubated with the membrane for 1 hour at room 
temperature whilst rolling.  The membrane was again washed 5 times for 5 minutes in TBST.  
In a dark room, Clarity™ Western ECL Blotting chemiluminescent substrate (Bio-Rad) was 
mixed according to manufacturer’s instructions (5 ml 1:1 ratio) and the membrane was placed 
in the substrate for 5 minutes, ensuring the entire surface of the membrane was covered with 
the solution. The membrane was removed from the substrate solution and sandwiched 
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between two acetate sheets and enclosed in a developing cassette with a sheet of Amersham 
Hyperfilm ECL (GE Healthcare Life Sciences). Thirty second, 10 minutes and 2-hour 
exposure times were used.  
Post-exposure, the film was developed by incubating for 5 minutes in Polycon manual X-ray 
Developer, followed by a 2-minute wash in water and fixed in Amfix Film and Paper Fixer 
for 5 minutes. A final water wash was completed to remove any residual fixer and the film 
was dried overnight at room temperature.  
3.14 Protein Dialysis and Quantification 
Expressed insoluble proteins (Mb0025 & Mb2235) were dialysed out of the 8 M urea elution 
buffer into a 2M urea elution buffer using a D-Tube™ Dialyzer Mini with a molecular weight 
cut-off of 6-8 kDa (Novagen). Imidazole was also removed from this solution. The dialysis 
was completed in two stages to prevent the insoluble protein from coming out of solution. 
The first stage took the urea concentration to 4 M and the second dialysis to 2 M. The dialysis 
buffer contained the desired urea concentration as well as 20 mM Tris and 500 mM NaCl at 
pH8. Both dialysis steps were completed overnight at 4˚C.  
Following dialysis, protein concentration was quantified using a Pierce ™ BCA Protein 
Assay Kit (ThermoFisher Scientific), following manufacturer’s guidelines.  
3.15 Peptide Synthesis 
Peptide synthesis was completed commercially by JPT Peptide Technologies. PepTrack 
peptides libraries were created for each protein, each library contained 20 amino acid long 
peptides with a 12-amino acid overlap between consecutive peptides. Peptides were pre-
pooled into groups of 10-15 peptides (see Appendix 3.3 for sequence details). Thirty-five 
peptides in 3 pools were created for YrbE1B, 66 peptides in 5 pools for PPE20 and 79 
peptides in 6 pools for Mb0086. In total 226 peptides were synthesised and 18 peptide pools 
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were created (table 3.5). Each peptide had a concentration of 54nmol/well, which results in 
approximately 100µg of peptide per well. High-performance liquid chromatography-mass 
spectrometry (HPLC-MS) was used to quality check the molecular weight of 5 % of the 
peptides. 
Protein Peptide Pools 
yrbE1B 1,2,3 
PPE20 4,5,6,7,8 
mb0086 9,10,11,12,13,14 
mb2235 (whole protein) 19 
mb0025 (whole protein) 20 
 
Table 3.5 18 peptide pools were commercially generated and 2 whole recombinant proteins 
were produced in house. The peptide pool number also relates to the position of the pool in 
the 96-well peptide plates created.  
3.16 Antigen Plate Preparation, PBMC Stimulation and Enzyme Linked 
Immunosorption Assays 
3.16.1 Preparation of Antigen Plates 
The 18 peptide pools provided by JPT Peptide Technologies were reconstituted in 80 µL 
RPMI and 20 µL DMSO, to give a final concentration of 1000 µg/ml of peptide in 20 % 
DMSO. The DMSO was added first to aid in the reconstitution. The peptide stock solution 
was diluted in RPMI complete media to create a working solution with a final peptide 
concentration of 50 µg/ml. The final peptide concentration required for the assay was 5 
µg/ml. The Mb2235 and Mb0025 recombinant proteins were diluted with RPMI complete 
media to achieve the 5µg/ml final concentration required. 20 µL of each working solution 
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was dispensed into 4 wells of 23x 96 well plates. The working solution was diluted in the 
plates with the addition of 80 µL RMPI complete media. The final volume in the plates once 
the PBMCs were added was 200 µL, thus resulting in a final peptide concentration of 5 
µg/ml. 
Control plates containing PPDA, PPDB, pokeweed mitogen (PWM), ESAT6/CFP10, RPMI, 
2M urea elution buffer and 8 M urea elution buffer were also created. PPDA and PPDB stock 
solutions were diluted 1 in 10 with RMPI complete media to result in a final concentration of 
1 in 100 in the plate. PWM stock solution was diluted to create a final concentration of 10 
µg/ml. The 2 M and 8 M elution buffers were diluted in the same volume as the proteins they 
were used to elute, these acted as a buffer control. Peptide plates were stored at -80°C until 
required and thawed at room temperature on the day of use. 
3.16.2 PBMC Counts, Stimulation and Storage 
Vials of bovine PBMCs (peripheral blood mononuclear cell) from bovine tuberculosis reactor 
and BCG vaccinated animals were gently thawed using a 37°C water bath. Cells were 
resuspended in 20 ml RPMI complete media. The media was added to the cells slowly, in 
drops, to prevent the rupture of cells due to osmotic shock as the DMSO in which they are 
stored leaves the cells. Cells were spun at 300 x g for 10 minutes at room temperature. 
Supernatants were removed and the cells resuspended in fresh RPMI complete media. Cells 
were counted using a trypan blue solution (0.4 % (Sigma-Aldrich)) to stain the cells and 
enable the differentiation of live from dead cells. 10 µL of cells was mixed with 90 µL stain, 
10 µL of the suspension was transferred to a Bright-Light™ Haemocytometer and cells were 
counted using a light microscope. Approximately 2x105 cells were required per well; the cell 
suspension was diluted with RPMI complete media to achieve the desired concentration of 
cells. To antigen wells, 100 µL of diluted cells was added. Each antigen/animal combination 
was completed in quadruplicate. The culture was incubated at 37°C in 5 % CO2 for 3 days.  
64 
 
Following incubation, plates are spun at 300 g for 10 minutes at room temperature. 
Supernatants were harvested by removing 150 µL from each well, with each set of 
quadruplicates being pooled into one well of a deep welled plate. The supernatants were 
stored at -80°C.  
3.16.3 Determination of bovine IFN-γ by sandwich ELISA 
The IFN-γ ELISA completed during the initial cattle challenge experiment and the later 
PBMC stimulation used the bovine tuberculosis surveillance assay, BOVIGAM (bovine 
interferon gamma test). Freeze dried components were reconstituted in deionised water, all 
other components were brought to room temperature before use, the only exception was the 
100x conjugated antibody, which remained between 2°C-8°C. Cells were thawed at room 
temperature for 2-3 hours. 50 µL of green diluent was added to each well of the 96-well pre-
coated ELISA plate provided with the kit. 50 µL of PBMC supernatant was added in 
duplicate wells on the plate and incubated at room temperature for 60 minutes. Following 
incubation, supernatant was discarded and the plate washed 5 times using an automatic 
micro-plate washer with the provided 20x wash buffer being appropriately diluted. Conjugant 
reagent was freshly prepared by diluting the 100x conjugated antibody with blue diluent. 100 
µL of conjugant reagent was added per well and incubated and room temperature for 60 
minutes. Plates were once again washed as described above. Enzyme substrate solution was 
prepared by diluting the 100x substrate in buffer and subsequently 100 µL was added to the 
wells and the plates were incubated at room temperature for 30 minutes ± 5 minutes. The 
appearance of a blue colour represents the presence of IFN-γ in the supernatant. To stop the 
reaction, 50 µL of enzyme stopping solution was added. Absorbance readings at 450 nm were 
taken within 10 minutes of terminating the reaction using an ELISA reader (Multiskan 
Ascent, Thermo Labsystems, Ascent software version 2.6). The positive and negative control 
included in the kit were used to confirm the reliability of the response. A bovine IFN-γ 
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standard was diluted and used to produce a standard curve, to allow the conversion of optical 
density to actual quantity of IFN-γ in ng/ml.  
3.16.4 Determination of bovine CXCL10 (IP-10) by sandwich ELISA 
Ninety-six well immuno-plates (MaxiSorp Nunc 96-well plates) were coated with 100 µL 
anti-bovine CXCL10 (capture antibody, rabbit antiserum, bovine CXCL10 affinity 
chromatography, 1 mg/ml, Kingfisher biotech) diluted 1:1000 to 1 µg/ml in 0.05 M 
carbonate-bicarbonate buffer pH 9.6. Plates were sealed with an adhesive film and incubated 
overnight at 4°C and stored for up to 7 days. Prior to use, plates were washed twice with 200 
µL/well PBS pH 7.4. For each wash, wells were filled with buffer and gently tapped for a few 
seconds before emptying on a paper towel.  
Emptied wells were blocked with 200 µL/well 3 % bovine serum albumin (BSA)/PBS pH 7.4 
for 60 minutes at room temperature. Following this, plates were washed twice with 200 
µL/well PBS-Tween20 (0.05 %) pH 7.4 (washing buffer) as described above.  Each well was 
then filled with 50 µL 1 % BSA/PBS followed by 50 µL/well of standard, sample or blank. 
Plates were covered with an adhesive film, shaken for approximately 1 minute on a plate 
shaker at 600 rpm and incubated at room temperature for 2 hours. Plates were washed five 
times with washing buffer as previously described. Detection antibody (biotinylated anti-
bovine CXCL10, rabbit antiserum purified by bovine CXCL10 affinity chromatography, 
1mg/ml, Kingfisher Biotech) was diluted 1:5000 to achieve a final concentration of 0.2 µg/ml 
in 1 % BSA/PBS, this was dispensed at 100 µl/well. Plates were covered with an adhesive 
film and incubated at room temperature for 1 hour. Plates were then washed 5 times with 
washing buffer as previously described. 
Streptavidin-horseradish peroxidase (HRP) was diluted 1:2000 in 1 % BSA/PBS, this dilution 
was then dispensed into wells at a volume of 100 µl/well. Plates were covered with adhesive 
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film and incubated for 30 minutes. Plates were washed 5 times with washing buffer as 
previously described.  
3,3’,5,5’-tetramethylbenzidine liquid substrate system for ELISA (TMB) was added at a 
volume of 100 µl/well, plates were incubated for between 5-15 minutes, depending on the 
speed of the reaction. Once wells had turned sufficiently blue, 100 µl/well stop solution 
(0.5M sulphuric acid) was added. Plates were gently tapped to ensure thorough mixing. 
Absorbance was read immediately using an ELISA reader at 450nm. The CXCL10 standard 
on each plate was used to produce a standard curve with which all samples (on the same 
plate) CXCL10 concentrations were determined. 
3.16.5 Determination of bovine Interleukin-17a (IL17a) by sandwich ELISA 
Ninety-six well immuno-plates were coated with 100 µL anti-bovine IL17a capture antibody 
(rabbit antiserum, bovine IL17a affinity chromatography, 1mg/ml, Kingfisher biotech) 
diluted 1:800 to 1µg/ml in 0.05M carbonate-bicarbonate buffer pH 9.6. Plates were sealed 
with an adhesive film and incubated overnight at 4°C and stored for up to 7 days. Prior to 
use, plates were washed twice with 200 µL/well PBS pH 7.4. For each wash, wells were 
filled with buffer and gently tapped for a few seconds before emptying and pounding on a 
paper towel.  
Emptied wells were blocked with 200 µL/well 3 % BSA/PBS pH 7.4 for 60 minutes at room 
temperature. Following this, plates were washed twice with washing buffer.  Each well was 
then filled with 50 µL 0.1 % BSA/PBS followed by 50 µL/well of standard, sample or blank. 
Plates were covered with an adhesive film, shaken for approximately 1 minute on a plate 
shaker at 600 rpm and incubated at room temperature for 2 hours. Plates were washed four 
times with washing buffer as previously described. Detection antibody (biotinylated anti-
bovine IL17a, rabbit antiserum purified by bovine IL17a affinity chromatography, 1 mg/ml, 
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Kingfisher Biotech) was diluted 1:1000 to achieve a final concentration of 0.2 µg/ml in 0.1 % 
BSA/PBS, this was dispensed at 100 µl/well. Plates were covered with an adhesive film and 
incubated at room temperature for 1 hour. Plates were then washed 5 times with washing 
buffer as previously described. 
Streptavidin-HRP was diluted 1:2000 in 0.1 % BSA/PBS, this dilution was then dispensed 
into wells at a volume of 100 µl/well. Plates were covered with adhesive film and incubated 
for 30 minutes. Plates were washed 5 times with washing buffer as previously described.  
TMB was added at a volume of 100 µl/well, plates were incubated for between 5-15 minutes, 
depending on the speed of the reaction. Once wells had turned sufficiently blue, 100 µl/well 
stop solution (0.5 M sulphuric acid) was added. Plates were gently tapped to ensure thorough 
mixing. Absorbance was read immediately using an ELISA reader at 450 nm. The IL17a 
standard on each plate was used to produce a standard curve with which IL17a concentrations 
were determined for all samples (on the same plate). 
3.16.6 Determination of bovine TNF-α, IL10, IL1-β and IL12 using a Mesoscale Discovery 
Electrochemiluminesence (ECL) Multiplex Assay 
MULTI-SPOT® 96-Well-7 Spot Plate Prototype Bovine 5-plex coated with bovine Il-1β, 
IL10, IL12, IL6 and TNF-α monoclonal capture antibodies (MSD) were used to determine 
the respective cytokines from the harvested supernatants. The IL6 assay was not used. 
Plates and required diluents were brought to room temperature. Diluent 7 and 8 were checked 
for solid material. If present, the diluents were warmed to 37˚C. If the solid material persisted 
the diluents were filter sterilized using a 0.2 µm filter.  
Diluent 7 was added in 50 µL volumes to each well to block the primary antibodies. Plates 
were sealed with a clear adhesive cover and incubated for 30-60 mins with vigorous shaking 
(600rpm) at room temperature. During the incubation a standard master mix was created. IL-
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1β (0.8 µg/ml), IL10 (5142 U/ml), IL12 (1550 U/ml) and TNF-α (4 µg/ml) standard stocks 
were stored at -80˚C and thawed at room temperature. Standards were diluted in cell culture 
medium to achieve final concentrations shown in Table 3.6. 
cytokines stock final concentration final dilution 
IL1-β 0.8 µg/ml 20 ng/ml 1:40 
IL10 5142 U/ml 180 U/ml 1:28.6 
IL12  1550 U/ml 500 U/ml 1:3.1 
TNF-α 4 µg/ml 80 ng/ml 1:2.5 
Table 3.6 Cytokine standard dilution scheme for use in the determination of bovine cytokine 
levels using the MSD format. 
The standard master mix was further diluted 1:3 seven times to produce 8 standard 
concentrations with which a standard curve was generated.  
Blocking buffer was removed by banging the plate on a paper towel. 25 µL/well of standards 
and samples was added to each plate, before sealing with a clear adhesive cover and 
incubating for 2h at room temperature with vigorous shaking. Wells were then washed three 
times as previously described in 3.16.4, with wash buffer from the BOVIGAM kit. Il-1β, 
IL10, IL12 and TNF-α detection antibody-SULFO-TAG™ was added to diluent 8 to achieve 
a final concentration of 1x (2760 µl diluent 8 + 60 µ each antibody for 1 plate). 25 µL per 
well was added of the detection antibody mix and plates were covered with adhesive foil and 
incubated for 1 hour at room temperature with vigorous shaking. Adhesive foil is use as the 
SULFO-TAG™ antibodies are light sensitive. Plates were washed a further 3 times.  
Following washing, 150 µL of 2x read buffer (4x diluted 1:2 with MilliQ water) was added to 
each well and the plates were read immediately using a SECTOR® Imager 6000. Standard 
curves were generated and used to convert ECL readings to concentration (ng/ml). 
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Chapter 4 
Transposon Library Creation and Experimental 
Validation using the Mycobacterial Heat-shock 
Response and Isoniazid Resistance Mechanisms 
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4.1 Introduction  
This chapter describes the generation of a BCG transposon mutants library using the mariner-
based transposable element, pMycoMar, delivered via a temperature sensitive phage- 
φMycoMarT7 (Rubin et al., 1999; Sassetti, Boyd and Rubin, 2001). Mariner is an insect 
derived transposon capable of efficiently inserting across domain boundaries. The transposon 
contains a kanamycin resistance gene to allow for the selection of transposon mutants, as well 
as a T7 promoter to promote transcription into the adjacent chromosomal DNA. The 
phagemid also contains the hyperactive C9 Himar1 transposase gene, which catalyses the 
insertion of the transposon 50 times more efficiently compared to a non-hyperactive 
transposase (Lampe et al., 1999; Sassetti, Boyd and Rubin, 2001). This transposon and 
delivery system has previously been used with great success to investigate a multitude of 
concepts, including; mycobacterial metabolism, virulence and gene essentiality (Sassetti, 
Boyd and Rubin, 2001; Sassetti and Rubin, 2003; Goldstone et al., 2009; Mendum et al., 
2015). Libraries generated using φMycoMarT7 have high gene coverage with often multiple 
potential TA insertion sites within a single gene.  An issue previously encountered with 
transposon libraries generated in this way is that small genes, with few TA sites present, tend 
to be under-represented (DeJesus et al., 2017). Approximately 9 % of the TA sites present 
were less permissible for insertion (DeJesus et al., 2017).  This is mainly of concern when 
investigating gene essentiality.  As the basis of this study was to screen a transposon library 
and identify proteins with potential antigenic properties, a definitive list was not required.  
The MycoMarT7 transposon inserts into TA sites within the mycobacterial genome, of which 
there are approximately 70,000 present in M. bovis (Sassetti, Boyd and Rubin, 2001). A large 
amount of the TA sites are located within essential genes and therefore mutants with 
insertions in these sites would not yield colonies.  
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Previous transposon libraries have been generated in other mycobacterial strains, such as M. 
tuberculosis, M. marinum and M. bovis BCG Pasteur (Sassetti, Boyd and Rubin, 2001; 
Griffin et al., 2011; Weerdenburg et al., 2015; DeJesus et al., 2017). This is the first instance 
in which a BCG Danish transposon library was required, therefore a BCG Danish library was 
generated. BCG Danish is the licensed strain for human vaccination in the UK and is also 
used in cattle experiments in the UK (Chambers et al., 2014).  It was expected that 
transposition of BCG Danish would yield approximately 105 transposon mutants due to 
previously created BCG Pasteur libraries achieving this level of saturation (Sassetti, Boyd 
and Rubin, 2001).   
It is essential to characterise the library in terms of coverage and ‘selectability’ so that it can 
be used in animal experiments with confidence. To do this, two validation selections, heat-
shock and INH sensitivity, were completed prior to the planned animal experiment to ensure 
the library was suitable. The aim of these selections was to identify genes known to be 
important in the respective pathways, for example hspR in the heat-shock selection and katG 
in the INH selection. hspR is a key repressor in the mycobacterial heat-shock response. It was 
expected that transposon insertions within this gene confer heat-shock resistance due to the 
constitutive expression of the Hsp70 operon (Stewart et al., 2002). More hspR mutants were 
therefore expected to be seen in the heat-shock selected library. The catalase-peroxidase 
KatG is required for INH activation and loss of function of KatG is known to produce INH 
resistant colonies (Ying Zhang et al., 1992). katG transposon mutants were expected to 
become resistant to INH. These two genes, hspR and katG, were ‘control’ genes, the presence 
of which in the analysis would reveal whether the library was suitable for animal 
experiments.  
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The specific objectives of this chapter were to: 
1) Create a saturated Mycomar transposon library in M. bovis BCG Danish 
2) Validate the use of the transposon library in selective screens by using the 
mycobacterial heat-shock response and INH resistance mechanisms. 
4.2 Generation of a Himar transposon mutant library in BCG 
4.2.1 Amplification and Quantification of MycoMarT7 phage 
The MycomarT7 temperature sensitive phage carries the Himar-1 transposon and is used to 
deliver the transposon to the mycobacterium genome. An initial MycoMarT7 phage stock 
was provided by Dr Tom Mendum (originally sourced from C. Sassetti (Sassetti, Boyd and 
Rubin, 2001)). To obtain a high titre phage suspension suitable for generation of a 
comprehensive mutant library in BCG, the MycomarT7 was amplified in M. smegmatis mc2 
155 cells.  M. smegmatis were grown to late log phase and 100 ml mixed with 1 ml of initial 
phage stock. This was then plated on NB2 at a dilution to achieve “lacey” plates. After 3 
days, plaques were obvious and the phage were harvested and filtered to produce a bacterium 
free phage stock solution (Section 3.2). The titre of the phage stock was determined by 
plaque assay with M. smegmatis to be 2.7 x 1010  PFU/ml. 
4.2.2 Mycomar7 transduction and Transposon mutant selection 
10 ml of the φMycoMarT7 stock was used to infect 100 ml of late log BCG as described in 
the methods (Section 3.3). The transductions were plated out on modified 7H11 and the 
resultant kanamycin resistant transposon mutants harvested into 10 % glycerol and frozen. 
The number of mutants in the library was assessed by plating out serial dilutions. Two mutant 
libraries were made by myself and several others by the researcher working on the BBSRC 
funded project that is linked to this PhD and shares the control animal group in the cattle 
infection experiment (Chapter 6). The mutant libraries were assessed to contain 8x104 and 
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1.7x104 CFU (mutants). The largest library was taken forward for validation of transposition 
and library complexity as well as validation of the selection and TnSeq procedure before use 
in subsequent animal experiments. 
4.3 Verification of transposition by individual Transposon Insertion Site sequencing  
Single mutants from the library generated above were sequenced to ensure true transposition 
had occurred. Single mutants were grown in broth and genomic DNA extracted (Section 
3.6.1). The insertion sites were amplified by PCR using a hemi-nested PCR anchored in the 
Himar transposon and the sequences determined by Sanger sequencing from the transposon 
out across the insertion site. The sequences were analysed to confirm the presence of TA 
nucleotides at the transposon insertion site. A by-product of this process was that an archive 
of individual BCG mutants was obtained. All of the strains sequenced and identified can be 
seen in Table 4.1.   
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Gene 
Product 
Cholesterol 
catabolism 
In vivo 
survival 
cadI Cadmium inducible protein   
cyp125 Probable cytochrome P450  x  
cysM Probable cysteine synthase    
dinF Possible DNA-damage-inducible Protein   
esxN Function unknown   
fadD35 Probable fatty-acid-CoA ligase    
far Probable fatty-acid-CoA racemase   
gcvB Probable glycine dehydrogenase   
icd1 Probable isocitrate dehydrogenase   
iunH Probable nucleoside hydrolase   
katG Catalase-peroxidase-peroxynitritase   
lprN Possible MCE-family lipoprotein x x 
lysX Lysyl-tRNA synthetase  x 
mmpL5 Probable conserved transmembrane transport protein   
papA2 Possible conserved polyketide synthase associated protein x  
PE2 PE family protein   
pepN Probable aminopeptidase N   
pncB1 Nicotinic acid phosphoribosyltransferase   
PPE28 PE family protein   
PPE37 PE family protein   
PPE5 PE family protein   
Rv0043c Probable transcriptional regulatory protein   
Rv0074 Conserved protein   
Rv0176 Probable conserved Mce associated transmembrane protein  x 
Rv0178 Probable conserved Mce associated membrane protein   
Rv0497 Probable conserved transmembrane protein   
Rv1337 Probable intergral membrane protein   
Rv1360 Probable oxidoreductase   
Rv1364c Possible sigma factor regulatory protein   
Rv1706A Conserved hypothetical protein   
Rv1882c Probable short-chain type dehydrogenase reductase   
Rv1993c Conserved protein   
Rv2896c Conserved hypothetical protein   
Rv3220c Probable two component sensor kinase   
Rv3253c 
Possible cationic amino acid transport integral membrane 
protein 
  
Rv3312c Conserved hypothetical protein   
Rv3703c Conserved hypothetical protein   
Rv3725 Possible oxidoreductase   
Rv3830c Transcriptional regulatory protein   
Rv3835 Conserved membrane protein   
Table 4.1 Isolated individual transposon insertion mutants. Presence of MycoMar transposon 
insertion at TA sites confirmed using Sanger sequencing. Gene essentiality for cholesterol 
catabolism and in vivo survival noted (Sassetti and Rubin, 2003; Griffin et al., 2011). 
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The majority of the sequences could be aligned to the M. bovis genome using the BLAST 
tool. TA nucleotides were seen at all transposon insertion sites when the insertion site could 
be located. In some cases, the sequence could not be aligned to the genome, this was mainly 
due to numerous unidentified bases (N) being present in the sequence result. None of the 
sequenced mutants had insertions within genes essential for M. bovis growth. As a substantial 
number of the TA sites occur within essential regions it is not possible to hit all the TA sites 
in the genome, making the number of mutants obtainable substantially less than 70,000. 
Although only a small number of transposon mutants were sequenced compared to the 
overall size of the libraries, no mutant was sequenced twice which could suggest an insertion 
bias is not overtly present. Genes identified with transposon insertions were spread across the 
genome, showing no evidence of a hotspot. Multiple insertions within a single strain have 
also not been found. A variety of genes with varying functions were shown to have inserts 
suggesting there is no bias towards a certain gene-family or function.  
4.4 Characterisation of the library by TnSeq 
A more detailed assessment of the complexity of the library could be provided by parallel 
sequencing of transposon insertion sites using next generation sequencing. There are many 
variants of this technique but the version adapted for this project was based on that described 
by Griffin et al 2011 (Griffin et al., 2011) which they called TnSeq. TnSeq was used here for 
the tracking and relative quantitation of the BCG library during infection of cattle lymph 
nodes (Chapters 5 and 6). Thus, it was necessary to demonstrate that TnSeq was a robust 
technique for en masse identification and quantitation of mutants in pools subjected to 
selective pressure; as it would be unethical to start animal experiments using reagents and 
techniques that had not been properly characterised and validated. Two selection experiments 
of the library were performed. The first involved selection of the mutant library during heat 
stress and the second involved selection of the library during exposure to the anti-
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mycobacterial antibiotic-isoniazid. In each case, mutant survival/fitness was assessed by 
TnSeq. In addition to validating the library and screening protocols, these experiments had 
the potential to produce novel understanding of the heat-shock response and isoniazid action. 
4.4.1 TnSeq of a heat stress selected BCG mutant library 
4.4.1.1 Optimisation of Heat-shock Selection Conditions 
Prior to the heat-shock selection of the transposon library, the optimal conditions of the 
selection had to be determined. A culture of log phase wild-type BCG Danish (1.2x108                                                                                  
CFU/ml) was incubated at 53˚C for 90 minutes (Group et al., 2001). A kill curve was 
generated from which an appropriate incubation time was selected to achieve an approximate 
4 log kill (Figure 4.1).   
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Figure 4.1 - Survival of BCG Danish at 53°C over a 90-minute period. A desired kill was 
achieved between the 60-90-minute period, resulting in an approximate 4 log reduction in the 
number of colonies. A room temperature control was completed which showed no reduction 
in the number of colonies over the period. 
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A 4-log kill was achieved between the 30 and 60-minute period. As the subsequent 
experiment is looking for mutants resistant to heat-shock, the 90-minute incubation was 
chosen as this yielded the lowest number of colonies i.e. the highest selection pressure. These 
surviving colonies following heat-shock should be enriched for mutants with heat stress 
resistance.  
4.4.1.2 Transposon mutant library Heat-shock Selection 
Heat-shock resistant mutants were selected using the optimised conditions determined from 
the experiment completed in 4.4.1.1. The heat stressed and control unselected broths were 
plated on 7H11 agar and grown to small colonies. Colony forming units were counted to 
monitor the extent of the selection. There was a 4 log kill in heat stressed BCG as compared 
to an untreated control, which was the intended level of killing (Figure 4.2). The colonies 
were harvested from the plates and genomic DNA extracted from each pool of mutants 
(Section 3.8). 
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Figure 4.2 Survival of BCG transposon library during 53˚C heat-shock after 90 minutes. 
Average CFU/ml post heat shock selection. The average CFU/ml for the heat shocked 
cultures was 6x103. An approximate 4log kill was achieved. Control counts were completed 
once. Heat-shock n=3. 
4.4.1.3 Heat-shock Transposon Library DNA Preparation for TnSeq 
The genomic DNA from the control and heat selected mutant pools was prepared for TnSeq 
sequencing as described (Section 3.8) The DNA first was sheared by sonication and checked 
for sufficient quantity and fragment size on an agarose gel. Figure 4.3 shows a smear at the 
500 bp mark, this is what was expected and shows that the DNA preparation was proceeding 
as intended.  The DNA was also quantified at this stage. This confirmed that DNA was 
present in the first well but, due to the size of the smear and quantity of DNA present, it could 
not be visualised.  
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Figure 4.3 Sheared heat-shocked transposon library DNA visualised on a 0.8% agarose gel. 
Gel electrophoresis was completed at 100 V for 60 minutes. Smeared bands can be seen 
around the 500 bp mark, confirming correct shearing. Heat-shock library 1 (HS1) band 
appears faint due to low DNA concentration present in the well. 
Following shearing, DNA was blunt end repaired and A-tailed. Neither of these processes 
could be visualised, therefore only DNA concentrations were determined to ensure DNA was 
not lost post clean up. The concentration of the samples was consistent throughout. 
Adapter sequences were ligated onto the prepared DNA, which could not be visualised, and 
the prepared DNA was amplified using the qPCR protocol described (Section 3.9). This 
process allowed the optimal cycle number for each individual library to be determined. This 
stage was required as it prevented PCR artefacts from accumulating, whilst allowing the 
index sequences to ligate to the library DNA.  
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Figure 4.4 Optimisation of PCR conditions for preparation of transposon containing DNA 
isolated from heat-shock selected and control transposon libraries for sequencing library 
preparation. A cycle number corresponding to mid-log phase amplification was selected to 
reduce the effect of PCR artefacts on the TnSeq. The following cycle numbers were selected- 
HS1: 26, HS2: 25, HS3: 25, C1: 28, C2: 25, C3: 27. 
Eva Green© dye alone does not fluoresce, once bound to dsDNA fluorescence is seen. This 
allows the quantity of DNA generated after each cycle to be visualised, and therefore the 
optimal cycle number for the preparative PCR to be selected (Figure 4.4). Each DNA 
preparation was labelled with primers carrying a different index sequence. The preparations 
were amplified for 40 cycles with real-time monitoring to determine the optimum cycle 
number for the individual samples. Heat-shock library 1 (HS1), HS2 and HS3 were amplified 
for 26, 25 and 25 cycles respectively. Control 1 (C1), C2 and C3 were amplified for 28, 25 
and 27 cycles respectively. Control amplifications consisting of primer with no DNA present 
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were also amplified to ensure the fluorescence seen was not through primer dimer production. 
The controls typically started to fluoresce at significant levels at cycle 30. 
Following the preparative PCR in which larger volumes of prepared DNA were amplified 
and separated on agarose gels (Figure 4.5). Fragments of approximately 250-750 bp were 
extracted from the agarose gel to ensure products of the correct size were quantified and 
sequenced.  
 
 
Figure 4.5 Preparative PCR reactions of heat-shock and control libraries.  a) HS1, b) HS2, 
c) HS3, d) C1, e) C2, f) C3. 200 µL reactions split into 7 wells containing approximately 28 
µL of product. Bands of around 500 bp were excised and DNA extracted to ensure fragments 
of correct size were sequenced.  
The cleaned-up fragments were quality checked on an Agilent bioanalyzer (Figure 4.6) 
allowing the size of the DNA fragments to be assessed more reliably than visualisation on an 
agarose gel. This also enables identification of unexpected amplification products which acts 
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as a level of quality control during the DNA preparation process; if unexpected bands were 
seen the DNA could be rerun on an agarose gel and bands excised with more stringent 
parameters to avoid taking unwanted products.  
Figure 4.6 Agilent bioanalyzer analysis of heat-shock and control libraries. Plots show DNA 
size/migration time versus fluorescence intensity. Sheared DNA centred at approximately 500 
bp is a 'bump' along the x-axis, the surface area under the curve can be used to estimate the 
DNA concentration. At either end of the x-axis are DNA markers which enable the 
determination of fragment size. 
The area under the curve around the 500 bp mark on the x-axis allows an approximation of 
the quantity of DNA present. For a more reliable assessment of the quantity of prepared 
DNA, which would ensure the required sample concentration was achieved for TnSeq, a 
Quantus Fluorometer was used (Table 4.2). The amplified DNA was then sent for single read, 
double index sequencing on an Illumina HiSeq platform. 
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Reaction DNA Quantity ng/µl 
HS1 7.9 
HS2 6.8 
HS3 11 
C1 12 
C2 12 
C3 8.8 
Table 4.2 DNA concentrations from excised bands post qPCR amplification of heat-sock and 
control libraries measured using Quantus Fluorometer.  
It is important to note the above TnSeq sequencing library preparation process was completed 
for all transposon pools throughout this thesis and similar gel/bioanalyzer images were 
obtained. For the sake of brevity these preparative steps will not be described and in this or 
subsequent chapters. Data regarding the preparation of the INH selected library can be found 
in Appendix 4.1. 
4.4.1.4 TnSeq Data Sorting and Analysis 
Raw TnSeq data was sorted and preliminarily analysed by Dr Huihai Wu, University of 
Surrey core bioinformatics support. Dr Wu had developed a pipeline (with help from Dr Tom 
Mendum) in which raw TnSeq data is filtered and sorted, producing data sets in a readable 
and analysable format. Figure 4.7 provides an example of how the raw data is received. The 
read represents the transposon and the disrupted gene, index 1 is the barcode which was 
incorporated to allow distinction between libraries when multiplexed and index 2 allows for 
the removal of PCR artefacts. These sequences could be matched due to them all having the 
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same unique position on the flow cell.  Spreadsheets were generated showing each TA site 
within every gene and the number of transposon insertions found within each of those TA 
sites. This was produced for every library in both heat-shock and control groups. This made it 
possible to compare transposon insertions between the groups and for conclusions to be 
drawn as to which mutants/genes are linked to the heat-shock response of M. bovis BCG.  
 
 
Figure 4.7 Example data obtained via one read two index Illumina sequencing. Read 1 shows 
the transposon sequence plus insertion site. Index 1 is from the barcode adaptor incorporated 
into the sequence to allow identification of libraries. Index 2 allows PCR artefacts to be 
removed. The sets of reads can be matched due to the unique position on the flow-cell they all 
share.  
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Sample 
Number 
of reads 
Read quality 
filter Transposon filter 
Aligned, Deduplicate, Map 
quality filter  
Bowtie2 overall 
alignment rate 
No. % No. % No. % 
HS1 3654277 3429073 0.938 3074735 0.841 2190900 0.600 92.73 % 
HS2 3053052 2941816 0.964 2767073 0.906 1962391 0.643 94.52 % 
HS3 7126854 6780295 0.951 6331425 0.888 3957812 0.555 93.32 % 
C1 1300055 1156268 0.889 1081511 0.832 713752 0.549 91.60 % 
C2 1062303 1006263 0.947 927206 0.873 667115 0.628 94.95 % 
C3 1560197 1463938 0.938 1387053 0.889 1004266 0.644 94.52 % 
Table 4.3 Heat-shock and control library TnSeq data sorting and filtering. Raw read data 
processing and filtering of heat-shock libraries lead to an approximate loss of 40 % of all 
reads. The largest loss was due to the removal of PCR duplicates. The difference between the 
lost reads for each library was statistically insignificant, suggesting the issue did not lie in 
the sample preparation but the protocol itself. 
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Initially, the number of reads per sample was determined (Table 4.3). There was, however, a 
disparity between the number of reads counted in the heat-shock samples and the control 
samples. The impact of this was reduced by normalising the counts before analysis. The first 
step of the data processing involved removing reads that did not have the required Q (quality) 
score, which was set at 50 (Illumina, 2011). If the read quality was lower than 50, which 
represents a 1 in 100,000 chance a nucleotide was miscalled, the read was not used. This led 
to the loss of approximately 6 % of the reads. The subsequent filter was applied in order to 
select reads with the transposon sequence (TGTTA), leading to a further loss of 10 %. PCR 
duplicates were removed and the remaining reads were mapped to the reference BCG 
genome using Bowtie2. This step lead to the largest loss of reads. Approximately 26 % of all 
reads were lost at this stage. The difference between the loss of reads per library was 
statistically insignificant, suggesting the loss was not due to variation in the sample 
preparation but due to the protocol and filtering parameters.  
The M. tuberculosis H37Rv genome contains 4,018 genes coding proteins, with 625 ORF’s 
being essential for growth in vitro (15.6 %) (DeJesus et al., 2017). The M. bovis genome 
contains 3,952 genes coding proteins. The M. bovis genome is >99.95 % identical at the 
nucleotide level to that of M. tuberculosis (Garnier et al., 2003).  This would suggest that if a 
similar level of essentiality is seen, assuming that essential genes between the two species are 
highly conserved, that approximately 590 genes are essential in M. bovis. Knowing this 
enables the quality of the transposon library to be assessed, as transposon inserts within 
essential genes would not yield any colonies. Therefore approximately 3300 gene mutants of 
non-essential genes were expected to be seen.  
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Sample 
Counted mutants 
No. Genome coverage 
HS1  3281 83% 
HS2  3285 83% 
HS3  3350 84% 
C1   3246 82% 
C2   3242 82% 
C3   3272 82% 
Table 4.4 Heat-shock and control libraries unique gene insertion mutants quantified as 
percentage of total gene number. Approximately 3300 mutants were expected to be seen. This 
demonstrates that gene insert saturation was achieved. Little variation was seen between 
gene inserts in all heat-shock and control groups. 
Each library was shown to have approximately 3300 unique genes with a transposon insertion 
(post processing), suggesting saturation was close to being achieved in all libraries (Table 
4.4). This allows the data to be analysed with confidence. If a fraction of the genes had inserts 
present, comparisons between pools could not be made due to the possibility of relevant 
genes being missed. However, as gene inserts were equally high amongst all pools all data 
sets could be compared.  
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Sample 
Counted mutants 
No. Genome coverage 
HS1  21537 29 % 
HS2  21544 29 % 
HS3  23235 31 % 
C1   19731 27 % 
C2   19912 27 % 
C3   20937 28 % 
Table 4.5 Heat-shock and control libraries unique TA site mutants quantified as percentage 
of total TA dinucleotide number. TA site transposon insertion saturation was low, leading to 
potential loss of data reliability due to the lack of insertion site variability. 
Alongside the recording of the number of transposon insertions within a given gene, the 
number of transposon insertions in specific TA sites was also monitored. The M. tuberculosis 
genome contains >70,000 TA dinucleotide sites; the calculated number of TA sites hit with 
this sequence run was a fraction of the total number of TA sites (Table 4.5). Re-sequencing 
the libraries has the potential to discover more TA inserts, or recreating the library so that TA 
site saturation is higher might improve coverage. Low TA saturation can be problematic. If 
there is a specific TA site within a gene that leads to the cell being less fit in the tested 
condition, this site could be missed if the saturation is not high enough. Low saturation can 
also make genes without insertions look essential or of importance in the tested (heat-shock) 
condition, when in actuality the gene has no role. This problem is greatened when looking at 
small genes with only a few TA sites (DeJesus et al., 2017). However, the gene coverage in 
the mutant pools in this experiment was high and thus problems of low TA saturation were 
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avoided by combining all TA insertions within a gene for the Rank Product analysis of 
mutant relative fitness/abundance in the conditions.  
4.4.2 Identification of Genes Involved in the M. bovis BCG Heat-shock Response  
The mycobacterial heat-shock response has been well studied (Stewart et al., 2002; Young & 
Garbe, 1991), therefore genes that are known to be regulators or involved in the pathway can 
be used as controls to ascertain the successfulness of the heat-shock selection and TnSeq 
procedure. For example, the protein HspR is a known negative regulator in the heat-shock 
response and ∆hspR mutants have been shown to increase M. tuberculosis survival under 
stress conditions (Stewart et al., 2001). HspR expression leads to repression of the Hsp70 
(DnaK) operon and other chaperones such as GroES, ClpB and Acr2 (Stewart et al., 2002). 
HspR is a DNA-binding protein which binds to either of two inverted repeat sequences 
(HAIRs) located in the promotor region of these genes and represses expression in unstressed 
conditions (Grandvalet et al, 1999). The Hsp70 operon consists of hsp70 (dnaK), grpE, dnaJ 
and hspR. DnaK has a role in the refolding of misfolded proteins that are essential under 
stress conditions as well as preventing aggregation of protein complexes (Hesterkamp and 
Bukau, 1998; Mogk et al., 1999). GrpE and DnaJ jointly stimulate the ATPase activity of 
DnaK, which otherwise possesses weak ATPase activity, therefore aiding the refolding 
ability of DnaK (Liberek et al., 1991). Acr2 is a small chaperone of the alpha-crystallin 
family and is thought to be involved in preventing protein aggregation during denaturing 
conditions. GroES is part of the GroE protein folding system. It was expected that 
hspR::mycomarT7 would result in increased resistance to heat-shock compared to wild-type 
due to the resulting constitutive expression of the Hsp70 operon and other regulated 
chaperones due to the lack of transcriptional repression.   
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It was evident when viewing the raw insertion data prior to Rank Product analysis that TA 
sites within the hspR gene had more transposon insertions in the heat-shock group compared 
to that of the control group. The significance was confirmed using rank product analysis (pfp 
< 0.1). This acted as a validation of the selection and experimental conditions. Transposon 
insertions within hspR lead to loss of function of the gene, therefore the Hsp70 operon is 
constituently expressed, resulting in heat-shock resistance. Genes with significantly (pfp < 
0.1) higher transposon insertions in the heat-shock group compared to the control are shown 
in Table 4.6. 
Gene 
Function 
Fold-
change 
hspR Heat shock protein transcriptional repressor 0.12 
mpb83 Cell surface lipoprotein 0.10 
Table 4.6 Genes with significantly more transposon inserts in the heat-shocked libraries 
compared to control libraries (pfp <0.1). hspR is a repressor of the mycobacterial heat-shock 
response. Mpb83 is a major antigen and has previously not been linked with the heat-shock 
response. Neither genes are essential for cholesterol metabolism or predicted to be for vivo 
survival (Sassetti and Rubin, 2003; Griffin et al., 2011). 
Another heat-shock regulator, hrcA, which has a role as a repressor in the system was of 
interest in this study. hrcA acts as a transcriptional controller of the Hsp60/GroE heat-shock 
family of proteins(Stewart et al., 2002). GroEL monomers assemble to create a heptameric 
cylinder which allows proteins to fold within it without risk of external protein interaction 
(Sigler, Xu and Horwich, 1997).  Interestingly, hrcA inserts were not more abundant in heat-
shock selected library. Inserts were found within this gene in both groups, but the pfp value 
generated from the analysis was >0.1 This could potentially be due to a loss of fitness with 
these mutants resulting in a slower growth rate. A lower growth rate would mean individual 
mutants are at a disadvantage when being pooled for sequencing. The study completed by 
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Stewart et al (2002) investigating the effect of a hrcA deletion on gene regulation could not 
delete this gene from M. tuberculosis. Perhaps expression of DnaK is a more relevant 
response to the selection in this experiment, high temperature. The monomeric protein has a 
role in prevention of misfolded protein aggregates, which with this type of selection may be 
the biggest risk to the survival of the mycobacterial cell as opposed to the correct folding of 
misfolded polypeptides of initial folding of de novo proteins, which is likely the primary role 
of GroE.  
There was only one other gene that was flagged as having significantly more insertions in the 
heat-shock group compared to the control group, which would indicate that its loss 
engendered heat shock resistance. This gene was mpb83. Mpb83 is a major M. bovis secreted 
lipoprotein antigen (Wiker, 2009). BCG Danish is known as a low-producer of Mpb83 
(Charlet et al., 2005), due to a mutation in the start codon of sigK. SigK is the positive 
regulator of Mpb83 and the paralogous secreted protein, Mpb70 (Veyrier, Saïd-Salim and 
Behr, 2008), making the significance of this finding difficult to determine although Mpb83 is 
still present in the cell wall of this strain. The function of Mpb83 is not known so it is 
difficult to interpret the apparent heat stress resistance of mpb83∆ strains. One explanation is 
that the absence of the cell wall associated mpb83 stresses the cell, leading to upregulation of 
general stress responses which in turn would increase the cell’s resistance to heat-shock, as 
well as other stress conditions. It would be interesting to examine the resistance of mpb83 
mutants to other stresses including antibiotic treatment. 
At the other end of the data (Table 4.7), the transposon insertions that lead to increased 
susceptibility to heat-shock, there are again known examples that can be used as controls to 
validate the selection. Transposon insertions in ponA2 have been previously shown to 
increase susceptibility to heat-shock and other stress conditions in M. tuberculosis (Vandal et 
al., 2009). The data generated from the TnSeq heat-shock selection also shows this 
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interaction. The number of transposon insertions in the ponA2 gene in the control group is 
significantly higher than that in the heat-shock group. There are 690 times more inserts in the 
control group compared to the heat-shock group (the highest fold-change seen between 
groups-Appendix 4.2). This suggests the inactivation of the ponA2 gene leads to increased 
heat-shock susceptibility. The exact mechanism for why this occurs is unknown, however 
ponA2 is known to have transglycosylase and transpeptidase activities, which are relevant to 
peptidoglycan synthesis (Cole et al., 1998). Disruption of this could lead to cell wall 
vulnerabilities, resulting in increased susceptibility to stress conditions.  
Gene Function 
Fold-
change 
Cholesterol 
catabolism 
In vivo 
survival 
Rv2257c conserved protein N/A   
pknG Serine/threonine-protein kinase N/A   
Rv0774c Probable conserved exported protein N/A   
glcB Malate synthase G N/A   
Rv2086 conserved hypothetical protein N/A   
Rv0203 Possible exported protein N/A   
Rv2001 conserved hypothetical protein N/A   
ponA2 
bifunctional membrane-associated 
penicillin-binding protein 187.81   
Rv2272 
Probable conserved transmembrane 
protein 107.40   
lppZ conserved lipoprotein 66.42   
lppU conserved lipoprotein 64.01   
Rv1738 conserved protein 52.23   
Rv1269c conserved probable secreted protein 52.18   
Rv0776c conserved hypothetical protein 45.97   
cysW 
Probable sulfate-transport integral 
membrane protein ABC transporter 35.25   
gltA2 Probable citrate synthase I 28.83   
cmr 
Probable transcriptional regulatory 
protein 27.98   
Rv2177c Possible transposase 25.80   
Rv1096 Possible glycosyl hydrolase 25.52 x  
PE25 PE family protein 25.26   
Rv2190c conserved hypothetical protein 23.52   
Rv3353c conserved hypothetical protein 22.47   
ksgA Probable dimethyladenosine transferase 22.25   
pafC Proteasome accessory factor C 21.40   
Rv0948c Involved in the shikimate pathway 20.20   
Rv3856c conserved hypothetical protein 19.00   
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Rv0238 Possible transcriptional regulatory protein 18.54   
pqqE 
Probable coenzyme PQQ synthesis 
protein 16.62 x  
hycP hydrogenase 16.41   
Rv2859c Possible amidotransferase 16.00   
Rv1184c Possible exported protein 15.97  x 
treS Trehalose synthase 15.92   
clpB 
Probable endopeptidase ATP binding 
protein  14.71   
Rv0180c 
Probable conserved transmembrane 
protein 13.54   
Rv1062 conserved hypothetical protein 13.05   
Rv2406c conserved protein 12.93   
lppM Probable conserved lipoprotein 12.74   
Rv1825 conserved protein 11.86   
Rv0699 hypothetical protein 11.71   
Rv3160c Possible transcriptional regulatory protein 11.47   
aceE Pyruvate dehydrogenase E1 component 11.28  x 
Rv1301 conserved protein 11.23   
adoK Adenosine kinase 10.99   
ephD Possible short-chain dehydrogenase 10.47   
amiA2 Probable amidase 9.97   
Rv0049 conserved hypothetical protein 9.29   
lpqT Probable conserved lipoprotein 9.29  x 
Rv3548c 
Probable short-chain type 
dehydrogenase/reductase 9.28 x  
vapC44 Possible toxin VapC44 9.15   
Rv3438 conserved protein 9.11   
Rv1232c conserved protein 8.26   
Rv1006 Unknown protein 8.16   
Rv3843c 
Probable conserved transmembrane 
protein 7.77   
lipZ Probable hydrolase 7.74   
Rv2663 hypothetical protein 7.70   
Rv1823 conserved protein 7.26   
Rv1262c hypothetical hit-like protein 7.05   
Rv3400 Probable hydrolase 6.88  x 
fbpC Secreted antigen 85-C 6.86   
gcvB Probable glycine dehydrogenase 6.57   
pbpA Probable penicillin-binding protein 6.53   
Rv0825c conserved protein 6.50   
Rv0492A hypothetical protein 6.45   
pks6 
Probable membrane bound polyketide 
synthase 6.35   
rpmB1 50S ribosomal protein L28-1 6.28   
Rv1836c conserve protein 6.25   
rimI 
Ribosomal-protein-alanine 
acetyltransferase 6.19   
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Rv2170 GCN5-related N-acetyltransferase 6.14   
Rv2118c RNA methyltransferase 5.92 x  
Rv2393 RNA methyltransferase 5.57   
Rv0375c 
Probable carbon monoxyde 
dehydrogenase 5.56   
lpqU Probable conserved lipoprotein 5.27   
Rv1401 Possible membrane protein 5.22   
fadA5 Probable acetyl-CoA acetyltransferase 5.14 x  
Rv1312 conservedhypothetical secreted protein 5.01   
pckA 
Probable iron-regulated 
phosphoenolpyruvate carboxykinase 5.01   
ndh Probable NADH dehydrogenase 5.00   
fadE25 Probable acyl-CoA dehydrogenase 4.91 x  
rimJ 
Ribosomal-protein-alanine 
acetyltransferase 4.80   
Rv2869c Membrane bound metalloprotease 4.73   
Rv2910c conserved hypothetical protein 4.16   
mprA 
Mycobacterial persistence regulator 
MRPA 4.03   
ureA Urease gamma subunit 3.84   
Rv1930c conserved hypothetical protein 3.71  x 
furA Ferric uptake regulation protein 3.52   
Rv2635 hypothetical protein 3.11   
aofH 
Probable flavin-containing monoamine 
oxidase 2.94   
vapC28 Possible toxin VapC28 2.73   
lipR Probable acetyl-hydrolase/esterase 2.68   
Rv1126c conserved protein 2.53   
nirD Probable nitrite reductase 2.52   
Rv3364c conserved protein 1.05   
htpX 
Probable protease transmembrane protein 
heat shock protein    
Table 4.7 Genes with significantly more transposon inserts present in the control group 
compared to the heat-shock group (pfp <0.1), suggesting transposition into these genes leads 
to increased susceptibility to heat-shock. Genes are ordered by fold-change. N/A signifies an 
infinite fold-change due to division by 0. Gene essentiality for cholesterol catabolism and in 
vivo growth noted (Sassetti and Rubin, 2003; Griffin et al., 2011). 
Many genes were shown to increase susceptibility to heat-shock once transposon insertion 
had prevented the gene function. The fold change of these genes can be seen in Figure 4.6. 
Several of these genes (pknG, glcB, rv0203, rv0774c, rv2001, rv2086, rv2257c) had no 
inserts in the heat-shock group, leading to an incalculable fold-change. These genes could be 
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crucial in the heat-shock or stress response, but as many of their functions are unknown 
(rv0203, rv0774c, rv2001, rv2086, rv2257c) their exact role in heat stress resistance is 
difficult to ascertain. Another possibility is that these genes are essential (pknG) for 
mycobacterial growth but the transposon inserted into a non-essential region of the gene and 
therefore gene expression and therefore cell growth is not disrupted. Other genes with 
significantly less transposon inserts in the heat-shock group compared to that of the control 
include 39 conserved hypothetical proteins with unknown function, lipoproteins with 
unknown function (lppZ, lppU, lppM) and genes that were once thought of as essential for M. 
tuberculosis growth, but recent studies have now deemed non-essential (cysW, Rv1738) 
(DeJesus et al., 2017). The genes above all exhibited a high fold change in transposon inserts 
between the heat-shock and control groups. 104 genes in total were identified as being 
significantly involved in heat-shock susceptibility. However, the fold-change of the number 
of insertions was low (ranging from 1x to 692x more inserts, genes with no inserts in the 
heat-shock group had an ‘infinite’ fold-change) in a lot of these cases, therefore their stress 
sensitive phenotype may be less than those with a higher fold change (Appendix 4.2). Gene 
ontology analysis searching for enriched functional groups was completed on this data set 
and no statistically significant results were seen (False Discovery rate (FDR) < 0.05) (Mi et 
al., 2017). Several of these genes have been shown to be essential for in vivo survival and 
cholesterol metabolism (Sassetti and Rubin, 2003; Griffin et al., 2011). Cholesterol is a 
critical carbon source during chronic infection (Griffin et al., 2012). Disrupting genes that are 
involved in both heat-shock susceptibility and cholesterol catabolism could lead to the 
development of novel control approaches. As the heat-shock response aids in the survival of 
in vivo mycobacteria, it was not unexpected to find that genes that lead to heat-shock 
susceptibility were essential for in vivo survival (Stewart et al., 2002).  
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4.4.2 Isoniazid Selection and TnSeq Data Analysis 
The second selection experiment to test the TnSeq technique involved exposing the mutant 
library to a sub-MIC concentration of isoniazid with the aim of identifying mutants with 
enhanced susceptibility to isoniazid and also mutants with increased resistance. Initially, the 
optimal concentration of isoniazid to select for isoniazid susceptible/resistant transposon 
mutants had to be determined. The concentration used had to be at a sub-MIC level to 
identify mutants with an isoniazid susceptible phenotype.  The isoniazid MIC of BCG Danish 
was recorded to be 0.4 mg/L by the Staten Serum Institut (supplier of the strain used in this 
study). A fraction of this concentration was required; therefore 0.12 mg/L, 0.06 mg/L and 
0.03 mg/L were chosen to select for the susceptible mutants. The largest percentage of 
surviving BCG in the presence of INH was at 0.03 mg/L INH (Figure 4.8) however the 
variation between the counts was high and resulted in no significant difference in counts 
compared to the 0 mg/L control (p = 0.1618). Both 0.12 and 0.06 mg/L had significantly 
different counts (p = 0.006 and 0.0074 respectively) compared to the control when analysed 
using a two-tailed T-test. A concentration of 0.06 mg/L was used for the experiment group 
because it produced the smallest significant percentage kill (p = 0.007). 
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Figure 4.8 Determination of BCG Danish kill upon exposure to INH. BCG Danish grown in 
the presence of 0.12 and 0.06 mg/L isoniazid exhibited significantly different levels of 
colonies in comparison to the 0 mg/L control. 0.06 mg/L killed 25 % of mutants. 0.12 mg/L 
killed 49.9 % of mutants. Counts obtained at 0.03 mg/L were not statistically different to the 
control counts. Error bars represent standard deviation of three biological replicates.  
1.5 ml of frozen BCG Danish transposon mutant library stock was cultured for 3-4 weeks on 
either modified 7H11 with 0.06 mg/ml INH or unmodified 7H11 (Section 3.5). Recovered 
colonies were harvested for DNA extraction and sequencing library preparation as described 
in Section 3.6. 3 replicate selections and controls were processed for antibiotic treatment and 
control.  
The quality control steps previously completed for the heat-shock samples were also 
completed during the isoniazid DNA preparation steps. The TnSeq data received was 
processed using the same pipeline developed by Dr Wu for the heat shock experiment. The 
percentage of genes with transposon inserts in the control and isoniazid groups can be seen in 
Table 4.8. Comparing the control and isoniazid groups as a whole, there was on average a 7.7 
% difference in the number of mutants. The differences in the number of unique gene mutants 
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was statistically significant (t-test, p= 0.00026). The percentage does not take into account 
specific mutants and it could not be assumed the same mutants were missing within the 
groups. It could be hypothesised that these missing genes are involved in isoniazid resistance 
or susceptibility pathways.  
Sample 
Counted Gene Mutants 
No. Genome coverage 
CTR1 3322 84 % 
CTR2 3316 83 % 
CTR3 3289 83 % 
ISO1 3044 77 % 
ISO2 3004 76 % 
ISO3 2965 74 % 
 
Table 4.8 INH and control libraries unique gene insertion mutants as a percentage of total 
genes present in the BCG genome. An approximate 8 % average difference in number of 
individual gene mutants was seen between the isoniazid and control group. A statistically 
significant difference in the number of unique mutants was seen (p = 0.00026). 
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Sample 
Counted TA Mutants 
No. Genome coverage 
CTR1 21597 29 % 
CTR2 21478 29 % 
CTR3 20506 28 % 
ISO1 13906 19 % 
ISO2 13176 18 % 
ISO3 12950 18 % 
 
Table 4.9 INH and control libraries unique TA site mutants quantified as percentage of total 
TA dinucleotide number present in the BCG genome. An approximate 10 % difference in TA 
mutants was seen between the isoniazid and control treatment groups. The number of unique 
TA mutants between each group was statistically significant (p < 0.05).  
The number of TA mutants in the control group (Table 4.9) was similar to that in Table 4.5, 
confirming the size off the transposon library created at 2.1x105 TA mutants. The number of 
gene mutants counted in Table 4.8 shows good coverage of the genes non-essential for 
growth, as seen previously with the heat-shock data. The TA mutants, again, were not 
approaching saturation, but as the number of gene mutants was high, this was not seen as an 
issue. The only problem that may have arisen is that if an insertion at one TA site within a 
gene does not reduce the function of said gene, compared to an insertion in a different TA site 
within the same gene.  
Mutation in fifteen genes (Table 4.10) was shown to be associated with increased resistance 
to INH. The fold-change represents the difference in the number of transposon insertions, the 
larger the fold change to more relevant the gene. Genes known to be critical in the 
mycobacterial response to the stress conditions used, such as katG, were identified prior to 
analysis to enable the effectiveness of the analysis to be assessed. katG activates INH and 
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polymorphisms within this gene lead to INH resistance (Y Zhang et al., 1992). Large 
numbers of transposon insertions within this gene were expected to be seen in the group 
exposed to INH. The gene with the most significant increase in number of insertions was 
katG. The presence of katG validates the screen due to its known ability to confer resistance 
once its function has been lost (Ying Zhang et al., 1992). The presence of fadE24 on the list 
acted as a further validation. fadE24  has previously been linked with INH resistance in 
mycobacteria (Wilson et al., 1999; Ramaswamy et al., 2003). fadE24 is an acyl-CoA 
dehydrogenase, thought to be involved in the degradation of fatty acids into acetyl-CoA 
subunits (Wilson et al., 1999). The mechanism of resistance is currently unknown. 
Interestingly, other genes known to be involved in INH resistance such as inhA were not 
identified. InhA mutations resulting in INH resistance in mycobacteria isolated from clinical 
samples exhibit a missense mutation, changing a Ser to Ala at position 94 (Banerjee et al., 
1994). The amino acid change prevents INH from inhibiting InhA, an enzyme involved in 
mycolic acid synthesis (Banerjee et al., 1994). A transposon insertion within inhA results in 
expression of the gene being lost and therefore, mimicking the action of INH. This explains 
why no Tn::inhA mutants were seen in either group in this study. Resistance associated with 
gene mutations within promoter regions of genes that lack a specific ID would not have been 
identified with the statistical analysis used. For example, mutations within the fabG1-inhA 
promoter lead to INH resistance, but were not identified in this study (Ramaswamy and 
Musser, 1998). Naturally occurring mutations resulting in hyperexpression of ahpC are often 
seen in katG null INH resistant mutants (Sherman et al., 1996). This mutation was not seen in 
this study as it is thought to be a compensatory survival mechanism developed in katG 
mutants after several passages, due to the loss of the catalase/peroxidase activity (Sreevatsan 
et al., 1997; Wilson et al., 1998). 
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Gene Product Fold-Change Cholesterol 
catabolism 
In vivo 
survival 
katG Catalase-peroxidase-peroxynitritase T Kat G 0.01   
rv2700 
Possible conserved secreted alanine rich 
protein 0.03 
  
fecB 
Probable FEIII-dicitrate-binding periplasmic 
lipoprotein 0.07 
  
pckA 
Probable iron-regulated 
phosphoenolpyruvate carboxykinase 0.09 
  
rv2962c Possible glycosyl transferase 0.20   
rv2446c 
Probable conserved integral membrane 
protein 0.22 
  
fadE22 Probable acyl-CoA dehydrogenase 0.28  x 
devB Probable 6-phosphogluconolactonase 0.40   
adoK Adenosine kinase AdoK 0.42   
ponA2 
Membrane-associated penicillin-binding 
protein 0.48 
  
mmpS3 Probable conserved membrane protein 0.52   
rv2135c Conserved protein 0.55   
fadE24 Probable acyl-CoA dehydrogenase 0.58   
PPE1 PPE family protein 0.64   
Table 4.10 Genes with significantly more transposon inserts present in the INH libraries 
compared to control libraries (pfp<0.1). Genes ordered by fold change of number of 
insertions between the two groups. katG was used a control gene and was expected to be seen 
high on the list. Gene essentiality for cholesterol catabolism and in vivo growth noted 
(Sassetti and Rubin, 2003; Griffin et al., 2011). 
Mutants in four genes were sequenced with greater than ten-fold increased abundance in the 
isoniazid treated pools compared to untreated pools, these were katG, rv2700, fecB and pckA. 
The function of rv2700 is unknown, however it is located in the cell wall or membrane and 
therefore may have an impact on INH uptake. fecB is potentially involved in iron transport 
across the membrane in mycobacterial species (Wagner et al., 2005). Iron has been 
previously linked with enhancing the susceptibility of pathogenic mycobacteria to INH 
(Sritharan et al., 2006). In the same study, iron deprivation was shown to limit peroxidase 
activity (katG) and therefore INH was not activated, creating a INH resistant cell. A fecB 
mutant may lead to iron deficiency due to the lack of transport of iron across the cell 
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membrane into the cytoplasm, which could then lead to INH resistance developing. The 
occurrence of pckA on this list is surprising, as it is an essential gene in gluconeogenesis and 
loss of function has been shown to reduce mycobacterial cell viability in vivo 
(Mukhopadhyay, Concar and Wolfe, 2001; Liu, Yu and Russell, 2003; Marrero et al., 2010). 
As it is a core enzyme in cellular metabolism, the mechanism by which a pckA∆ cell develops 
resistance to isoniazid is unknown. pckA expression is induced in iron deficient environments 
and therefore there may be a link with the previously described iron dependent nature of 
KatG activity (Rodriguez and Smith, 2003).  
ponA2 mutants have previously been shown to have increased sensitivity to lipophilic 
antibiotics such as rifampicin, but have similar sensitivity to nonlipophillic INH (Vandal et 
al. 2009; Patru & Pavelka 2010). Mutations in ponA2 have been linked with increased 
resistance to β-lactam antibiotics, whilst transposon disruption of the gene results in β-lactam 
sensitivity  (Billman-Jacobe, Haites and Coppel, 1999; Wivagg et al., 2016).  ponA2 has a 
key role in peptidoglycan synthesis and this data suggests disruption of this gene may result 
an alternative cell wall phenotype, leading to increased INH resistance (Kieser et al., 2015). 
The mechanism behind this phenotype is unknown.   
Gene ontology analysis searching for enriched functional groups was completed on this data 
set and no statistically significant results were seen (FDR < 0.05) (Mi et al., 2017). 
Cells with transposon inserts in genes making them more susceptible to isoniazid compared 
to wild-type cells were identified. A list of approximately 100 genes was created which had 
significantly fewer transposon inserts in the INH group compared to the control group at sub-
MIC concentrations of INH (Appendix 4.3). This suggests that loss of function of these genes 
leads to the cells being more susceptible to the sub-MIC INH concentration. Many of these 
had no inserts present in any of the INH libraries, suggesting they were essential for growth 
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when the cells were exposed to INH. The majority of the genes identified were conserved 
hypothetical proteins with unknown function, making the mechanism by which they are 
involved in INH pathways difficult to ascertain. An example of a gene identified in this 
screen is bcpB. bcpB insertion mutants were shown to increase susceptibly to INH. bcpB is 
involved in superoxide detoxification and endogenous superoxide has been linked with 
intracellular INH activation (Wang, Burger and Drlica, 1998; Jaeger, 2007). BcpB is in the 
Prx family (Rhee et al., 2001). A member of this family (AhpC) is known to have a 
compensatory affect in KatG deficient strains of mycobacteria by detoxifying reactive 
oxygen species (Sherman et al., 1996). BcpB may have a similar role and therefore a lack of 
BcpB may result in hyper-sensitivity to INH. mmpS5 is part of an export system which is 
required for the secretion of iron-chelating compounds-siderophores, as INH activity has 
been linked with intracellular iron levels, disruption of iron homeostasis within the cell may 
lead to increased susceptibility to INH (Sandhu and Akhter, 2017). Resistance to other 
antibiotics has been linked with increased transcription of the mmpS5-mmpL5 two component 
export system  (Milano et al., 2009). Another enzyme essential to iron metabolism, MbtH 
was identified. MbtH is involved in the production of mycobactins- iron-chelating growth 
factors (Snow, 1970). Gene ontology analysis searching for enriched functional groups was 
completed on this data set and no statistically significant results were seen (FDR < 0.05) (Mi 
et al., 2017). 
4.5 Discussion 
This chapter describes the generation of a MycomarT7 transposon libraries in M. bovis BCG 
Denmark and characterisation of the coverage of insertional mutagenesis across the 
mycobacterial genome. The transposon appeared to insert without obvious bias except for the 
requirement of a TA sequence. A pool of 8 x 104 transposon transformed colonies was shown 
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to contain approximately 3.25 x 103 unique gene insertions. Two selection experiments were 
then conducted using the mycobacterial heat-shock response and INH resistance pathways. 
The aim of these experiments was to validate the ability of TnSeq to differentiate and 
quantify transposon mutants found within groups exposed to different conditions. This was 
required to ensure the subsequent cattle experiment (Chapters 5 and 6) would yield relevant 
results and most importantly, was ethical. If the in vitro selections revealed the inability of 
the protocol to reveal differences, large or discrete, in the number of transposon mutants in 
each pool, then in vivo experiments could not ethically be completed. Two selections were 
completed- heat-shock and isoniazid susceptibility-to ensure a robust validation process. Both 
selection conditions were chosen due to the available literature highlighting genes relevant in 
the respective pathways, allowing specific genes to be used as controls in each condition. The 
control in the heat-shock experiment was hspR. It was expected that more hspR::Tn would be 
seen in the heat-shock selected group as it is a negative regulator in the pathway (Mangan et 
al., 2002). Mutants lacking hspR have been shown to have increased resistance to heat-shock 
(Group et al., 2001).  Significantly more transposon mutants were seen in the heat-shock 
groups and therefore this validation was a success. The method was able to quantify mutant 
numbers in both groups allowing mutants with a selective advantage to be identified. 
Conversely mutants with a disadvantage could also be determined by comparing the pools. 
Genes with more insertion mutants in the control conditions compared to the conditions of 
stress all have the potential to cause the organism to be sensitive to that condition. The same 
principle was applied to the INH selection experiment. KatG is a catalase-peroxidase enzyme 
required for the activation of INH and a method mycobacterial resistance to INH is due to 
mutations in this gene (Ying Zhang et al., 1992). It was expected that there would be more 
katG::Tn in the libraries exposed to INH compared to the quantity in the control group. 
Transposon insertions within this gene would lead to loss of function and therefore 
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generation of resistant cells resulting in a growth advantage. The TnSeq data revealed there 
were significantly more (pfp=0 with a 75x more mutants in the INH exposed group) katG 
mutants present in the INH exposed group and therefore this validation was also a success. 
Both hspR and katG were identified and the validations were successful, resulting in the 
cattle challenge experiment being approved.  Furthermore, fadE24, a gene previously linked 
with INH resistance in mycobacteria was also identified, further validating the experiment 
(Wilson et al., 1999). 
The by-product of these validation experiments was the identification of potentially novel 
genes involved in the heat-shock response and isoniazid susceptibility/resistance pathways. It 
is important to note that these results have not been experimentally validated using individual 
knock-out strains and complementation. The TnSeq data revealed one gene that could also be 
linked with heat-shock resistance-mpb83. Mpb83 is a cell surface lipoprotein and a major M. 
bovis antigen with an unknown function (Wiker, 2009). The mechanism by which cells 
lacking Mpb83 gain heat-shock resistance has not previously been reported. It is predicted 
that Mpb83 is a core component of the cell wall and lack of production leads to the cell 
becoming stressed, leading to the upregulation of general stress responses, such as to 
oxidative stress (Vandal et al. 2009). The increase expression of stress responses would 
include those expressed during heat-shock and therefore increase the cells heat-shock 
resistance. ponA2 insertion mutants were shown to be more abundant in the control group 
compared to the heat-shock group. The data coincides with published data linking ponA2 
disruption with hypersensitivity to stress conditions (Vandal et al. 2009). Many lipoproteins 
were identified to increase susceptibility to heat-shock once expression had been disrupted. 
Lipoproteins are a class of cell-envelope proteins and knockout mutants have been shown to 
be attenuated in macrophages as well as being more susceptible to stress conditions (Sakthi 
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and Narayanan, 2013). The TnSeq data suggests mycobacterial cells deficient in certain 
lipoproteins may also become susceptible to heat-shock.  
The INH selection identified genes potentially related to the INH resistance and susceptibility 
pathways. Alongside katG, many genes linked with iron metabolism and transport were 
identified to be involved in sensitivity and resistance, suggesting iron is a key substance 
required for INH activation or metabolism. The data suggests disruption of iron homeostasis 
within the cell results in an altered INH resistance phenotype. Insertion mutants lacking an 
iron import mechanism (fecB) were suggested to be more resistant to INH. Alternatively, 
enzymes such as bcpB may be linked with hyper-sensitivity due to their potential superoxide 
detoxification impacting INH activation. This INH mechanism impact activation to a lesser 
extent than katG, but mutants lacking these systems may become hyper-sensitive to INH. 
MmpS5, a gene essential is siderophore transport also may have a role in INH sensitivity. 
The movement of iron from the cytoplasm to the periplasmic space is facilitated by the two-
component system MmpS5 belongs to (Sandhu and Akhter, 2017). An abundance of iron in 
the cytoplasm may result in more efficient INH activation and therefore the cells are more 
susceptible.  
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Chapter 5 
TnSeq selection for BCG mutants that have increased 
persistence in immunised compared to naïve cattle.  
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5.1 Introduction 
Vaccination with M. bovis BCG is known to have variable efficacy in cattle, with many 
parameters such as the age of the calves at vaccine administration, route of immunisation and 
the effect of revaccination all playing important roles in the development of a protective 
response (Buddle et al., 2003; Hope et al., 2005b; Wedlock et al., 2011; Parlane et al., 2014). 
Due to the variable efficacy, there are currently major efforts to develop vaccination 
strategies that improve the protections conferred by BCG vaccination. A proposed method of 
increasing the protection inferred by BCG vaccination is a heterologous prime-boost strategy 
consisting of priming the immune system with wild-type BCG, following by boosting with a 
sub-unit vaccine containing protective antigens that are present in BCG.  The most effective 
attempts at the prime-boost strategy have used subunit vaccines based on DNA or virally 
vectored booster vaccines (Skinner, Buddle, et al., 2003; Vordermeier et al., 2006; Maue et 
al., 2007; Vordermeier, Villarreal-Ramos, et al., 2009). These approaches have been shown 
to be successful in increasing protection in vivo in controlled laboratory conditions, however 
the efficacy is yet to be determined in field-trials. We aim to identify novel antigens, already 
present in BCG, for the use in a sub-unit vaccine which can be used as part of a prime-boost 
strategy to induce a protective immune response against bovine tuberculosis. Although large 
scale antigen-mining studies have been completed to identify novel antigens for use in 
vaccines, these studies lacked the un-bias in vivo selection within the model organism that 
this study proposes (Ewer et al., 2006; Jones et al., 2013).  
This chapter describes the process of selecting BCG transposon mutants in a cattle lymph 
node challenge model previously developed by Villarreal-Ramos and colleagues (Villarreal-
Ramos et al., 2014). Two groups of cattle, immunologically naïve and BCG vaccinated, were 
intranodally challenged in the prescapular lymph node with approximately 1x108 transposon 
mutants for 4 weeks. Post-challenge, animals were culled and left and right prescapular 
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lymph nodes were removed, with surviving transposon mutants being harvested and cultured. 
We hypothesised that transposon mutants surviving longer in BCG vaccinated animals, and 
therefore more abundant when cultured post-challenge compared to the quantity found in the 
immunologically naïve animals, are missing potentially protective antigens. A transposon 
mutant missing a protective antigen may evade the T-cell-mediated immune response 
developed through vaccination, whereas the same mutant present in an animal lacking that 
protective response will have no advantage against the innate immune system. Mutants 
surviving selection were identified using TnSeq and Rank Product analysis was completed to 
produce a hierarchy of potential antigens based on differences in rank between the two cattle 
groups and fold-change in TnSeq sequence reads.   
The specific objectives of this chapter were: 
1) Use a cattle challenge model to select for transposon mutants with greater survival in 
BCG vaccinated calves. 
2) Recover surviving transposon mutants from the cattle challenge and quantify the 
number of transposon mutants using TnSeq. 
3) Select genes with greater transposon inserts and therefore survival in vaccinated 
calves compared to immunologically naïve calves for cloning and recombinant 
protein expression in E. coli. 
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5.2 TnSeq comparison of BCG survival in BCG immunised and naïve cattle 
In the previous chapter, generation of pools of Himar transposon mutant BCG Denmark was 
described. This UoS- and APHA-funded PhD project forms part of a wider research 
programme led by UoS/APHA including a BCG project grant to develop a new strain of 
BCG compatible with a defined skin test. This latter project involved a TnSeq selection 
experiment in naïve cattle and for ethical reasons it was decided that this animal cohort would 
also be used as the naïve animal group in the present PhD project. In the research programme, 
a number of BCG mutant pools were generated using the same clone of Mycomar and batch 
of BCG Denmark. The largest pool of mutants generated in the joint research programme was 
chosen for use in the animal experiments (naïve and vaccinated). This pool contained 
approximately 1.2x105 individual mutants and was collected by Dr K. Williams. 
Choosing this pool ensured a wide genome coverage in the cattle lymph node selection. 
Insertions at the beginning or end of a gene may not fully disrupt the expression of the gene. 
Consequently, the larger the number of mutants, the higher the chance TA sites in the middle 
of the gene acquire a transposon and the genes function is disrupted. Prior to challenge, the 
library was cultured to achieve a final concentration of approximately 1x108 CFU/ml, 
equating to approximately 1000 copies of each mutant per ml of culture/inoculum. The naïve 
animals acted as a control to compare the survival rate of mutants within the BCG vaccinated 
calf lymph nodes.  
5.2.1 Lymph Node Challenge with BCG Transposon Mutant Library 
Right and left prescapular lymph nodes from 6 Holstein-Friesian calves were used to select 
for transposon mutants. The 6 animals were split into two groups: vaccinated (772, 774 and 
778) and unvaccinated (773, 778 and 804). The vaccinated group were subcutaneously 
vaccinated with BCG Danish 6 weeks prior to challenge. Animals were bled on the day of 
vaccination. Animals from both groups were bled a further 4 more times over the course of 
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the challenge, including on the day of challenge and cull. IFN-γ production from these whole 
blood samples in response to PPDB were quantified by a BOVIGAM™ TB kit (Figure 5.1). 
It was expected that vaccinated animals would show a more rapid IFN-Ƴ response once 
challenged with the library, compared to the time of the response in the immunologically 
naïve animals (Widdison et al., 2006; Wedlock et al., 2007; Rizzi et al., 2012).  
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Figure 5.1 IFN-γ release from vaccinated and immunologically naïve cattle throughout the 
10-week challenge with the transposon library. Blood samples taken from cattle at specified 
time points throughout the challenge were stimulated with bovine PPD and IFN-γ levels 
quantified (ng/ml). Red lines represent immunologically naïve animals (773, 778), full lines 
are vaccinated animals (772,774,778). All animals exhibited similar levels of IFN-γ post-
challenge.  
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Animals 774 (vaccinated) and 778 (unvaccinated) showed elevated levels of the IFN-γ at 
week 0, prior to challenge (Figure 5.1). These animals likely had previous contact with 
environmental mycobacteria, resulting in a cytokine response when stimulated with PPDA 
(Avian). The PPDA responses for animals 774 and 778 at week 0 were elevated, confirming 
this (Appendix 5.1). This effect was maintained in these animals for all the time points prior 
to challenge. The remaining immunologically naïve animals showed no response to PPDB 
prior to challenge. Post-challenge, all animals showed an elevated IFN-γ response. There was 
no difference in the post-M. bovis challenge IFN-γ response to PPDB between the vaccinated 
and unvaccinated animals. This may have been due to the variable background anti-
mycobacterial response generated by exposure to environmental mycobacteria (M. avium). 
Due to the small number of time points, the rapidity of the response could not be assessed. 
This may be another reason why no difference was detected between vaccinated and 
unvaccinated animals, as vaccination could result in a more rapid anti-mycobacterium IFN-γ 
response. IFN-γ levels began to wane for all animals at time of cull. The third naïve animal 
became sick during the study and was put down. The animal was replaced in order to 
maintain the planned BCG mutant TnSeq selection in 6 challenged lymph nodes, and 
therefore no data was available for this animal. 
The weight of the right and left lymph nodes was measured during processing (Figure 5.2). 
Immune response and blood flow can be correlated with immune response weight (Herman et 
al., 1976; Hay and Hobbs, 1977). With the influx of immune cells into the lymph nodes to 
counteract the challenge, an increased weight in those with more mutant clearance may have 
been exhibited. Post-selection and lymph node processing, surviving mutants in the lymph 
nodes were cultured and counted on Middlebrook media (Figure 5.3). 
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Table 5.1 Left and right prescapular lymph node weight and mutant library colony counts 
from BCG vaccinated (v) and unvaccinated calves 4 weeks post-challenge. Whole lymph 
nodes were weighed prior to maceration. CFU counts were obtained by diluting lymph node 
macerate 1:10 with PBS followed by growth on 7H11+kan solid media.  A correlation 
coefficient of R=0.549 calculated using Spearman’s rank correlation coefficient shows a 
moderate positive correlation between lymph node mass and colony count. 
 
 
Animal Left Prescapular 
Mass (g) 
Total CFU Right Prescapular 
Mass (g) 
Total CFU 
772(v) 12.11 1.26x104 17.84 2.24x105 
774(v) 20.66 1.33x105 14.78 4.69x103 
777(v) 16.63 1.54x104 18.87 1.96x104 
773 19.61 3.01x104 16.41 1.61x104 
778 15.55 6.34x104 16.39 3.15x105 
804 33.33 21.1x105 36.74 1.02x105 
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Figure 5.2 Lymph node weights (g) recorded for each animal post-challenge. Whole 
prescapular lymph nodes were excised and weighed prior to processing. There was no 
significant difference in weight between the two groups. Mean and SEM shown. 
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There was no significant difference seen between the lymph node weights in the two groups 
when compared with a two-tailed unpaired t-test although the two heaviest lymph nodes were 
in the naïve group. However, the correlation does not take into account the natural variation 
in lymph node size between animals. Another variable effecting the lymph node weight is the 
age of the animals. Although the animals are all within the correct age bracket, young 
animals grow rapidly, approximately 1kg per day. A small variability in age could lead to 
larger calves and therefore lymph nodes of variable weights (Kertz, Prewitt and Ballam, 
1987). 
A large variation in bacterial load was seen within the lymph nodes, but there was no 
significant difference in load between the two groups (Figure 5.3). The average number of 
bacterial cells recovered from the vaccinated animals was however lower than the naïve 
animals. The biggest loss was seen in animal 774, in which the original 1x108 CFU/ml was 
reduced to 6.7 x 102 CFU/ml. Cattle vaccination with BCG Danish is known to have variable 
efficacy with only a proportion (approximately 60%) of cattle showing a protective response, 
which may be an explanation as to why variable bacterial cell counts are seen within the 
vaccinated groups (Vordermeier et al., 2016). Indeed it is interesting that four out of six 
lymph nodes had low bacterial loads, a proportion that is consistent with the estimated 
efficacy of BCG in cattle (Vordermeier et al., 2016).There was no correlation between PPDB 
IFN-γ responses and CFU. 
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Figure 5.3 Surviving mutant CFU/ml recovered from left and right prescapular lymph nodes 
from immunologically naïve and BCG vaccinated calves 4 weeks post-challenge with the 
BCG mutant library. A two tailed T-test demonstrated the two groups were not significantly 
different. Mean and SEM shown.  
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A correlation coefficient of 0.549 was generated for the CFU (bacterial load) and lymph node 
weight data. This correlation may simply reflect that larger lymph nodes can retain larger 
numbers of BCG post challenge but alternatively may suggest that the higher the 
mycobacterial load in the lymph node, the higher the influx of immune cells, and thus the 
greater the lymph node mass. Ideally, flow cytometry would have been completed to identify 
the number of immune cells and bacterial cells in the lymph nodes. 
5.2.2 Transposon Library DNA Preparation for TnSeq 
The total volume of lymph node homogenate was diluted 1 in 10 to remove the inhibitory 
effect of neat lymph node homogenate, and plated on 7H11+kan and incubated at 37˚C for 
approximately 3 weeks.  
Bacterial DNA was extracted and prepared for TnSeq as previously described (Section 3.8). 
The quality of the DNA through sequencing library preparation was monitored at each stage 
using both gel electrophoresis and quantification methods as previously described in Chapter 
4. Briefly, gDNA was extracted from the surviving transposon mutants. gDNA was sheared 
to achieve fragments of approximately 500 bp, which were then end repaired and a-tailed to 
allow adapter ligation required for TnSeq. A small amount of adapter-ligated gDNA was 
amplified by qPCR with indexed primers to optimise the amplification cycle number required 
for efficient production of library DNA without PCR artefacts and without excess 
amplification cycles that would adversely affect the quantitative capacity of subsequent 
sequencing data.  Appendix 5.2 shows the recorded qPCR readouts. A cycle number of 29 
was chosen for optimal amplification of all libraries. Large scale amplification was 
completed with the optimal cycle number and the prepared DNA was QC checked using a 
2100 Bioanalyzer and quantified using a Qubit Fluorometer (Appendix 5.2). Samples were 
sent to Eurofins Scientific for NGS sequencing on the Illumina HiSeq 2500 platform.  
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5.3 TnSeq Data Sorting and Analysis 
 
The raw TnSeq data generated from single read double index sequencing using the Illumina 
HiSeq platform was sorted and preliminarily analysed as described in the methods with the 
help of the bioinformatics unit. The number of reads per library, shown in Table 5.2, reveals a 
large disparity between the number of reads for the lymph nodes from the vaccinated animal 
777 compared to the number of reads obtained from the other animals. The low number of 
reads does not correlate with a low number of transposon mutants recovered from that animal 
(as judged by CFU counts) or lymph node weight.  The deficiency may be due to poor DNA 
quality that was missed during the quality control stages, or some other issue with the 
sequencing itself. It is possible that the DNA indexes used for sample identification of the 
777 lymph node specimens did not perform as well during the sequencing reaction. The low 
reads of 777R may correlate with the lower plateau witnessed during the qPCR amplification, 
which may suggest an inhibitory substance being present in the solution. However, this was 
not witnessed in the 777L qPCR readouts.  Whatever the reason, given greater resources, 
more sequencing reads could have been collected to provide confidence that the dataset was 
capturing the diversity of the mutant pool.  
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Sample 
Total number of 
sequences 
772L 1061304 
772R 1366794 
774L 1701625 
774R 3731277 
777L 837750 
777R 560014 
773L 1903621 
773R 7721873 
778L 3332476 
778R 3603607 
804L 1829407 
804R 8100329 
Control 3742874 
 
Table 5.2 Number of TnSeq reads obtained from each transposon library sample from 
immunologically naïve (red) and BCG vaccinated animals. 
 
The number of gene mutants sequenced for both vaccinated and immunologically naïve 
animals can be seen in Figure 5.4. Comparing the number of mutants with unique gene 
inserts as a percentage of the total number of genes present in the genome (Figure 5.5) 
reveals fewer unique gene mutants survived in the vaccinated animals, compared to the naïve 
animals. A high variation in number of unique gene mutants was seen in libraries selected in 
vaccinated calf lymph nodes. Vaccination with BCG Danish is known to induce variable 
efficacy depending on a multitude of conditions, which may be an explanation as to why a 
large discrepancy in mutant number between animals is witnessed (Vordermeier et al., 2016). 
The variability in gene mutants seen in the naïve group is low, suggesting the innate immune 
response is consistent between animals. This data does not specify individual mutants found 
in each pool, and therefore different mutants may be present in each group.  
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Figure 5.4 The number of unique transposon insertion mutants obtained from vaccinated and 
naïve cattle as a percentage of the total number of genes within the BCG Pasteur genome. 
The control library yielded 92 % coverage (dotted line). Naïve animals showed an average 
decrease in coverage of 16 %. Vaccinated groups exhibited an average reduction of 36 %, 
with high variance. A one tailed unpaired t-test revealed the number of mutants identified 
between the two groups was statistically significant (p<0.05) 
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Figure 5.5 Average transposon insertion coverage per group as a percentage of the total 
number of genes present in the genome. High variation of unique mutants exhibited in the 
vaccinated group shows the variability of protection inferred by BCG vaccination. Naïve 
animals show a small level of killing and variation compared to vaccinated animals, 
suggesting a consistent innate immune response. Input n=0, naïve and vaccinated n=3. Error 
bars represent standard deviation of the mean. 
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Interestingly, 92 % of genes maintained a transposon insertion in the control group. This 
validates previous statements that not all transposon insertions in essential genes lead to loss 
of function.  Previous studies investigating gene essentiality in M. tuberculosis using 
transposon mutagenesis state that 625 open reading frames are essential for optimal growth in 
vivo, of M. tuberculosis (DeJesus et al., 2017). As 307 genes were identified in the input 
library without transposon insertions, it can be assumed that insertions in non-essential 
regions of essential genes can occur. Alternatively, the TnSeq may be sequencing the 
genomes of non-viable mutants that remain in the pool. The control library was cultured in 
vitro and essential genes for in vivo growth would not be selected out, therefore mutant 
survival was expected to be higher in the control. Many of the genes missing in the naïve and 
vaccinated group have previously been reported as being essential for growth in vivo (such as 
thiE, senX3, murI, coaA), explaining the absence of recovery of transposon mutants with 
inserts disrupting these genes from both cattle groups (Sassetti and Rubin, 2003). 194 
mycobacterial genes have been identified as specifically being essential in vivo (Sassetti and 
Rubin, 2003).  Transposon insertions leading to the disruption of essential genes would lead 
to cell death, and therefore it is unknown whether these insertions lead to altered adaptive 
immune recognition of these transposon mutants. Transposon insertions within essential 
genes that do not lead to cell death would imply insertion within a non-essential region of the 
gene and are therefore of no interest. 
Identification of essential genes required for growth in cattle lymph nodes was not the aim of 
the study, therefore TA site saturation was not required (Appendix 5.3) (Griffin et al., 2011). 
High TA site saturation increases the statistical power of the data, which is required to 
determine gene essentiality (DeJesus et al., 2017). The total gene saturation was of concern 
and a high level was achieved. Low gene saturation could have led to key genes being missed 
from the analysis.  
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To compare relative fitness/abundance of mutants in the vaccinated versus the naïve cattle, 
we used rank product analysis to compare the number of insertions in individual genes in the 
two experimental animal groups. Mutants were considered to be differentially selected when 
their rank was significantly different between the two groups. A gene is given a rank based 
on the number of transposon insertions present, this is done for both immunised and 
vaccinated data sets. A percentage false positive (pfp) cut-off of 0.1 was used to indicate 
significance. Fold-change in transposon insertions was also a factor studied when choosing 
genes to take forward for further testing. A gene outside the pfp cut-off was chosen - 
Mb0025/Mb0025- as an attempt to compare statistically significant genes with those just 
outside the significance bracket. All genes with significantly more inserts (from normalised 
datasets) present in the vaccinated animals compared to the immunologically naïve are shown 
in Table 5.3. Genes with more insertions in the vaccinated group indicated mutants that had a 
relative selective advantage in the vaccinated compared to naïve animals. These were 
predicted to either be potential protective antigens or in genes that encode enzymes involved 
in synthesis of non-protein antigens such as cell wall glycolipids or enzymes involved in cell 
wall morphology.
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Gene Name Product 
Function Naïve/Vaccinated Fold-
change  
Pfp value 
Mb2077c ppm1 Transfers mannose from GDP-mannose to all endogenous polyprenol-phosphates 0.02 0 
Mb0086 NA Probable oxidoreductase 0.03 0.1 
Mb1422 PPE20 PPE Family Protein 0.07 0.07 
Mb1309 NA Hypothetical protein 0.09 0.07 
Mb0174 yrbE1B Conserved integral membrane protein 0.09 0.06 
Mb2235 NA Adenylyl cyclase  0.09 0.07 
Mb3570c ltp2 Probable lipid transfer protein or keto acyl-CoA thiolase 0.10 0.1 
Mb1197 typA Possible GTP-binding translation elongation factor 0.14 0.08 
Mb0025/Mb0025 NA Peptidoglycan amidase 0.15 0.16 
Mb0308 vapB2 Possible antitoxin 0.16 0.08 
Mb1943c katG Catalase-peroxidase-peroxynitritase 0.33 0 
Table 5.3 Genes with significantly more transposon inserts present in the libraries recovered from vaccinated animals compared to libraries 
recovered from naïve animals (pfp < 0.1).  Fold-change represents the number of insertions found within the control group/vaccinated group. 
Significance was calculated by Rank Product Analysis and expressed as pfp. Genes highlighted in blue were taken forward for recombinant 
expression (Chapter 5). 
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Ppm1 is an example of a gene that most likely is itself not an antigen, but the lack of the 
protein results in alterations in cell wall morphology that alters susceptibility to immune 
killing by the adaptive immune response. Polyprenol monophosphomannose synthase (Ppm1) 
is involved in the synthesis of long mannose polymers in lipomannan (LM) and 
lipoarabinomannan (LAM) (Besra et al., 1997; Gurcha et al., 2002). Both of these glycolipids 
have roles in mycobacterial cell wall integrity and pathogenesis  and have also been shown to 
be highly immunogenic  (Chan et al., 1991; Fukuda et al., 2013). CD1 restricted responses 
have been shown to activate T-cells in human with M. tuberculosis infection (Ulrichs et al., 
2003). CD1 molecules are a family of antigen-presenting molecules that bind lipids for 
presentation to T-cells, leading to cell-mediated immune responses. This is a process by 
which non-protein antigens are recognised by the host immune response (Ulrichs and 
Porcelli, 2000). Preventing the formation of complete LM and LAM may reduce the 
immunogenicity of these glycolipids and consequently a higher magnitude of ppm1 mutants 
appear in the vaccinated group. Ppm1 is a polypeptide consisting of two domains.  One 
domain is sufficient for the synthase activity whilst the other is membrane anchored via six 
transmembrane anchors (Gurcha et al., 2002; Rana et al., 2012). Importantly, transposon 
inserts were found in both segments of the protein.  Although this gene showed the greatest 
fold change in reads, it was not selected for recombinant protein expression because it 
seemed most likely that it was not an important antigen itself but the synthetic enzyme for 
important non-protein cell wall components. However, the differential survival of these 
mutants in BCG immunised and naïve cattle strongly implicates the importance of mannose 
capped LAM as an antigen in the BCG protective response (Kaur et al., 2008). Future studies 
could investigate the inclusion of mannose capped LAM in subunit vaccines.  
Mutants in Mb0086 were also demonstrated to have a selective advantage in the vaccinated 
animals. Mb0086 is a protein with unknown function (Cole et al., 1998). It has potential 
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oxidoreductase properties due to 29 %-35 % sequence similarity with a E. coli hydrogenase 4 
(hyf) -a membrane bound enzyme- (NP_416977.1), Streptomyces coelicolor NADH 
dehydrogenase NuoL2 (NP_628768.1) and Neisseria meningitides NADH dehydrogenase 
(NP_273313.1) (Trchounian and Trchounian, 2013) . Mb0086 is a large protein (640 amino 
acids) and due to low homology with the previously mentioned sequences, therefore it cannot 
be assumed it is also membrane bound. However, Mb0086 was selected for recombinant 
protein expression due to its potential membrane bound nature which would increase the 
chance that it is exposed on the surface of the bacterium and thus to the host immune 
response.  
PPE20 is an uncharacterised PPE family protein (Cole et al., 1998). PPE family proteins are 
conserved genes which count for approximately 10 % of the M. tuberculosis genome (Cole et 
al., 1998). PPE family proteins have previously been linked with immunogenicity, resulting 
in IFN-γ production and CD4+ T cell activation (Demangel et al., 2004; Sayes et al., 2012). 
PPE family proteins have been shown to modulate the immune response, specifically PPE18 
can modulate the host response through TLR-2, resulting in macrophage IL-10 production, 
and PPE38 induces TNF-α production (Nair et al., 2009; Dong et al., 2012). Many PPE 
proteins are known to be exported from the cell or to be cell surface receptors (Song et al., 
2008; Mitra et al., 2017). Although the role of PPE20 has not currently been identified, there 
is a strong chance it is present on the cell surface (Doran et al., 1992). Furthermore, PPE 
family proteins have been reported to be recognised by CD4+ T-cells, resulting in a strong 
Th1-type response, which is a key part of the host response in the control of mycobacterial 
infections (Salgame, 2005; Chaitra, Shaila and Nayak, 2008; Sayes et al., 2016). PPE18 
(Mtb72F) and PPE42 are currently being assessed in clinical trials as vaccine components for 
the control of human tuberculosis, further validating the potential immunogenicity of PPE20 
(Brennan, 2017). All of these factors make PPE20 a prime candidate as a protective antigen 
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for use in a sub-unit vaccine. PPE20 was chosen for recombinant protein expression due to it 
potentially cell surface location, the high-fold change in insertions and that other PPE20 
family proteins are known to modulate the immune response. 
Mb1309 encodes a conserved hypothetical protein (Cole et al., 1998). The protein shares no 
sequence similarity with other organisms, apart from others in the mycobacterial complex. 
The function of this protein is unknown. Although the fold-change exhibited was high there 
was no other biological evidence supporting its potential significance as an antigenic protein, 
thus it was not chosen for further study as a vaccine candidate.  
yrbE1B encodes a conserved integral membrane protein (Cole et al., 1998). It is part of the 
mce1 operon which is thought to encode virulence-related proteins that likely serve as a 
hetero-oligomeric lipid transporter with functions including mycolic acid re-importation 
(Forrellad et al., 2014). This protein has been associated with in vivo survival, with 
inactivation of yrbE1B resulting in reduced bacterial burden in mice lungs (Gioffré et al., 
2005). YrbE1B has a similar sequence and secondary structure to the transmembrane 
permease subunits of ABC transporters, suggesting a role in transmembrane transport (Joshi 
et al., 2006).  As this protein is thought to be found on the surface -due to it being a 
membrane protein- and the high fold change seen, as well as its potential association with 
virulence, it was selected to be taken forward for recombinant protein expression.  
Mb2235 is an adenylyl cyclase (AC), an enzyme involved in cAMP synthesis (Cole et al., 
1998). The function of this category of enzymes has been linked to gene expression changes 
related to survival in mouse macrophages (Rickman et al., 2005). Evidence also suggests that 
cAMP produced by M. tuberculosis is secreted within the host, resulting in production of 
TNF-α (Agarwal et al., 2009). This data implies that mycobacterial cells can alter the host 
immune response, using cAMP, in order to increase its survival chances within the host. 
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Hsp60-driven Rv2212 (the M. tuberculosis  homolog of Mb2235) expression in BCG led to 
increased expression of key stress related proteins- GroEl-2, DnaK and BfrB,- suggesting 
cAMP levels regulate stress responses in vivo (Pedroza-Roldán et al., 2015).  This may be 
especially relevant to Mb2235 as it has been shown to have the highest ATP/cAMP 
conversion rate out of all 10 mycobacterial adenylyl cyclase (Motaal et al., 2006).  Rv2212, 
the M. tuberculosis homolog of Mb2235 has been linked with the M. tuberculosis 
extracellular protein Exported Repetitive Protein (ERP), which is a crucial virulence 
associated factor involved in the survival and multiplication of mycobacterial cells within 
macrophages (Goguet de la Salmonière et al., 2001; Ganaie et al., 2016). Overexpression of 
Rv2212 improves in vivo fitness and enhances M. tuberculosis virulence in mice (Shleeva et 
al., 2017). Mutants lacking Rv2212/Mb2235 would exhibit a reduced survival phenotype in 
vivo. The reason for comparatively better survival of Tn::mb2235 mutants in vaccinated 
animals is unclear, however the reduced expression of cAMP may play a role. Mb2235 was 
chosen for recombinant protein expression due to the large fold-change in transposon reads 
seen. There was no evidence suggesting that this protein was located on the cell surface and 
most likely would adhere to the second hypothesis and result in a change in cell morphology 
or chemistry, consequentially increasing survival in the host. However, previous studies have 
identified proteins involved in intracellular metabolism as being immunogenic and therefore 
this protein was chosen for further study (Xiao et al., 2016). 
Ltp2 is a probable lipid transfer protein or keto acyl-CoA thiolase (Cole et al., 1998). It is 
possible that such a cytosolic protein is a protective antigen, however, it was not chosen for 
further study in this project because we prioritised proteins predicted to be exposed on the 
cell surface. Ltp2 is thought to be involved in lipid metabolism and there is no suggestion that 
it appears on the cell surface or has antigenic properties. The previously described CD1 
molecules behave as lipid transfer proteins and assist in the processing of 
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phosphatidylinositol mannosides (PIM), cell-wall and/or plasma membrane components 
essential for cellular growth and viability and the precursor to LM/LAM (Morita et al., 2004; 
Cala-De Paepe et al., 2012).  Ltp2 may be involved in lipid biosynthesis and therefore 
mutants of Ltp2 result in the loss of immunogenic glycolipids located on the cell surface. 
Alternatively, loss of Ltp2 may alter the mycobacterial proteome, leading to the loss of 
antigenic proteins (Pedroza-Roldán et al., 2015).  
TypA or BipA is a possible GTP-binding translation elongation factor with a probable 
function of interacting with ribosomes in a GTP dependant manner (Cole et al., 1998).  TypA 
has high sequence similarity to the bipA found in Piscirickettsia salmonis, an intracellular 
pathogen of marine species (HQ259054). Isla et al have shown that the expression of BipA in 
P. salmonis significantly increases during ex vivo infection (Isla et al., 2014). They suggest 
BipA aids in the adaption of the P. salmonis cell to the hostile environment found inside the 
macrophage. Although this has not been reported for mycobacterial species, it is possible that 
the function is maintained between these intracellular prokaryotic pathogens. A typA 
transposon mutant may lack some of the tools required for intracellular survival within a 
macrophage and are therefore more easily cleared by a phagocyte driven response. Why this 
is more prevalent in immunologically naïve animals is unclear although the modes of 
immune clearance in these groups have significant differences. There was no evidence of this 
protein having antigenic properties or being exposed on the cell surface, thus it was not 
chosen for further study. 
Mb0024 and Mb0025 are two parts of one protein annotated in M. tuberculosis as Rv0024. 
This protein is a putative secreted P60-related protein.  P60 family proteins are major 
extracellular proteins involved in the invasion of host-cells (Cole et al., 1998). Rv0024 has 
recently been associated with biofilm formation and mycobacterial cell wall resistance to 
anti-tuberculosis drugs, including INH (Padhi et al., 2016). The study describes Rv0024 as 
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potentially being associated with cell wall assembly and bacterial replication, it is also 
suggested that it is involved in anti-tuberculosis drug resistance generated via biofilm 
formation. This may be why the previously completed experiment identifying gene relevant 
to INH resistance and susceptibility did not identify this gene, as a biofilm would not be 
created in vitro on an agar plate. These genes were selected for recombinant protein 
expression on the basis that the M. tuberculosis equivalent, Rv0024, was thought to be an 
extracellular protein potentially being present on the cell surface.  Importantly, this gene was 
just outside of significance, however due to its potential function it was selected. Its inclusion 
also provides a level of validation for the method used to identify significance.  
Mb0308 encodes VapB2 (Virulence associated protein), a possible antitoxin with unknown 
function (Cole et al., 1998). VapBC family toxins are highly conserved in the M. tuberculosis 
complex and exhibit ribonuclease activity in vitro (Ahidjo et al., 2011). Several of the family 
have also been shown to have increased expression when M. tuberculosis is under stress 
conditions. Toxin-antitoxin systems are linked with bacterial growth arrest and persistence 
(Ramage, Connolly and Cox, 2009; Page and Peti, 2016). The M. tuberculosis homolog, 
Rv0300, reverses the effect of the Rv0301 toxic protein-which inhibits translation via RNase 
activity (Ramage, Connolly and Cox, 2009). It is suggested that the cessation of translation 
may not be an untargeted event, instead specific messages are targeted, resulting in a discrete 
change in gene translation, resulting in growth cessation. Transposon insertion within this 
gene may lead to prolonged survival in vaccinated animals due to this effect (Ramage, 
Connolly and Cox, 2009). There was, however, no suggestion that Mb0308 is located on the 
cell surface and the fold-change in insertion numbers is on the lower end of scale. 
KatG, the catalase-peroxidase-peroxynitritase enzyme previously mentioned as being 
required for activation of INH, was the final significant protein/gene identified. KatG 
mediates the mycobacterial resistance to killing by hydrogen peroxide and organic peroxides 
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produced by phagocytic cells (Manca et al., 1999). Buddle et al have previously shown that 
cytotoxic T-cell responses are generated in response to M. bovis infection of cattle as a major 
part of the adaptive immune response (Skinner, Parlane, et al., 2003). KatG would have less 
of an effect on the killing mechanisms generated by cytotoxic T-cells, specifically the release 
of cytotoxic proteases that induce cell death of infected macrophages. It was assumed that an 
adaptive response was generated in this group due to the prior vaccination. Furthermore, as 
the organ responsible for T-cell activation was the site of challenge, the lymph nodes, a faster 
adaptive response could have been generated (Wolf et al., 2008).  However, there is evidence 
that KatG may have a level of antigenicity leading to the generation of antigen specific CD4+ 
and CD8+ T-cell responses in non-mycobacterial infections such as pulmonary sarcoidosis 
(Oswald-Richter et al., 2010; Wu et al., 2010). This antigenic property in a mycobacterial 
response has not been previously reported. The fold-change in transposon insertions seen 
between groups was low and the gene was at the lower end of significance and therefore was 
not chosen for recombinant protein expression.  
5.4 Discussion 
This study is the first to describe a genome wide screen of a mutant library within the natural 
host to identify organisms that avoid a vaccine induced immune response. It is hypothesised 
that immune evasion is a result of mutants lacking an antigenic protein that is the target of the 
host adaptive vaccine induced response. Further, there is currently no published work 
describing the use of TnSeq in cattle. Few transposon library screens have been completed in 
the natural host of the pathogen. A small-scale M. tuberculosis transposon library screen (326 
mutants) has previously been completed in non-human primates (NHP), identifying 
mycobacterial genes involved in the transport of various biomolecules, including lipid 
virulence factors; biosynthesis of cell-wall arabinan and peptidoglycan; DNA repair; sterol 
metabolism; and mammalian cell entry (Dutta et al., 2010).  
132 
 
A transposon library of 1.2x105 individual mutants was cultured to achieve a final library size 
of approximately 1x108 CFU/ml. The library was predicted to contain 1000 copies of each 
mutant, allowing a robust challenge and selection to be completed. Blood was drawn from 
both the vaccinated and immunologically naïve animals with the hope of revealing an IFN-γ 
vaccine effect. An IFN-γ rise was seem shortly after vaccination, showing the animals 
responded to the vaccine. Post-challenge no difference in IFN-γ levels was seen between the 
two cattle groups. This may have been, however, due to the limited number of bleeds 
completed, and if blood samples were taken more frequently post-challenge, a more rapid 
response may have been seen.  
A large variation was seen in the number of gene mutant numbers obtained via TnSeq, 
although significantly fewer were identified in the vaccinated animals, suggesting vaccination 
did have an effect and resulted in significantly increased killing of the transposon library in 
the vaccinated calves. The variability was again seen when comparing the number of 
transposon mutants recovered from the vaccinated animals. The vaccination did not lead to 
statistically significant differences in recovered transposon mutants, post-lymph node 
selection. This suggests that transposon insertions were present that lead to slow growing 
cells that were not identified during mutant quantification. The data demonstrates the 
variability in the efficacy of the BCG Danish vaccine in calves, which is attributed to a 
multitude of factors covered in the review written by Vordermeier et al (Vordermeier et al., 
2016). The lack of difference and high variability in recovered mutants from the vaccinated 
animals is consistent with previous studies recording the efficacy of BCG vaccination in 
calves, with field studies reporting a 56-68 % efficacy (Ameni et al., 2010; Lopez-Valencia et 
al., 2010). Figure 5.3 demonstrated 2/6 libraries recovered from the lymph nodes in 
vaccinated animals had similar bacterial burden to the naïve animals, suggesting a lack of 
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protection conferred by the BCG vaccination. Ideally, more animals would have been used to 
account for this known variability in efficacy but that was not feasible in this study.  
Genes were selected for recombinant protein expression based on their significance in this 
study as well as any previous literature reporting a function or potential antigen/immunogenic 
properties. Significance in this study was passed on rank product analysis. Genes with a pfp 
<0.1 and a high fold change were predominantly selected, unless the literature revealed a 
mechanism which may have led to the gene potentially lacking antigenic properties.  
Several of the genes identified, such as ppm1, ltp2 and potentially mb2235 are most likely 
involved in changing cell surface morphology and chemistry, rather than possessing antigenic 
properties themselves. These genes are good candidates for further study. Ppm1 has not 
previously been linked with the production of immunogenic glycolipids and its role in this 
process would be interesting to investigate. Likewise, Ltp2 may also be involved in the 
synthesis of antigen lipids. The fold-change in the number of transposon mutants found in the 
vaccinated animals compared to the naïve is stark for ppm1, adding to the potential 
importance of this gene. Glycolipid antigens would be recognised via the CD1 antigen 
presenting pathway, as opposed to MHC class II used by antigen presenting cells presenting 
protein antigens. Ppm1 is involved in lipomannan and LAM synthesis- mycobacterial cell 
wall proteins and immune agonists (Doz et al., 2007; Rana et al., 2012). Mannose-capped 
LAM has been reported as possessing immunogenic properties (Garg et al., 2008; Richmond 
et al., 2012). Its identification in this study suggests incomplete formation of these 
glycolipids leads to the loss of their antigenic properties and therefore adaptive immune 
evasion. It may be of interest to assess protection conferred by fully synthesised lipomannan 
and LAM, in particular mannose-capped LAM, in a subunit vaccine.  
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Genes that were extracellular, located in the membrane or potentially secreted were of 
interest. Mb0086-probable oxidoreductase, PPE20- PPE family protein, YrbE1B-intergral 
membrane protein and originally Mb0024 and Mb0025- thought to be P60 secreted proteins, 
were examples of these. Mb0024 and Mb0025 were selected based on the fact they may have 
been secreted proteins, however after selection research was published suggesting they had a 
role in cell wall morphology, due to a potential function as a peptidoglycan amidase, and 
were therefore not likely to possess antigenic properties themselves (Padhi et al., 2016). 
Mb0086 was selected due to its potential membrane-bound nature. PPE family proteins have 
previously been reported as possessing immunoregulatory properties, as well having cell 
surface exposure, thus PPE20 was selected (Nair et al., 2009). YrbE1B was selected due to 
its potential membrane-bound nature. High fold-change in the number of transposon inserts 
was also exhibited by these proteins.  
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Chapter 6 
Immunogenicity of selected BCG antigens in BCG 
vaccinated cattle 
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6.1 Introduction 
 
In the previous chapter, a library of mutant BCG was selected in BCG immunised cattle and 
mutant survival compared to that in naïve cattle. Mutants with enhanced survival in 
immunised, compared to naïve, cattle were hypothesised to include those in which expression 
of protective antigens had been knocked out. This chapter describes the process of cloning 
the selected genes into an E. coli expression vector, subsequent recombinant protein 
expression and testing the immunogenicity of the expressed proteins (or synthetic peptides 
for those proteins that could not be expressed) in bovine peripheral blood mononuclear cells 
from BCG vaccinated cattle. 
Six genes were chosen for cloning, protein expression and immunogenicity tests: mb0024, 
mb0025, mb0086, mb2235, yrbE1b, PPE20. These genes had significantly more transposon 
insertions present in the BCG vaccinated group compared to the immunologically naïve 
animals, suggesting that they may directly encode the targets of a protective immune 
response (Chapter 5). An alternative explanation for their selection in vaccinated animals was 
that the genes may be involved in pathways related to the  synthesis of non-protein antigens, 
such as ppm1 (Cole et al., 1998), although testing this latter hypothesis was beyond the scope 
of this thesis.  
Recombinant protein expression in E. coli is a long established method to produce large 
amounts of  heterologous protein and was used in this study (Baneyx, 1999). Mycobacterial 
proteins have previously been expressed using E. coli expression systems, including the 
pet15b expression vector used in this study (Thole et al., 1985; Brennan et al., 2001; Kim et 
al., 2006; Scherr et al., 2009). Proteins that could not be expressed were purchased as 
synthetically produced peptides, which were tested as peptide pools. 
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PBMC stimulation is a well-documented method of assessing the immunogenicity of antigens 
(Turner and Dockrell, 1996; Lenarczyk et al., 2000; Meade et al., 2008). In this study, the 
individual recombinant BCG antigens were tested against PBMC from cattle pre- and post- 
BCG vaccination. The immunogenicity was assessed using cytokine readouts, generated by 
enzyme-linked immunosorbent assays (ELISA) and mesoscale discovery (MSD) techniques.  
The  cytokines used in this study were: IFN-γ, IP10, IL-17a, IL-10, IL-12, IL-1β and TNF-α, 
all of which have previously been shown to be involved in the host immune response to 
mycobacterial infections  (Kaufmann et al., 2014). Some of them, like IP10 and IL-17a have 
previously been described as immune correlates of protection in the bovine system (as 
reviewed by Vordermeier et al 2016). IL-10, IL-12, IL-1β and TNF-α were selected due to 
their relevance in the bovine immune response to M. bovis infection and their previous use in 
immunogenicity studies (Jones et al., 2013; Coppola et al., 2016; Hamilton et al., 2016). This 
is significant as it cannot be assumed that the immune response generated after exposure to 
these proteins or peptides is indicative of a robust adaptive response leading to protection 
against M. bovis infection. However, these assays were a reasonable way to assess the 
antigenic properties of these proteins as an increase in cytokine production is a relevant 
response  (Mustafa et al., 2006; Vordermeier, Gordon and Hewinson, 2011; Kassa et al., 
2012; White et al., 2015). Of particular relevance to the selection of cytokines to be assessed 
in this chapter is a recent study completed by Coppola et al investigating M. tuberculosis 
antigens and cytokine responses (Coppola et al., 2016). This paper identified IP10, IL-17a 
and TNF-α production to be prominently induced in PBMCs isolated from people differently 
exposed to mycobacteria when exposed to their predicted antigens. These cytokines were 
therefore especially relevant to this study.  
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The specific objectives of this chapter were to: 
1) Express recombinant proteins encoded by the genes mb0024, mb0025, mb0086, 
mb2235, yrbE1b, PPE20 in E. coli using the pet15b expression plasmid. 
2) Purify and quantify the recombinant proteins. 
3) Assess the post-BCG vaccination immunogenicity of expressed proteins and synthetic 
peptides via bovine PBMC stimulation and immunoassays quantifying the release of 
IFN-γ, IP10, IL-17A, IL-10, IL-12, IL-1β and TNF-α.  
6.2 Gene Cloning, Recombinant Protein Expression and Purification 
6.2.1 Cloning and Sequence Confirmation 
Six genes were selected for cloning: mb0024, mb0025, mb0086, mb2235, yrbE1b, PPE20. 
Initially, the genes were amplified from the BCG Danish genome using PCR, as described in 
Section 3.11.1. A number of iterative optimisations (annealing temperature, additives such as 
glycerol) were performed in order to successfully amplify products of the expected size: 
mb0024 had a predicted size of 834 bp, mb0025 270 bp, mb0086 1929 bp, mb2235 1134 bp, 
yrbE1b 870 bp and PPE20 1620 bp (Figure 6.1). A single PPE20 product was not produced 
however, sufficient product of the correct size was produced to allow attempted cloning 
(Figure 6.1). All the genes were amplified with primers incorporating either Xho1 or Nde1 
restriction digest sites at the start and end of each sequence to facilitate in-frame, sticky end 
ligation into a pet15b expression plasmid (Appendix 3.2). Library Efficiency DH5 Competent 
Cells were transformed with the ligation reactions and the resultant colonies were picked for 
direct colony PCR to assess the presence of the insert within the plasmid (Figure 6.2).  
Despite several attempts at ligation and transformation, no colonies were obtained for the 
PPE20-pet15b ligation/transformations. This suggested that PPE20 may be toxic for E. coli. 
For the mb0025 and mb2235 ligation/transformations, all colonies were picked for 
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confirmation by PCR. One colony for mb0025 and two for mb2235 were confirmed to 
contain the plasmid with the desired insert and were selected for plasmid propagation and 
further characterisation by restriction enzyme digest (Figure 6.2).  
The success of the ligation and transformations with the genes mb0024, mb0086 and yrbE1b 
was also checked by colony PCR. The presence of these inserts in the plasmid preparation 
was confirmed in a number of transformants (Figure 6.3).   
 
 
  
Figure 6.1 PCR amplification of putative antigen encoding genes from within the BCG 
Danish genome. mb0024 (834 bp), mb0025 (270 bp), PPE20 (1620 bp) and mb0086 (1929 
bp) were successfully amplified with primers incorporating Xho1 restriction sites(A). yrbE1b 
(870 bp) and mb2235 (1134 bp) were successfully amplified and Xho1 and Nde1 restriction 
sites were respectively incorporated (B). Promega 1kb ladder used. A no-template negative 
control was used. 
 
 
 
 
750bp 
140 
 
 
Figure 6.2 Confirmation PCR to detect the presence of mb0025 and mb2235 within pet15b 
plasmid isolated from transformed DH5α E. coli. Ten ampicillin resistant DH5α E. coli 
colonies were picked and the presence of mb0025 (270 bp) insert was checked. Colony 8 
contained the correct insert (A). Sixteen colonies were picked and the presence of mb2235 
(1134 bp) insert was checked. Colonies 4 and 15 contained the correct size insert (B). 
Promega 1kb ladder used. A no-template negative control was used.  
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Figure 6.3 Confirmation PCR to detect the presence of mb0024, mb0086 and yrbE1b in 
pet15b plasmid isolated from transformed DH5α E. coli.  A showing colonies with the 
presence of mb0024 (834 bp), B the presence of mb0086 (1929 bp) insertions and C the 
presence of the yrbE1b (870 bp) sequence in the pet15b plasmid. Colonies containing the 
desired plasmid were picked and cultured for plasmid extraction. Promega 1kb ladder used. 
A no-template negative control was used. 
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To confirm the PCR-based indication of cloning success and to assess the orientation of the 
insert within these plasmids, the relevant transformants were cultured and plasmid was 
extracted. The plasmids were then cut by restriction enzymes chosen to give restriction 
fragments that would be diagnostic of the insert and orientation. For mb2235c, the plasmid 
was cut with sph1 and produced fragments consistent with the expected sizes of 6084 bp and 
761 bp, which confirmed successful cloning in the correct orientation (Figure 6.4A). The 
restriction enzyme used (BamH1) to assess the orientation of mb0025 yielded a 97 bp 
fragment. As the molarity of DNA required to visualise this size fragment (97 bp) on an 
agarose gel is high, this fragment was difficult to observe. Therefore, the plasmid was also 
cut with Xho1 to confirm the presence of the mb0025 insert (Figure 7.4). However, digestion 
with this restriction enzyme could not confirm insert orientation. The insertion site was also 
sequenced to confirm no fidelity and orientation of the sequence during the amplification.   
For the yrbE1B-pet15b cloning, one of the colonies identified by PCR yielded a plasmid that 
was successfully cut with BssHII to yield restriction fragments consistent with cloning of 
yrbE1B in the correct orientation (4405 and 2173 bp) (Figure 6.5). This was confirmed by 
sequencing and taken forward for protein expression trials. 
For the mb0024 and mb0086 cloning, restriction digest of plasmid from the PCR-positive 
transformants indicated that none contained the desired inserts. This suggested that the PCR 
of putative mb0024-pet15b and mb0086-pet15b transformants gave false positives and that 
the PCR product was probably derived from residual non-ligated insert DNA remaining from 
the ligation reaction. A further several hundred colonies for each mutant were screened for 
cloning of these two genes but without success. It was also attempted to clone the mb0024 
and mb0086 genes into sub-cloning vectors with commercial TOPO systems (ThermoFisher 
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Scientific). This was also unsuccessful suggesting that the gene products may be toxic to E. 
coli. 
In summary: the yrbE1b-pet15b, mb0025-pet15b and mb2235-pet15b, expression plasmids 
were successfully generated and taken forward for protein expression. For the remaining 
genes that could not be successfully cloned, peptides were later purchased as individual 
peptide pools from JPT Peptide Technologies.  
 
 
Figure 6.4 Restriction enzyme digests of putative pet15b plasmid ligated to yrbE1B and 
mb0025 gene DNA. Bands of 6084 bp and 761 bp obtained through pet15b-mb2235 Sph1 
digest confirm the insert mb2235 is correctly orientated (A). pet15b-mb0025 cut with BamH1 
confirms the correct orientation of the inserted gene (B). Due to the low molarity of the 97 bp 
fragment, the band is faint. pet15b-mb0025 cut with Xho1 confirms the presence of the 
mb0025 insert (C). Promega 1kb ladder used.  
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Figure 6.5 Restriction enzyme digests of putative pet15b plasmid ligated to yrbE1b, mb0024 
and mb0086 gene DNA. Inserts were cut with BssHII, BamH1 and Nru1 respectively. yrbE1b 
1 shows bands of the expected sizes (2173/4405) once cut. All other samples show no 
presence of insert due to only one band being seen at the expected size of the pet15b plasmid. 
Promega 1kb ladder used. 
7.2.2 Protein Expression and Purification  
 
BL21 competent E. coli were transformed with yrbE1B-pet15b, mb0025-pet15b and mb2235-
pet15 for protein overexpression. Protein bands of approximately 10.7 kDa (Mb0025), 40.7 
kDa (Mb2235) and 31 kDa (YrbE1b) were expected to be seen via SDS-PAGE when the 
BL21 E. coli whole cell lysate was purified using a His SpinTrap column. Mb0025, Mb2235 
and YrbE1b are 9.64 kDa, 39.75 kDa and 30.29 kDa respectively, however as an N-terminal 
poly-histidine tag has been incorporated into the protein, the estimated weight is increased by 
1 kDa.  The tag was necessary to enable the purification of the required protein from the E. 
coli proteome.  Expression was induced in transformants containing mb0025-pet15b and 
mb2235-pet15 plasmids. Mb0025 and Mb2235 preparations both had bands of the expected 
sizes present after purification. The YrbE1b preparation showed no protein band of the 
desired size, suggesting this protein was not expressed in E. coli. yrbE1b is part of the mce1 
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operon and is a conserved integral membrane protein (Shimono et al., 2003). Over-
expression of membrane proteins is known to be commonly toxic in this expression system, 
resulting in the death of the E. coli  cells (Miroux and Walker, 1996). Thus, the lack of 
expression may be due to the toxic effect of the protein, resulting in the death of the cells and 
therefore no detectable recombinant protein expression. Lower temperatures (30˚C) and an 
alternative E. coli expression strain which is more resistant to toxic proteins (CD41 E. coli) 
were used but to no avail (data not shown).  
Analysis of the expressed proteins demonstrated that Mb0025 and Mb2235 could only be 
isolated from the insoluble fraction of the preparation (Figure 6.6). There was no presence of 
either protein in the soluble fraction of the lysate. This suggested that both proteins are 
hydrophobic in the conditions used. Lower induction temperatures have been used to increase 
expression of proteins in the soluble fraction but were unsuccessfully tried for both proteins 
in this study. However, the solubility of the proteins for the immunological experiment 
described later in this chapter was not of concern as the function of the protein was not 
required and even proteins of low solubility can be processed and presented successfully to T 
cells (M. Vordermeier, personal communication). However, insoluble misfolded proteins 
forming aggregates may impact the quality of the generated immune response resulting under 
or over-evaluation of immunogenicity (Ratanji et al., 2014, 2016). The non-physiological 
buffers the insoluble proteins were eluted in may also impact antigen presentation (Van Ness, 
Laemmli and Pettujohnt, 1984).  The expression was repeated with a no insert negative 
control and an acr2-pet15b positive control and the expressed proteins were purified using a 
His SpinTrap column.  Figure 7.7 shows the results of this purification step. The wash and 
lysate flow-through can also be seen on this image. No bands representing Mb0025 and 
Mb2235 can be seen in these wells, showing the efficiency of the purification step. In the 
elution, a band with the expected molecular weight of around 40 kDa was found for Mb2235. 
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In addition, a large band at approximately 100 kDa was also seen. This his-rich protein could 
be Mb2235 with an attached chaperone or it could be a histidine rich protein innately found 
in E. coli of approximately 100 kDa, such as AceE. As the Mb2235 concentration in this 
preparation was high, the unexpected protein was sufficiently diluted out of the preparation 
when the sample was diluted for PBMC stimulation. Mb0025 purified at the expected 11 kDa 
weight. Post his-tag purification an Acr2 band was seen at the expected size (18 kDa) in the 
positive control and the no insert negative control showed no bands. As the negative control 
lacked any histidine rich proteins, this suggests the 100 kDa band in the Mb2235 preparation 
is in fact Mb2235 with a chaperone attached, or possibly a Mb2235 homodimer. 
 
 
 
 
 
 
 
 
Figure 6.6 SDS-PAGE identification of recombinant proteins mb0025 and mb2235 from 
whole cell lysate expressed using pet15b vector in BL21 E. coli. His-tagged proteins were 
purified using HisSpin Trap columns and visualised using SDS-PAGE. Mb0025 and Mb2235 
were identified in the insoluble fraction of the lysate. Thermo Fisher Scientific PageRuler 
plus Prestained protein ladder used.  
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The buffer used in this purification protocol contained 8M urea and imidazole which would 
have destroyed the PBMC used for the immunological experiments.   To lower the 
concentrations found of these substances in the buffer, the protein was dialysed into a buffer 
containing the desired concentrations (2M urea and no imidazole). The presence of the 
proteins in the new buffer was determined using SDS-PAGE (Figure 6.8).  
The protein concentration post purification and dialysis was determined using a BCA-assay. 
The protein concentrations achieved were 9.5 mg/ml and 5 mg/ml for Mb0025 and Mb2235 
respectively. The samples with the were taken forward for dialysis and for use in the 
immunoassays. Mb0025 could not be recovered post-dialysis. This was potentially due to the 
small size of the protein (approximately 10 kDa), meaning it was lost through the column 
membrane during the dialysis process despite a stated cut-off pore size of 10 kDa. 
Consequently, Mb0025 was used in the native insoluble elution buffer to stimulate the bovine 
PBMCs. The dilutions performed to achieve the required assay concentration of protein for 
the stimulation of the bovine PBMC did, however, mean that the urea and imidazole were 
sufficiently diluted to have no negative effects on the immunoassays.  As Mb0086, YrbE1B 
and PPE20 could not be prepared as recombinant proteins, overlapping sets of synthetic 
peptides pools purchased from JPT Peptide Technologies (see Appendix 3.3 for sequence 
details). The peptide pools consist of a number of 20 amino acid long peptides, with a 12-
amino acid overlap between sequential peptides to ensure potential epitopes are not lost. 
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Figure 6.7 His SpinTrap purification of Mb0025 and Mb2235 visualised using SDS-PAGE. A 
his-tagged acr2 expression control was used and isolated in the soluble fraction post 
purification. A no insert negative control was used, no proteins were seen post purification. 
Lysate and wash samples show no presence of desired proteins in both protein preparations. 
Thermo Fisher Scientific PageRuler plus Prestained protein ladder used. 
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Figure 6.8 SDS-PAGE visualisation of Mb2235 and Mb0025 after dialysis into 2M urea 
buffer. Mb2235 and the 100 kDa band can be seen using SDS-PAGE. Mb0025 was not seen 
and was believed to have been lost through the dialysis membrane due to its small size. Acr2 
positive control was seen at the predicted size of 18 kDa. Thermo Fisher Scientific PageRuler 
plus Prestained protein ladder used. 
 
6.3 BCG Vaccinated and Immunologically Naïve PBMC Stimulation 
6.3.1 Immunological analysis 
Bovine PBMCs isolated from BCG vaccinated or immunologically naïve animals were used 
to evaluate the antigenicity of the proteins and peptides. Immunologically naïve (in terms of 
BCG vaccination) PBMCs were purified from blood samples collected from the BCG 
vaccinated animals prior to vaccination. This allowed a direct, pair-wise determination of a 
BCG vaccination effect on the recognition of these antigens. If exposure to these potential 
antigens post-BCG vaccination led to a greater cytokine response compared to exposure in 
naïve PBMCs, this would support the hypothesis that these antigens are targets of the BCG-
induced immune response contributing to protection.  
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Bovine PBMCs were exposed for 3 days to the proteins/peptide pools. Following exposure, 
cell supernatants were harvested and stored at -80oC until further analysis. Cytokine levels 
were analysed using ELISAs (IFN-γ, IP10, IL-17a) or MSD (IL-10, IL-12, IL-1β, TNF-α).  
6.4 Cytokine Profiles of Bovine PBMCs Stimulated with PPDB 
Initially, the response to bovine tuberculin PPD (PPDB) was assessed to demonstrate that 
BCG induced immune responses in these calves following vaccination (Figure 6.9). Increased 
cytokine levels post-vaccination to PPDB, confirms that the animal had responded to the 
vaccine. TNF-α release was highly variable, possibly anomalous, with 8/10 samples showing 
no detectible cytokine release. Only 1/10 demonstrated a vaccine-induce increase in TNF-α 
production. Based on this, all cytokines, bar TNF-α, were taken forward to be measured 
during protein/peptide pool exposure. Significant increases in IP10 (8/10), IL-17A (8/10), IL-
1β (9/10) and IL-12 (9/10) were exhibited in PBMCs isolated from vaccinated animals 
compared to pre-BCG levels (p<0.05).  Although not statistically different as a complete 
dataset, three out of ten PBMC samples produced increased IFN-γ post-vaccination and 5/10 
PBMCs produced more IL-10 post-vaccination.  
151 
 
P
re
P
o
s
t
0
2
4
6
8
IF N -
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
IP 1 0
n
g
/m
l
P
re
P
o
s
t
0
1
2
3
4
IL -1 7 a
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
IL -1 
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
IL -1 0
n
g
/m
l
P
re
P
o
s
t
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
0 .2 5
IL -1 2
n
g
/m
l
2
1
2
9 2
* *
* *
 
Figure 6.9 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated from 
cattle pre- and post BCG vaccination upon stimulation with PPDB. Cytokine levels were 
quantified using ELISA (IFN-γ, IP10, IL-17a) and MSD (IL-10, IL-12, IL-1β, TNF-α). IP10, 
IL-17a, IL-1β, and IL-12 release was significantly higher in PBMCs isolated from vaccinated 
cattle. No statistically relevant increase was seen in IFN-γ and IL-10 release.  A one-tailed 
paired t-test was used to assess significance (p<0.05). Numbers above data sets represents 
the number of PBMC samples with undetectable levels of cytokine.  
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These results were promising as they confirm the ability of the selected PBMCs from BCG 
vaccinated calves to establish a multi-cytokine response to PPDB. Next, the multi-cytokine 
responsiveness of PBMC from BCG vaccinated calves was assessed after stimulation with 
the recombinant proteins and peptides introduced above.  
6.5 Cytokine Profiles of Bovine PBMCs Stimulated with the Recombinant Proteins 
(Mb2235, Mb0025) and Peptide Pools (YrbE1B, PPE20, Mb0086) 
PBMCs harvested from cattle prior and post BCG vaccination were stimulated for 3 days 
with Mb2235 and Mb0025 recombinant proteins. Supernatants were harvested and stored at -
80oC. Supernatants were thawed and immunoassays quantifying the levels of IFN-γ, IP10, 
IL-17a, IL-1β, IL-10 and IL-12 were completed to profile the cytokine response following 
protein stimulation. TNF-α release was not measured due to the lack of response seen to 
PPDB seen in these cultures. PWM positive controls were completed with all assays 
confirming the ability of the cultures to generate a multi-cytokine response.  
6.5.1 Cytokine Responses to Recombinant Proteins 
 
Responses to Mb0025: 
Figure 6.10 highlights the cytokine profiles of PBMCs stimulated by Mb0025 recombinant 
protein. Insignificant post-vaccination increases in the production of IFN-γ (5/10 increased), 
IL-17a (6/10), IL-1β (3/10) and IL-12 (6/10) were observed. No increase in the production of 
IP10 and IL-12 was observed in any animal post-vaccination.   
Responses to Mb2235: 
Figure 6.11 shows the cytokine response when bovine PBMCs from BCG vaccinated calves 
were exposed to the recombinant protein Mb2235. PBMCs harvested from the same animal 
before and after vaccination were compared. Increased responses were seen in some 
individual cattle for the production of IFN-γ (5/10 increased, not significant (ns)), IP10 (0/10, 
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ns), IL-17a (3/10, ns), IL-1β (3/10, ns), IL-10 (6/10, ns) and IL-12 (2/10, ns). There was 
however, no significant difference between the groups. The high IL-10 response may have 
led to reduced expression of IL-12. The lower IP10 levels correlates with the low IFN-γ 
responses.  
6.5.2 Responses to Synthetic Peptides  
Unfortunately, due to financial resource constraints, procurement of enough synthetic 
peptides to test only 3 BCG vaccinated animals pre and post-BCG vaccination was possible.   
Data generated from individual peptide pools per protein were combined and the average 
response over all pools calculated.  
Response to Mb0086 
Figure 6.12 presents the cytokine profiles of PBMCs stimulated with Mb0086. Increased 
response post-vaccination were observed in the production of IFN-γ (1/3 positive, ns), IP10 
(3/3, p<0.05), IL-17a (3/3, ns), IL-1β (2/3, ns) and IL-10 (3/3, ns). No increase in IL-12 
production was seen. 
Response to YrbE1B 
Figure 6.13 presents data generated after PBMC stimulation with YrbE1b. Increased 
responses post-vaccination were observed in the production of IFN-γ (1/3 positive, ns), IP10 
(3/3, p< 0.05), and IL-17A (3/3, ns) and IL-10 (3/3, ns) and IL-1β (1/3, ns). No increased 
production of IL-12 was observed post-BCG. 
Response to PPE20 
Figure 6.14 highlights the cytokine profiles of PBMCs stimulated with synthetically derived 
PPE20.  Increased responses post-vaccination were seen in the production of IFN-γ (1/3 
positive, ns), IP10 (3/3, p<0.05), IL-17a (2/3, ns), IL-1β (2/3, ns) and IL-10 (2/3, ns). No 
increase in IL-12 production post-vaccination was seen in any animals. 
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Figure 6.10 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated from 
cattle pre- and post BCG vaccination upon stimulation with Mb0025 recombinant protein. 
Concentrations quantified using ELISA and MSD. IP10 and IL-12 was not produced in 
animals post-BCG. IFN-γ release was increased in 50 % of animals post-vaccination. 60 % 
demonstrated increased release of IL17a and IL-10 post-vaccination. IL-1β release was 
increased in 30 % of vaccinated animals. The number of cultures with undetectable levels of 
cytokine is symbolised by the figure above the data sets. A one-tailed paired t-test was used to 
assess significance (p<0.05).  
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Figure 6.11 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated from 
cattle pre- and post BCG vaccination upon stimulation with Mb2235 recombinant protein. 
Concentrations quantified using ELISA and MSD. 5/10 of cultures had increased IFN-γ 
production post-vaccination. A loss of an IP10 response was seen in all cultures. 3/10 of 
cultures had increased IL-17a and IL-1β production. 6/10 had increased IL-10 production. 
2/10 showed increased IL-12 production. The number of cultures with undetectable levels of 
cytokine is symbolised by the figure above the data sets. A one-tailed paired t-test was used to 
assess significance (p<0.05).
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Figure 6.12 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated from 
cattle pre- and post BCG vaccination upon stimulation with Mb0086 peptide pools. 
Concentrations quantified using ELISA and MSD. Mean response from all pools shown. 3/3 
PBMC cultures exhibited an increase in IP10, IL-17a and IL-10 post vaccination. 2/3 
cultures had an increase in IL-1β. 1/3 cultures exhibited an increase in IFN-γ. IL-12 was 
undetectable in all cultures. The number of cultures with undetectable levels of cytokine is 
symbolised by the figure above the data sets. A one-tailed paired t-test was used to assess 
significance (p<0.05).
157 
 
 
P
re
P
o
s
t
0
2
4
6
IF N -
n
g
/m
l
P
re
P
o
s
t
0 .0 0
0 .0 5
0 .1 0
0 .1 5
0 .2 0
IP 1 0
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .2
0 .4
0 .6
0 .8
IL -1 7 a
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .1
0 .2
0 .3
IL -1 
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .5
1 .0
1 .5
2 .0
IL -1 0
n
g
/m
l
P
re
P
o
s
t
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
IL -1 2
n
g
/m
l
3 2
3 3
*
 
Figure 6.13 13 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated 
from cattle pre- and post BCG vaccination upon stimulation with YrbE1B peptide pools. 
Concentrations quantified using ELISA and MSD. Mean response from all pools shown. 3/3 
PBMC cultures exhibited an increase in IP10, IL-17a and IL-10 post vaccination. 1/3 
exhibited an increase in IFN-γ and IL-1β. IL-12 production was undetectable in all cultures. 
The number of cultures with undetectable levels of cytokine is symbolised by the figure above 
the data sets. A one-tailed paired t-test was used to assess significance (p<0.05). 
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Figure 6.14 IFN-γ, IP10, IL-17a, IL-1β, IL-10 and IL-12 release from PBMCs isolated from 
cattle pre- and post BCG vaccination upon stimulation with PPE20 peptide pools. 
Concentrations quantified using ELISA and MSD. Mean response from all pools shown.3/3 
PBMC cultures exhibited an increase in IP10 post vaccination. 2/3 exhibited increased 
release of IL-17a, IL-1β and IL-10. 1/3 exhibited an increase in IFN-γ. IL-12 was 
undetectable in all cultures. The number of cultures with undetectable levels of cytokine is 
symbolised by the figure above the data sets. A one-tailed paired t-test was used to assess 
significance (p<0.05). 
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6.6 Discussion 
 
Five proteins were selected for recombinant protein expression and purification- Mb0025, 
Mb0086, YrbE1B, PPE20 and Mb2235. Mb0025 and Mb2235 were successfully expressed 
and purified using the pet15b E. coli expression system. The incorporated histidine tag was 
used to purify the proteins. Mb0086, YrbE1B and PPE20 failed to be expressed due to 
problems encountered throughout the protocol. These proteins were purchased as peptide 
pools, simulating the entire the protein and the corresponding potential T-cell epitopes. To 
avoid the loss of any epitopes the peptides were synthesised as 20mers with a 12mer overlap 
between each peptide. The original intention was to use whole recombinant proteins in the 
assays, however due to the inability of YrbE1B, PPE20 and Mb0086 to be expressed this was 
not possible. These proteins may possess toxic properties when artificially produced in non-
native species, explaining the lack of expression in this E. coli system. Recombinant protein 
expression is an economical way to mass produce desired proteins, whereas synthesising 
peptides is an expensive process. For these proteins to be viable in a subunit vaccine the 
process first must be optimised to enable recombinant protein expression. 
Bovine PBMCs harvested from animals pre and post BCG vaccination were stimulated with 
the recombinant proteins and peptides pools, and immunoassays quantifying cytokine profiles 
were completed. As the PBMCs were harvested from the same animals prior to and post 
vaccination, this enabled the direct comparison of cytokine responses after stimulation to be 
made. Unfortunately, due to financial constraints, the quantity of peptides purchased only 
allowed for a small number of stimulations to be completed for Mb0086, YrbE1B and PPE20 
peptide pools.  
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  IFN-γ IP10 IL-17a IL-1β IL-10 IL-12 
PPDB 3/10 8/10* 8/10* 9/10* 5/10 9/10* 
Mb0086 1/3 3/3* 3/3 2/3 3/3 0/3 
YrbE1B 1/3 3/3* 3/3 1/3 3/3 0/3 
PPE20 1/3 3/3* 2/3 2/3 2/3 0/3 
Mb0025 5/10 0/10 6/10 3/10 6/10 0/10 
Mb2235 5/10 0/10 3/10 3/10 6/10 2/10 
 
Table 6.1 Summary of cytokine responses detected upon PBMC stimulation with predicted 
antigenic proteins. Increases in cytokine production frequencies in cells harvested from 
vaccinated animals compared to immunologically naïve animals are tabulated. n=10 for 
PPDB, Mb2235 and Mb0025. N=3 for YrbE1B, PPE20 and Mb0086. Responder frequencies 
with an * have a statistically significant increase in cytokine release post-vaccination (paired 
one tail t-test, p<0.05) 
We proposed that a multi-cytokine response is potentially beneficial for a protein to be 
protective. This is based on the hypothesis put forward and data generated by the Ottenhoff 
group who stipulated that, in particular, increased IP10 and IL-17 responses are relevant 
when assessing antigen immunogenicity (Coppola et al., 2016). Their predicted antigens 
stimulated a multi-cytokine response in whole blood supernatants isolated from individuals 
differently exposed to mycobacteria, with a focus on IFN-γ, IP10, IL-17 and TNF-α 
production. The study highlights the need for a wider range of cytokines in the antigen 
discovery process, and identifies the previously mentioned cytokines as being induced upon 
stimulation with predicted antigens. Table 6.1 summarises the results obtained from the 
PBMC stimulations completed in this study.  Although the increases in the proportions of 
cytokine responders post-vaccination compared to pre-vaccination values were only 
statistically significant for IP10 for YrbE1B, PPE20 and Mb0086, a trend of increased 
cytokine production post-vaccination was seen with IL-17a and IL-10 for Mb0086, YrbE1B, 
PPE20 and Mb0025.  
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Responses after stimulation with PPDB: 
Interestingly, IFN-γ, a cytokine established to be involved in the host response to 
mycobacterial infections increased only in 30 % of BCG Danish vaccinated calves when 
stimulated with PPDB. This was not entirely surprising however, because  previous studies 
have shown IFN-γ release to PPDB post-BCG vaccination can be low (Widdison et al., 2006; 
Wedlock et al., 2007; Rizzi et al., 2012). IFN-γ release has been linked with protection 
(Vordermeier et al., 2016). After PPDB stimulation 80 % of cultures showed an increase in 
IP10 and IL-17a production post-vaccination. A high IL-17a response in vaccinated animals 
was promising because  IL-17a has previously been identified as being indicative of a 
protection (Vordermeier, Villarreal-Ramos, et al., 2009; Aranday Cortes et al., 2010; Rizzi et 
al., 2012; Aranday-Cortes et al., 2013). IL-17a is a pro-inflammatory cytokine produced by 
Th17 cells with a role in the neutrophil-mediated inflammatory response, T-cell mediated 
IFN-γ production and granuloma formation (Umemura et al., 2007). IP10 is currently not 
known as being an indicator of vaccine efficacy, however its release does correlate with 
disease and pathology (Aranday-Cortes et al., 2012). Increase in IP10 secretion is promising, 
as it signifies the recognition of the proteins and peptides. In this experiment, eight out of the 
ten animals responded to vaccination by increased production of IL-17a post-vaccination 
after in vitro PPDB stimulation. IL-12 is a immunoregulatory cytokine and is known to be 
crucial in the differentiation of naïve T-cells, promoting a protective Th1 response in mice 
infected with M. tuberculosis (Macatonia et al., 1995; Cooper et al., 1997). Therefore, the 
observation that nine out of ten cattle showed increase IL-12 responses after vaccination is 
encouraging. 90 % of cultures had an increase in IL-12 and IL-1β response post-vaccination. 
50 % of cultures showed an increase in IL-10 production post-vaccination. This was not an 
unexpected result, as previous studies have demonstrated both a low IL-10 response in BCG 
vaccinated calves when challenged with M. bovis as well as an increase in IL-10 expression 
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in vaccinated animals following challenge  (Hope et al., 2005b; Widdison et al., 2006; 
Vordermeier, Villarreal-Ramos, et al., 2009). Interestingly, IL-10 can inhibit production of 
IL-12 in M. tuberculosis infected macrophages as well as suppressing MHC-II expression in 
these conditions, resulting in a compromised Th1 response. This suggests high IL-10 levels 
would coincide with low levels of IL-12 (McNab et al., 2014; Richardson et al., 2015). 
Lower expression of MHC-II may also lead to the lack of development of a protective 
response due to antigen presentation being jeopardised. Although IL-10 is an anti-
inflammatory cytokine that suppresses the immune response and may not itself be protective, 
its release is still significant as it shows that the bovine immune response is recognising and 
responding to the antigenic proteins. Increased IL-1β levels have been associated with M. 
bovis infection  in cattle, therefore stimulation with immunogenic proteins was expected to 
lead to an increase IL-1β production (Jones et al., 2010). IL-1β is required for antigen-
specific T-cell activation in mice and is involved in the induction of inflammation in cell-
mediated immunity (Nambu, Nakae and Iwakura, 2005). The cytokine profiles upon 
stimulation of PPDB are highly relevant as they demonstrate the ability of the cells to 
generate a multi-cytokine response to M. bovis antigens.  
Responses after stimulation with recombinant proteins or synthetic peptides: 
As outlined in the introduction and based on the recent study completed by Coppola et al 
2016 investigating M. tuberculosis antigens and cytokine responses, our gating criteria for 
selection of potential protective antigens to be tested, e.g. in small animal models, were 
multi-cytokine responses and in particular,  IP10, IL-17a and TNF-α production (Coppola et 
al., 2016). This study also suggests a lack of IFN-γ response does not necessarily mean a lack 
of protection.  PBMC stimulation with the proteins and peptides tested in this study, 
specifically YrbE1b, PPE20 and Mb0086 induced an IP10 and IL-17a response, suggesting 
these be the best candidates to take forward for further analysis, specifically with the aim to 
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test whether they are protective antigens (Table 6.1). A trend of increase in IL-1β was seen 
with Mb0086 and PPE20 and IL-10 in Mb0086 and PPE20. However, as the sample number 
in this study was low, the top priority would be to further investigate their in vitro cytokine 
profiles.  The induction of an IL-17a response is highly relevant due to its link with 
protection against M. bovis infection in cattle (Vordermeier, Villarreal-Ramos, et al., 2009; 
Bhuju et al., 2012). The lack of IL-12 response with all proteins does not suggest a lack of 
protection, and may have been a result of the increase in IL-10 production post-vaccination 
(Richardson et al. 2015; McNab et al. 2014). Importantly, the cytokine profiles do not 
inherently equate to a protective response, and further studies are required to assess the 
protective efficacy of these proteins.  
Stimulation with the recombinantly expressed proteins Mb2235 and Mb0025 did not lead to 
the production of a multi-cytokine response (Table 6.1). Importantly, cytokines previously 
linked with protection such as IL-17a, were not shown to increase post-vaccination. The lack 
of IP10 and IL-1β production after vaccination also suggest the lack of development of a 
robust protective response. This could be attributed to the insoluble proteins forming 
aggregates or the non-physiological buffer interfering the immunogenicity. Further studies 
would be required to assess this, with the first aim being to attempt to fully solubilise these 
proteins (Van Ness, Laemmli and Pettujohnt, 1984; Ratanji et al., 2014).  
Following confirmation of these data, small animal or further cattle studies should be 
completed to assess the protection inferred when used as a sub-unit vaccine as part of a 
prime-boost strategy alongside BCG Danish. Small animal studies are more economical and 
completion on a small scale prior to cattle studies to confirm the generation of a protective 
response may be the best course of action, however data generated from cattle experiments is 
highly relatable to the study aim. Further examination of the cytokine responses could also be 
completed using flow cytometry techniques and Enzyme-Linked ImmunoSpot (ELISPOT).  
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In conclusion, three proteins, Mb0086, YrbE1B and PPE20 were identified that generated an 
increased multi-cytokine response in vaccinated animals. Although protection has not been 
proven, this study has acted as a gate to select the best possible candidates for further 
experimentation. Importantly, an increased IL-17a response was seen to these antigens which 
has previously been linked with protection in cattle. Furthermore, an increase in IP10 after 
stimulation with these antigens, another possible predictor of protection in cattle (Bhuju et 
al., 2012) further supported the selection of these proteins for further study (Bhuju et al., 
2012).  
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Chapter 7 
Final Discussion 
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Bovine tuberculosis is an infectious disease of cattle which is of huge economic and animal 
welfare importance throughout the world with the estimated cost globally thought to be 
approximately US$3 billion annually (Waters et al., 2012). The most common causative 
agent of this chronic granulomatous caseous-necrotising inflammatory disease is M. bovis 
(Domingo, Vidal and Marco, 2014). M. bovis is part of the Mycobacterium tuberculosis 
complex, members of which cause tuberculosis in a wide variety of species, including 
humans. Along with its association with bTB, M. bovis has been linked with disease of wild 
life species such as the European badger (UK and Ireland), the White-tailed deer (US) and the 
possum (New Zealand) which act as environmental reservoirs of the disease, making disease 
control and eradication difficult (Krebs, 1997; Waters, Palmer and Whipple, 2002). The 
economic importance of bTB in Great Britain should not be understated. The associated cost 
of the disease over the 2013-2014 financial year was £99 million (Department for 
Environment Food & Rural Affairs, 2014b).  
The current control strategy involves a test and slaughter approach, with annual skin testing 
and whole blood IFN-γ release assays being completed in high risk areas to assess herd 
reactivity to PPDB. Animals exhibiting a response to PPDB are slaughtered and movement of 
cattle from infected herds is prohibited until an official bTB free status is awarded. In 
countries lacking a wildlife reservoir of M. bovis this strategy has led to the eradication of the 
disease (Cousins, 2001). In countries with a wildlife reservoir, controlled culling and strict 
implementation of the test and slaughter strategy can be successful (Livingstone et al., 2015). 
However, the culling of wildlife reservoirs is a controversial method of control in the UK. 
Meles meles (European badger) is a protected species in the UK and is known to harbour M. 
bovis. M. bovis is thought to be transmitted between badgers and cattle  (Krebs et al., 1998). 
Little is known about the routes of transmission between these species, however strain typing 
of M. bovis isolated from badgers and cattle revealed similar strains were found in both 
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animal species (Olea-Popelka et al., 2005; Godfray et al., 2013). The effectiveness of wide-
spread badger culling in the UK is yet to be determined, with many studies predicating 
compromised local control of bTB in cattle (Bielby et al., 2014, 2016), however modelling 
suggests an initial cull to remove infected badgers followed by a vaccination programme may 
be effective in the control of bTB in badgers (Abdou et al., 2016). With wide spread badger 
culling not currently a viable strategy in the UK, additional control measures are required to 
control bTB. On their own, the current test and slaughter measures are not sufficient for 
control and alternative control measures need to be adopted (Brooks-Pollock, Roberts and 
Keeling, 2014). 
Cattle vaccination is a promising strategy to aid in this endeavour. This premise has long 
been researched in the UK with many potential vaccines based on a prime-boost strategy or 
vaccination alongside BCG being developed (Tanghe et al., 2000; Vordermeier et al., 2001; 
Maue et al., 2007; Vordermeier, Villarreal-Ramos, et al., 2009). However, the vaccines 
developed in these previous studies have yet to be field tested and therefore the efficacy in a 
natural transmission setting has yet be ascertained. In addition to this, failure of a recent 
human TB vaccine approach using a vaccinia virus expressing Ag85A to boost neonatal BCG 
provides further reason to maintain all (cattle and human) TB vaccine development 
programmes until such point that an improved vaccine is found (Tameris et al., 2013). It is of 
note that this Ag85A approach used an antigen for which there was little evidence that it 
formed a protective immune antigen in the BCG response. The present PhD project has taken 
a more rational approach to identify the protective antigens of BCG in the target species to be 
vaccinated (cattle in this case), with a view to using these specific molecules to boost BCG 
primary vaccination.  
In the present project, vaccinated and immunologically naïve calves were intranodally 
challenged using a Mycomar transposon mutant library generated in BCG Danish. This 
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challenge system had been recently developed and shown to be capable of differentiating 
between BCG vaccinated and naïve cattle (Villarreal-Ramos et al., 2014). Mutant survival 
was quantified using the technique of TnSeq, which tracks the survival of thousands of 
mutant strains. It was hypothesised that the ability of a mutant to survive for longer/in 
increased numbers in the vaccinated animals, compared to the naïve, indicated that the 
mutant was lacking a protective antigen recognised by the adaptive immune response induced 
by BCG. This study did identify genes that upon transposon disruption lead to increased 
mycobacterial survival in vaccinated animals, these were: mb0024/25, mb0086, yrbE1B, 
vapB2, typA, mb1309, PPE20, katG, mb2235, ppm1 and ltp2. Upon review, not all of these 
genes could be associated with having antigenic properties and five (mb0025, mb0086, 
yrbE1B, PPE20 and mb2235) were selected for immunogenicity investigation.  
Initially, the ability to select genes within the transposon library relevant to a selection 
pressure needed to be validated. This was required to ensure the ethical use of animals in the 
subsequent challenge experiments. In this study, the mycobacterial heat-shock and INH 
resistance pathways were used to verify this. Both of these pathways are well researched, 
with essential genes in each pathway being established (Ying Zhang et al., 1992; Group et 
al., 2001). hspR was the chosen ‘control’ gene in the heat-shock selection experiment. HspR 
is a transcriptional repressor of the Hsp70 operon, transcription of which is essential for the 
mycobacterial heat-shock response. Transposon mutants disrupting the expression of hspR 
alleviate Hsp70 repression, resulting in the constitutive expression of the Hsp70 operon and 
increased heat-shock resistance (Group et al., 2001).  Thus, it was predicted that Tn::hspR 
mutant BCG contained in the transposon mutant library would gain an advantage when 
exposed to high temperatures and this survival advantage would be detectable by culture of 
the selected library on 7H11 media and then assessment of the mutant pool by TnSeq. Indeed, 
a larger quantity of Tn::hspR sequences, and thus mutants, were seen in the heat-shock 
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selected transposon library compared to the control library kept at room temperature. The 
statistical test, Rank Product Analysis, was used to assess significance of the results across 
three replicate experiments, confirming the hypothesis and aiding in the validation of the 
experimental design. The by-product of this experiment was the identification of potentially 
novel genes involved in the mycobacteria heat-shock response. The only other mutants with 
enhanced survival were those with transposon insertion in Mpb83, which is a major antigen 
of M. bovis and is highly expressed in this species (Wiker, 2009). A link between Mpb83 and 
mycobacterial stress responses has not previously been made thus this observation may be a 
useful guide to focus future experiments on MPB83. However, BCG Danish exhibits reduced 
expression of Mpb83 due to a start codon mutation in sigK, its positive regulator (Charlet et 
al., 2005). Further work needs to be completed to confirm the effect of Mpb83 on 
mycobacterial cell survival in response to heat-shock and other stress conditions. This would 
include creating independent gene-knockouts and assessing cell phenotype in response to 
stress, as well as complementation to confirm recovery of WT phenotype. The assay also 
identified 93 genes whose deletion made BCG sensitive to heat stress. 
To further validate the use of the transposon library in the subsequent animal experiment, 
another well-established response/selection was investigated by TnSeq, namely 
resistance/susceptibility to INH. The gene predominantly associated with INH resistance is 
katG. INH is a prodrug and its activity is induced upon peroxidative activation by the 
catalase-peroxidase enzyme KatG (Timmins and Deretic, 2006). Thus, mutants lacking katG 
expression become resistant to INH. It was therefore hypothesised transposon insertions 
within this gene would have a selective advantage upon exposure to INH (Ying Zhang et al., 
1992). This hypothesis was confirmed when, in the presence of sub-MIC concentrations of 
INH, a significant increase in Tn::katG mutants was detected by TnSeq compared to libraries 
cultured on un-modified media. Furthermore, fadE24, a gene previously linked with INH 
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resistance/susceptibility in mycobacteria was also identified in this selection (Wilson et al., 
1999; Ramaswamy et al., 2003). This acted as further validation for the ability of the mariner 
transposon mutant pools and TnSeq to identify genes involved in survival against a selective 
pressure.  
Once again, a productive off-shoot of this “TnSeq validation” experiment was the 
identification of novel genes involved in INH susceptibility/resistance.  102 genes were 
identified with a potential role in INH susceptibility as mutants in these genes were 
determined by TnSeq to be less abundant than the average mutant following exposure to 
INH. Many of the genes identified, such as fecB, mmpS5 and mbtH were linked with iron 
metabolism, suggesting disruption of iron homeostasis plays a role in the way the cell 
responds to INH (Snow, 1970; Wagner et al., 2005; Sandhu and Akhter, 2017). Supporting 
this, iron status within the host has previously been linked with INH effectiveness (Lounis et 
al., 2003; Sritharan et al., 2006). The disruption of these genes or gene products leads to 
increased susceptibility to INH. Therefore, compounds targeting these genes or gene products 
could be used synergistically with INH in a dual drug treatment strategy to increase the 
efficacy of INH (Neyrolles et al., 2015). 
Having validated the transposon mutagenesis and TnSeq approach with BCG, 
immunologically naïve and BCG vaccinated calves were intranodally challenged with a pool 
of BCG Danish transposon mutants. Surviving mutants were recovered by plating of lymph 
node homogenate and transposon insertion frequency was assessed using TnSeq.  Transposon 
mutants with preferential survival in the vaccinated calve lymph nodes compared to the 
immunologically naïve were identified using Rank Product analysis. We predicted transposon 
mutants lacking protective BCG antigens would survive comparatively better in vaccinated 
animals compared to survival in immunologically naïve animals due to adaptive immune cell 
evasion inferred by the lack of a target protective antigen. There was no significant difference 
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between the number of recovered transposon mutants from the two challenged groups. There 
was however a significant difference in the number of unique mutants recovered when the 
two groups were compared, suggesting BCG vaccination did induce an adaptive response 
leading to the increased clearance of particular transposon mutants.  
Those genes that were linked with preferential survival in vaccinated calves and therefore 
selected for further study as putatively protective antigens were mb0025, mb0086, yrbE1B, 
PPE20 and mb2235. Alongside a significant difference in transposon insertion frequency, 
these genes were selected based on their possible function and location within the cell, with 
proteins predicted to be surface expressed being preferentially selected. The fold-change 
difference in the number of transposon insertions between the groups, as well as a literature 
search to ascertain any potential antigenic properties was completed to ensure the best 
candidates were chosen. Two of these proteins, Mb0025-an extracellular P60 protein, and 
Mb2235- an adenyl cyclase, were successfully expressed and purified using an E. coli 
expression system, pet15b. The remaining three, Mb0086- a possible oxidoreductase, 
YrbE1B- conserved integral membrane protein, and PPE20- a PPE family protein, were 
purchased as peptide pools in order to mimic the proteins and consequently T-cell epitopes 
(Cole et al., 1998).  
To provide further data to support the belief that these proteins were important antigens 
recognised in BCG vaccinated cattle, bovine PBMC stimulation followed by cytokine 
profiling was used to ascertain the immunogenicity of the recombinant proteins and peptide 
pools. A multi-cytokine response in the PBMCs harvested from the vaccinated PBMCs post-
stimulation would be indicative of the development of a robust adaptive response. Previous 
studies have highlighted the requirement of a multi-cytokine response in the antigen 
discovery process (Coppola et al., 2016). As well as stimulating the expression of cytokines 
known to be indicative of protection, secretion of a wide range of cytokines shows antigen 
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recognition by the immune response and is a promising readout when searching for novel 
immunogens. In conjugation with a multicytokine profile, release of singular cytokines such 
as IL-17a, is also relevant due to previous studies identifying it as a correlate of protection in 
cattle (Vordermeier, Villarreal-Ramos, et al., 2009; Bhuju et al., 2012). Expression of IL-1β, 
IL-12 and IP10 may not be indicative of protection, but they are key cytokines involved in 
the generation of cellular immunity (Cooper and Khader, 2008; Salam et al., 2008). Initial 
stimulation with PPDB was used as a control to assess the ability of the PBMCs to generate a 
multi-cytokine response to antigenic proteins. A significant increase in IP10, IL-17a, IL-1β 
and IL-12 post-vaccination was seen with PPDB stimulation, confirming the ability of the 
cells to generate a multi-cytokine response. The most promising candidates for further 
analysis were Mb0086, YrbE1B and PPE20.  A significant increase in IP10 was seen post-
vaccination after stimulation with these peptides. An increase in IL-17a, a cytokine linked 
with protection against M. bovis, IL-10 and IL-1β was also seen with these peptides, 
supporting the ability of these peptides to generate a multi-cytokine response in PBMCs 
isolated from vaccinated animals. Although a significant increase in these cytokines was not 
seen, a trend of increase was exhibited. This study was intended to act as guidance for the 
identification of novel protective antigens and trend of increased of cytokine release, 
although not statistically significant, is a relevant response. The cytokine readouts generated 
from Mb0025 and Mb2235 were not indicative of protection or recognition.  Following this, 
study small animal studies should be completed to assess the protective efficacy of these 
selected proteins, specifically Mb0086, YrbE1B and PPE20. Proteins with possible a possible 
association with virulence, such as YrbE1B and PPE20, may also be good targets because as 
well as being direct targets for microbicidal immune responses, the immune response may 
also block the virulent function of these genes, leading to a bacterium lacking virulence 
mechanisms (Gioffré et al., 2005; Akhter et al., 2012). These proteins have the potential to be 
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used in a subunit vaccine in a prime-boost strategy alongside BCG Danish to control bovine 
tuberculosis. Guinea pig and murine models of tuberculosis infection have long been used to 
ascertain tuberculosis vaccine efficacy, and this is mostly likely the next step in path of 
assessing the generation of protective immunity for these proteins (Clark, Hall and Williams, 
2014; McShane and Williams, 2014). Dependant on the success of small animal studies, the 
protective efficacy of these proteins in a subunit vaccine would go on to be assessed in cattle.  
Furthermore, genes such as ppm1 and ltp2 were identified to have a potential role in the 
generation of antigenic glycolipids. Studies analysing the cell-wall morphology and potential 
adaptive immune response evasion of ppm1 and ltp2 gene knockouts could elucidate the role 
of these genes in BCG antigenicity. Understanding the function of these genes, alongside the 
biochemistry and antigenicity of the synthesised cell wall lipids could lead to advancements 
in the use of non-protein antigens as a subunit vaccine to boost BCG and generate protection. 
Implementation of cell wall glycolipid antigens into a subunit vaccine could lead to the 
development of a CD8+ T cell response, and iNKT cell/ CD4+ T cell activation via CD1 
antigen presentation (Porcelli et al., 1989; Rosat et al., 1999; Sieling et al., 2000; Hiromatsu 
et al., 2002; Venkataswamy et al., 2014). A prime/boost strategy incorporating cell wall 
glycolipids and protein antigens, may result in robust cellular immunity via activation of 
CD4+ and CD8+ T cells (Sieling et al., 2000).  
In conclusion, the novel use of the cattle challenge model in conjunction with TnSeq was 
capable of selecting and identifying transposon mutants with preferential survival in 
vaccinated cattle compared to immunologically naïve animals. This led to the identification 
of three potentially protective antigens: Mb0086, YrbE1B and PPE20. Although further 
studies are required to assess whether protection is inferred upon vaccination with these 
antigens -alongside wild-type BCG, as part of a prime-boost strategy- this study does 
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highlight that novel antigen mining approaches do have the potential to discover new 
antigens which may be key in controlling bovine tuberculosis via vaccination.   
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3.1 Media, Buffers, Strains and Antibodies 
7H9 Broth 
Prepared as per manufacturer’s instruction (Difco) with the addition of 10% OADC and 0.1% 
Tween80 prior to pouring. 
 
7H11 Agar  
Prepared as per manufacturer’s instructions (Difco) with the addition of 10% OADC prior to 
pouring. 
 
Complete Cell Culture Media 
500ml   RPMI 1640+ GlutaMAX (1x) 
50ml   Foetal Calf Serum 
5ml  Penicillin/Streptomycin (10,000U/ml)  
5ml   Minimum Essential Medium Non-Essential Amino Acids 
0.5ml  β-mercaptoethanol 
 
Denaturing Binding Buffer 
 20mM  Tris+HCl 
 8M  Urea 
 500mM  NaCl 
 5mM  Imidazole 
 +1mM  β-mercaptoethanol 
 pH8 
 
Denaturing Elution Buffer 
 20mM  Tris+HCl 
 8M  Urea 
 50mM  NaCl 
 500mM  Imidazole 
 +1mM  β-mercaptoethanol 
 pH8 
 
Dialysis Buffer 
 
 20mM  Tris 
 500mM  NaCl 
 4M/2M  Urea 
 pH8 
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Mycobacteriophage Buffer 
 50mM  Tris 
 150mM  NaCl 
 10mM  MgCl2 
 2mM  CaCl2 
     
Native Binding Buffer 
 20mM  Na3PO4 
 500mM  NaCl 
20mM  Imidazole 
pH7.4 
 
Native Elution Buffer 
20mM  Na3PO4 
 500mM  NaCl 
500mM  Imidazole 
pH7.4 
 
Nutrient Broth No. 2 
Prepared as per manufacturer’s instructions (Oxoid). 
Nutrient Broth No. 2 Agar 
Prepared as per manufacturer’s instructions (Oxoid) with the addition of 1.5 % Bacteriological 
Agar 1 (Oxoid) or 0.7% Bacteriological Agar 1 for molten agar.  
 
LB (Luria-Bertani) Agar 
15g   Tryptone 
5g   Yeast extract 
5g   NaCl 
1.5 %  Bacteriological Agar 1 
1L   Dist. H2O 
 
LB (Luria-Bertani) Broth 
15g  Tryptone 
5g   Yeast extract 
5g   NaCl 
1L   Dist. H2O 
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S.O.C Medium 
2%  Tryptone 
0.5%   Yeast Extract 
10mM  NaCl 
2.5mM KCl 
10mM  MgCl2 
10mM  MgSO4 
20mM  Glucose 
Up to 10ml Dist. H2O 
 
Tris-buffered Saline with Tween20 
  
 20mM  Tris 
 150mM  NaCl 
 0.1%  Tween20 
 pH 7.5 
 
Western Transfer Buffer 
 
25mM  Tris 
190mM  Glycine 
20%  Methanol 
pH8.3 
  
Bacterial Strains: 
 
M. bovis BCG Vaccine Danish Strain 1331 
Mycobacterium smegmatis mc2 155 
Escherichia coli Library Efficient® DH5ɑ™ Competent Cells 
Escherichia coli One Shot® Bl21 (DE3) Chemically Competent 
 
Antibodies: 
 
IP10 capture antibody: anti-bovine CXCL10 polyclonal antibody (PB0385B-10 Kingfisher 
biotech) 
IP10 detection antibody: anti-bovine CXCL10 polyclonal antibody-biotinylated (PBB0393B-
050 Kingfisher biotech) 
IL-17a capture antibody: anti-bovine IL-17a polyclonal antibody (PB0274B-100 Kingfisher 
biotech) 
IL-17a detection antibody: anti-bovine Il-17a polyclonal antibody-biotinylated (PBB0277B-
050 Kingfisher biotech) 
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3.2 Pet15b vector maps 
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Appendix 3.2 pet15b vector maps highlighting restriction enzyme sites and key features of the 
pet15b plasmid 
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3.3 Peptide Sequences and Pools 
 
Index Index-protein peptide sequence protein/ID Pool 
1 1 MSTAAVLRARFPRAVANLRQ yrbE1B_Peptide_001 1 
2 2 ARFPRAVANLRQYGGAAARG yrbE1B_Peptide_002 1 
3 3 NLRQYGGAAARGLDEAGQLT yrbE1B_Peptide_003 1 
4 4 AARGLDEAGQLTWFALTSIG yrbE1B_Peptide_004 1 
5 5 GQLTWFALTSIGQIAHALRY yrbE1B_Peptide_005 1 
6 6 TSIGQIAHALRYYRKETLRL yrbE1B_Peptide_006 1 
7 7 ALRYYRKETLRLIAQIGMGT yrbE1B_Peptide_007 1 
8 8 TLRLIAQIGMGTGAMAVVGG yrbE1B_Peptide_008 1 
9 9 GMGTGAMAVVGGTVAIVGFV yrbE1B_Peptide_009 1 
10 10 VVGGTVAIVGFVTLSGSSLV yrbE1B_Peptide_010 1 
11 11 VGFVTLSGSSLVAIQGFASL yrbE1B_Peptide_011 1 
12 12 SSLVAIQGFASLGNIGVEAF yrbE1B_Peptide_012 1 
13 13 FASLGNIGVEAFTGFFAALI yrbE1B_Peptide_013 2 
14 14 VEAFTGFFAALINVRIAGPV yrbE1B_Peptide_014 2 
15 15 AALINVRIAGPVVTGVALAA yrbE1B_Peptide_015 2 
16 16 AGPVVTGVALAATVGAGATA yrbE1B_Peptide_016 2 
17 17 ALAATVGAGATAELGAMRIS yrbE1B_Peptide_017 2 
18 18 GATAELGAMRISEEIDALEV yrbE1B_Peptide_018 2 
19 19 MRISEEIDALEVMGIKSISF yrbE1B_Peptide_019 2 
20 20 ALEVMGIKSISFLASTRIMA yrbE1B_Peptide_020 2 
21 21 SISFLASTRIMAGLVVIIPL yrbE1B_Peptide_021 2 
22 22 RIMAGLVVIIPLYALAMIMS yrbE1B_Peptide_022 2 
23 23 IIPLYALAMIMSFLSPQITT yrbE1B_Peptide_023 2 
24 24 MIMSFLSPQITTTVLYGQSN yrbE1B_Peptide_024 3 
25 25 QITTTVLYGQSNGTYEHYFQ yrbE1B_Peptide_025 3 
26 26 GQSNGTYEHYFQTFLRPDDV yrbE1B_Peptide_026 3 
27 27 HYFQTFLRPDDVFWSFLEAL yrbE1B_Peptide_027 3 
28 28 PDDVFWSFLEALIITAIVMV yrbE1B_Peptide_028 3 
29 29 LEALIITAIVMVSHCYYGYA yrbE1B_Peptide_029 3 
30 30 IVMVSHCYYGYAAGGGPVGV yrbE1B_Peptide_030 3 
31 31 YGYAAGGGPVGVGEAVGRSM yrbE1B_Peptide_031 3 
32 32 PVGVGEAVGRSMRFSLVSVQ yrbE1B_Peptide_032 3 
33 33 GRSMRFSLVSVQVVVLFAAL yrbE1B_Peptide_033 3 
34 34 VSVQVVVLFAALALYGVDPN yrbE1B_Peptide_034 3 
35 35 VVLFAALALYGVDPNFNLTV yrbE1B_Peptide_035 3 
36 1 MTEPWIAFPPEVHSAMLNYG PPE20_Peptide_001 4 
37 2 PPEVHSAMLNYGAGVGPMLI PPE20_Peptide_002 4 
38 3 LNYGAGVGPMLISATQNGEL PPE20_Peptide_003 4 
39 4 PMLISATQNGELSAQYAEAA PPE20_Peptide_004 4 
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40 5 NGELSAQYAEAASEVEELLG PPE20_Peptide_005 4 
41 6 AEAASEVEELLGVVASEGWQ PPE20_Peptide_006 4 
42 7 ELLGVVASEGWQGQAAEAFV PPE20_Peptide_007 4 
43 8 EGWQGQAAEAFVAAYMPFLA PPE20_Peptide_008 4 
44 9 EAFVAAYMPFLAWLIQASAD PPE20_Peptide_009 4 
45 10 PFLAWLIQASADCVEMAAQQ PPE20_Peptide_010 4 
46 11 ASADCVEMAAQQHAVIEAYT PPE20_Peptide_011 4 
47 12 AAQQHAVIEAYTAAVELMPT PPE20_Peptide_012 4 
48 13 EAYTAAVELMPTQVELAANQ PPE20_Peptide_013 4 
49 14 LMPTQVELAANQIKLAVLVA PPE20_Peptide_014 4 
50 15 AANQIKLAVLVATNFFGINT PPE20_Peptide_015 5 
51 16 VLVATNFFGINTIPIAINEA PPE20_Peptide_016 5 
52 17 GINTIPIAINEAEYVEMWVR PPE20_Peptide_017 5 
53 18 INEAEYVEMWVRAATTMATY PPE20_Peptide_018 5 
54 19 MWVRAATTMATYSTVSRSAL PPE20_Peptide_019 5 
55 20 MATYSTVSRSALSAMPHTSP PPE20_Peptide_020 5 
56 21 RSALSAMPHTSPPPLILKSD PPE20_Peptide_021 5 
57 22 HTSPPPLILKSDELLPDTGE PPE20_Peptide_022 5 
58 23 LKSDELLPDTGEDSDEDGHN PPE20_Peptide_023 5 
59 24 DTGEDSDEDGHNHGGHSHGG PPE20_Peptide_024 5 
60 25 DGHNHGGHSHGGHARMIDNF PPE20_Peptide_025 5 
61 26 SHGGHARMIDNFFAEILRGV PPE20_Peptide_026 5 
62 27 IDNFFAEILRGVSAGRIVWD PPE20_Peptide_027 5 
63 28 LRGVSAGRIVWDPVNGTLNG PPE20_Peptide_028 5 
64 29 IVWDPVNGTLNGLDYDDYVY PPE20_Peptide_029 6 
65 30 TLNGLDYDDYVYPGHAIWWL PPE20_Peptide_030 6 
66 31 DYVYPGHAIWWLARGLEFFQ PPE20_Peptide_031 6 
67 32 IWWLARGLEFFQDGEQFGEL PPE20_Peptide_032 6 
68 33 EFFQDGEQFGELLFTNPTGA PPE20_Peptide_033 6 
69 34 FGELLFTNPTGAFQFLLYVV PPE20_Peptide_034 6 
70 35 PTGAFQFLLYVVVVDLPTHI PPE20_Peptide_035 6 
71 36 LYVVVVDLPTHIAQIATWLG PPE20_Peptide_036 6 
72 37 PTHIAQIATWLGQYPQLLSA PPE20_Peptide_037 6 
73 38 TWLGQYPQLLSAALTGVIAH PPE20_Peptide_038 6 
74 39 LLSAALTGVIAHLGAITGLA PPE20_Peptide_039 6 
75 40 VIAHLGAITGLAGLSGLSAI PPE20_Peptide_040 6 
76 41 TGLAGLSGLSAIPSAAIPAV PPE20_Peptide_041 6 
77 42 LSAIPSAAIPAVVPELTPVA PPE20_Peptide_042 6 
78 43 IPAVVPELTPVAAAPPMLAV PPE20_Peptide_043 7 
79 44 TPVAAAPPMLAVAGVGPAVA PPE20_Peptide_044 7 
80 45 MLAVAGVGPAVAAPGMLPAS PPE20_Peptide_045 7 
81 46 PAVAAPGMLPASAPAPAAAA PPE20_Peptide_046 7 
82 47 LPASAPAPAAAAGATAAGPT PPE20_Peptide_047 7 
83 48 AAAAGATAAGPTPPATGFGG PPE20_Peptide_048 7 
84 49 AGPTPPATGFGGFPPYLVGG PPE20_Peptide_049 7 
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85 50 GFGGFPPYLVGGGGPGIGFG PPE20_Peptide_050 7 
86 51 LVGGGGPGIGFGSGQSAHAK PPE20_Peptide_051 7 
87 52 IGFGSGQSAHAKAAASDSAA PPE20_Peptide_052 7 
88 53 AHAKAAASDSAAAESAAQAS PPE20_Peptide_053 7 
89 54 DSAAAESAAQASARAQARAA PPE20_Peptide_054 7 
90 55 AQASARAQARAARRGRSAAK PPE20_Peptide_055 7 
91 56 ARAARRGRSAAKARGHRDEF PPE20_Peptide_056 7 
92 57 SAAKARGHRDEFVTMDMGFD PPE20_Peptide_057 8 
93 58 RDEFVTMDMGFDAAAPAPEH PPE20_Peptide_058 8 
94 59 MGFDAAAPAPEHQPGARASD PPE20_Peptide_059 8 
95 60 APEHQPGARASDCGAGPIGF PPE20_Peptide_060 8 
96 61 RASDCGAGPIGFAGTVRKEA PPE20_Peptide_061 8 
97 62 PIGFAGTVRKEAVVKAAGLT PPE20_Peptide_062 8 
98 63 RKEAVVKAAGLTTLAGDDFG PPE20_Peptide_063 8 
99 64 AGLTTLAGDDFGGGPTMPMM PPE20_Peptide_064 8 
100 65 DDFGGGPTMPMMPGTWTHDQ PPE20_Peptide_065 8 
101 66 TMPMMPGTWTHDQGVFDEHR PPE20_Peptide_066 8 
102 1 MTAAPTAGGVVTSGVGVAGV Mb0086_Peptide_001 9 
103 2 GVVTSGVGVAGVGVGLLGMF Mb0086_Peptide_002 9 
104 3 VAGVGVGLLGMFGPVRVVHV Mb0086_Peptide_003 9 
105 4 LGMFGPVRVVHVGWLLPLSG Mb0086_Peptide_004 9 
106 5 VVHVGWLLPLSGVHIELDRL Mb0086_Peptide_005 9 
107 6 PLSGVHIELDRLGGFFMALT Mb0086_Peptide_006 9 
108 7 LDRLGGFFMALTGAVAAPVG Mb0086_Peptide_007 9 
109 8 MALTGAVAAPVGCYLIGYVR Mb0086_Peptide_008 9 
110 9 APVGCYLIGYVRREHLGRVP Mb0086_Peptide_009 9 
111 10 GYVRREHLGRVPMAVVPLFV Mb0086_Peptide_010 9 
112 11 GRVPMAVVPLFVAAMLLVPA Mb0086_Peptide_011 9 
113 12 PLFVAAMLLVPAAGSVTTFL Mb0086_Peptide_012 9 
114 13 LVPAAGSVTTFLLAWELMAI Mb0086_Peptide_013 9 
115 14 TTFLLAWELMAIASLILVLS Mb0086_Peptide_014 9 
116 15 LMAIASLILVLSEHARPQVR Mb0086_Peptide_015 10 
117 16 LVLSEHARPQVRSAGLWYAV Mb0086_Peptide_016 10 
118 17 PQVRSAGLWYAVMTQLGFIA Mb0086_Peptide_017 10 
119 18 WYAVMTQLGFIAILVGLVVL Mb0086_Peptide_018 10 
120 19 GFIAILVGLVVLAAAGGSDR Mb0086_Peptide_019 10 
121 20 LVVLAAAGGSDRFAGLGAVC Mb0086_Peptide_020 10 
122 21 GSDRFAGLGAVCDGVRVAVF Mb0086_Peptide_021 10 
123 22 GAVCDGVRVAVFMLTLVGFG Mb0086_Peptide_022 10 
124 23 VAVFMLTLVGFGSKAGLVPL Mb0086_Peptide_023 10 
125 24 VGFGSKAGLVPLHAWLPRAH Mb0086_Peptide_024 10 
126 25 LVPLHAWLPRAHPEAPSPVS Mb0086_Peptide_025 10 
127 26 PRAHPEAPSPVSALMSAAMV Mb0086_Peptide_026 10 
128 27 SPVSALMSAAMVNLGIYGIV Mb0086_Peptide_027 10 
129 28 AAMVNLGIYGIVRFDLQLLG Mb0086_Peptide_028 10 
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130 29 YGIVRFDLQLLGPGPRWWGL Mb0086_Peptide_029 11 
131 30 QLLGPGPRWWGLALLAVGGT Mb0086_Peptide_030 11 
132 31 WWGLALLAVGGTSALYGVLQ Mb0086_Peptide_031 11 
133 32 VGGTSALYGVLQASVAADLK Mb0086_Peptide_032 11 
134 33 GVLQASVAADLKRLLAYSTT Mb0086_Peptide_033 11 
135 34 ADLKRLLAYSTTENMGLITL Mb0086_Peptide_034 11 
136 35 YSTTENMGLITLALGAATLF Mb0086_Peptide_035 11 
137 36 LITLALGAATLFADTGAYGP Mb0086_Peptide_036 11 
138 37 ATLFADTGAYGPASIAAAAA Mb0086_Peptide_037 11 
139 38 AYGPASIAAAAAMLHMIAHA Mb0086_Peptide_038 11 
140 39 AAAAMLHMIAHAAFKSLAFM Mb0086_Peptide_039 11 
141 40 IAHAAFKSLAFMAAGSVLAA Mb0086_Peptide_040 11 
142 41 LAFMAAGSVLAATGLRDLDL Mb0086_Peptide_041 11 
143 42 VLAATGLRDLDLLGGLARRM Mb0086_Peptide_042 11 
144 43 DLDLLGGLARRMPATTVFFG Mb0086_Peptide_043 12 
145 44 ARRMPATTVFFGVAALGACG Mb0086_Peptide_044 12 
146 45 VFFGVAALGACGLPLGAGFV Mb0086_Peptide_045 12 
147 46 GACGLPLGAGFVSEWLLVQS Mb0086_Peptide_046 12 
148 47 AGFVSEWLLVQSLIHAAPGH Mb0086_Peptide_047 12 
149 48 LVQSLIHAAPGHDPIVALTT Mb0086_Peptide_048 12 
150 49 APGHDPIVALTTPLAVGVVA Mb0086_Peptide_049 12 
151 50 ALTTPLAVGVVALATGLSVA Mb0086_Peptide_050 12 
152 51 GVVALATGLSVAAMTKAFGI Mb0086_Peptide_051 12 
153 52 LSVAAMTKAFGIGFLARPRS Mb0086_Peptide_052 12 
154 53 AFGIGFLARPRSTQAEAARE Mb0086_Peptide_053 12 
155 54 RPRSTQAEAAREAPASMRAG Mb0086_Peptide_054 12 
156 55 AAREAPASMRAGMAIAAGAC Mb0086_Peptide_055 12 
157 56 MRAGMAIAAGACLVLAVAPL Mb0086_Peptide_056 12 
158 57 AGACLVLAVAPLLVAPMVRR Mb0086_Peptide_057 13 
159 58 VAPLLVAPMVRRAAATLPAA Mb0086_Peptide_058 13 
160 59 MVRRAAATLPAAQAVKFTGL Mb0086_Peptide_059 13 
161 60 LPAAQAVKFTGLGAVVRLPA Mb0086_Peptide_060 13 
162 61 FTGLGAVVRLPAMSGSIAPG Mb0086_Peptide_061 13 
163 62 RLPAMSGSIAPGVIAAAVLA Mb0086_Peptide_062 13 
164 63 IAPGVIAAAVLAAALAVAVL Mb0086_Peptide_063 13 
165 64 AVLAAALAVAVLARWRFRRR Mb0086_Peptide_064 13 
166 65 VAVLARWRFRRRPAPARLPL Mb0086_Peptide_065 13 
167 66 FRRRPAPARLPLWACGAADL Mb0086_Peptide_066 13 
168 67 RLPLWACGAADLTVRMQYTA Mb0086_Peptide_067 13 
169 68 AADLTVRMQYTATSFAEPLQ Mb0086_Peptide_068 13 
170 69 QYTATSFAEPLQRVFGDVLR Mb0086_Peptide_069 13 
171 70 EPLQRVFGDVLRPDTDIEVT Mb0086_Peptide_070 13 
172 71 DVLRPDTDIEVTHTAESRYM Mb0086_Peptide_071 14 
173 72 IEVTHTAESRYMAERITYRT Mb0086_Peptide_072 14 
174 73 SRYMAERITYRTAVADAIEQ Mb0086_Peptide_073 14 
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175 74 TYRTAVADAIEQRLYTPVVG Mb0086_Peptide_074 14 
176 75 AIEQRLYTPVVGAVAAMAEL Mb0086_Peptide_075 14 
177 76 PVVGAVAAMAELLRRAHTGS Mb0086_Peptide_076 14 
178 77 MAELLRRAHTGSVHRYLAYG Mb0086_Peptide_077 14 
179 78 HTGSVHRYLAYGALGVLIVL Mb0086_Peptide_078 14 
180 79 RYLAYGALGVLIVLVVARCT Mb0086_Peptide_079 14 
Appendix 3.3 Peptide sequences of pools purchased from JPT Technologies.  
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Appendix 4.1 Optimisation of PCR conditions for preparation of transposon containing DNA 
isolated from INH selected and control transposon libraries for sequencing library 
preparation. 
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4.2 Heat-shock Library Fold-Change 
 
 
 
 
 
 
 
 
 
 
 
R
v
0
0
1
6
c
R
v
0
0
4
9
R
v
0
0
8
5
R
v
0
1
0
5
c
R
v
0
1
2
6
R
v
0
1
2
9
c
R
v
0
1
8
0
c
R
v
0
2
0
3
R
v
0
2
1
1
R
v
0
2
3
8
R
v
0
2
5
3
R
v
0
3
7
5
c
R
v
0
3
8
4
c
R
v
0
4
1
0
c
R
v
0
4
9
2
A
R
v
0
5
6
3
R
v
0
6
0
9
R
v
0
6
9
3
R
v
0
6
9
9
R
v
0
7
7
4
c
R
v
0
7
7
6
c
R
v
0
8
2
5
c
R
v
0
8
9
6
R
v
0
9
4
8
c
R
v
0
9
8
1
R
v
0
9
9
5
R
v
1
0
0
6
R
v
1
0
1
0
R
v
1
0
1
6
c
R
v
1
0
2
2
R
v
1
0
6
2
R
v
1
0
9
6
R
v
1
1
2
6
c
R
v
1
1
8
4
c
R
v
1
2
3
2
c
R
v
1
2
6
2
c
R
v
1
2
6
9
c
R
v
1
3
0
1
R
v
1
3
1
2
R
v
1
4
0
1
R
v
1
6
7
5
c
R
v
1
7
3
8
R
v
1
8
2
3
R
v
1
8
2
5
R
v
1
8
3
2
R
v
1
8
3
4
R
v
1
8
3
6
c
R
v
1
8
3
7
c
R
v
1
8
4
8
R
v
1
8
5
4
c
R
v
1
9
0
9
c
R
v
1
9
3
0
c
R
v
2
0
0
1
R
v
2
0
8
6
R
v
2
0
9
5
c
R
v
2
1
1
8
c
R
v
2
1
7
0
R
v
2
1
7
1
R
v
2
1
7
7
c
R
v
2
1
9
0
c
R
v
2
2
0
2
c
R
v
2
2
1
4
c
R
v
2
2
4
1
R
v
2
2
5
7
c
R
v
2
2
7
2
R
v
2
3
6
3
R
v
2
3
9
3
R
v
2
3
9
8
c
R
v
2
4
0
6
c
R
v
2
4
3
1
c
R
v
2
6
3
5
R
v
2
6
6
3
R
v
2
7
8
4
c
R
v
2
8
5
9
c
R
v
2
8
6
9
c
R
v
2
9
1
0
c
R
v
3
0
0
6
R
v
3
0
8
4
R
v
3
1
6
0
c
R
v
3
1
7
0
R
v
3
2
7
4
c
R
v
3
3
2
0
c
R
v
3
3
5
3
c
R
v
3
3
6
4
c
R
v
3
4
0
0
R
v
3
4
2
0
c
R
v
3
4
3
8
R
v
3
5
4
6
R
v
3
5
4
8
c
R
v
3
6
8
2
R
v
3
8
4
3
c
R
v
3
8
5
6
c0
1
2
3
L
o
g
 F
o
ld
 C
h
a
n
g
e
Appendix 4.2Fold change of transposon mutants when comparing control group to heat-shock group. Genes with a log 
change of 3 had 0 inserts in the heat-shock group, suggesting essentiality in this condition. 
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4.3 Genes with Potential Role in INH Sensitivity 
 
Gene Product  Function 
Rv0080 Conserved hypothetical 
protein 
Unknown 
Rv0088 Possible polyketide 
cyclase/dehydrase 
Unknown 
Rv0106 Conserved hypothetical 
protein 
Unknown 
Rv0124 PE_PGRS2 Unknown 
Rv0164 TB18.5 Unknown 
Rv0253 nirD Involved in nitrate assimilation  
Rv0299 Hypothetical protein Unknown 
Rv0310c Conserved hypothetical 
protein 
Unknown 
Rv0312 Conserved hypothetical 
proline and threonine 
rich protein 
Unknown 
Rv0456A Possible toxin MazF1 Unknown 
Rv0478 deoC Nucleotide and deoxyribonucleotide catabolism  
Rv0492A Conserved hypothetical 
protein 
Unknown 
Rv0513 Possible conserved 
transmembrane protein 
Unknown 
Rv0566c Conserved hypothetical 
protein 
Unknown 
Rv0579 Conserved hypothetical 
protein 
Unknown 
Rv0607 Conserved hypothetical 
protein 
Unknown 
Rv0627 Possible toxin VapC5 Unknown 
Rv0629c recD Involved in homologous recombination 
Rv0677c mmpS5 Unknown 
Rv0688 Putative ferredoxin 
reductase 
Electron transfer 
Rv0819 MshD Involved in the fourth step of mycothiol 
biosynthesis 
Rv0825c Conserved hypothetical 
protein 
Unknown 
Rv0842 Probable conserved 
integral membrane 
protein 
Unknown 
Rv0844c narL Involved in transcriptional mechanism and 
regulates nitrate/nitrite. 
Rv0880 Possible transcriptional 
regulatory protein 
Thought to be involved in transcriptional 
mechanism 
221 
 
Rv0970 Probable conserved 
integral membrane 
protein 
Unknown 
Rv1021 Conserved hypothetical 
protein 
Unknown 
Rv1027c kdpE Member of the two-component regulatory system 
KDPD/KDPE involved in the regulation of the 
KDP operon 
Rv1028A kdpF Member of the two-component regulatory system 
KDPD/KDPE involved in the regulation of the 
KDP operon 
Rv1037c, 
Rv3619c, 
Rv1198 
esxI-ESAT-6 like protein Unknown 
Rv1112 Probable GTP binding 
protein 
Unknown 
Rv1116 Conserved hypothetical 
protein 
Unknown 
Rv1123c bpoB Supposedly involved in detoxification reactions. 
Rv1169c PE11 Function unknown 
Rv1196 PPE18 Function unknown 
Rv1037c, 
Rv3619c, 
Rv1198 
esxL-ESAT-6 like 
protein 
Unknown 
Rv1231c Probable membrane 
protein 
Unknown 
Rv1237 sugB Involved in active transport of sugar across the 
membrane (import) 
Rv1261c Conserved hypothetical 
protein 
Unknown 
Rv1329c dinG Probable helicase involved in DNA repair and 
perhaps also replication 
Rv1350 fabG2 Involved in the fatty acid biosynthesis pathway 
Rv1357c Conserved hypothetical 
protein 
Unknown 
Rv1422 Conserved hypothetical 
protein 
Unknown 
Rv1531 Conserved hypothetical 
protein 
Unknown 
Rv1593c Conserved hypothetical 
protein 
Unknown 
Rv1608c bcpB Peroxide detoxification 
Rv1623c cydA Involved in the respiratory chain 
Rv1624c Probable conserved 
membrane protein 
Unknown 
Rv1674c Probable transcriptional 
regulatory protein 
Involved in transcriptional mechanism 
Rv1679 fadE16 Function unknown, but involvement in lipid 
degradation 
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Rv1682 Probable coiled-coil 
structural protein 
Unknown 
Rv1805c Conserved hypothetical 
protein 
Unknown 
Rv1834 Probable hydrolase Unknown 
Rv1850 ureC Involved in the conversion of urea to NH3 
Rv1870c Conserved hypothetical 
protein 
Unknown 
Rv1938 ephB Role in xenobiotic metabolism by degrading 
potential toxic epoxides 
Rv1959c Possible toxin ParE1 Unknown 
Rv1960c Possible antitoxin ParD1 Unknown 
Rv1962A Possible antitoxin 
VapB35 
Unknown 
Rv2043c pncA Converts amides such as nicotinamide to 
corresponding acid 
Rv2179c Conserved hypothetical 
protein 
Unknown 
Rv2189c Conserved hypothetical 
protein 
Unknown 
Rv2301 cut2 Hydrolysis of cutin 
Rv2321c rocD2 Involved in arginine metabolism 
Rv2374c hrcA Involved in transcriptional regulation (repression) 
of class I heat shock proteins 
Rv2377c mbtH Thought to be involved in the biogenesis of the 
hydroxyphenyloxazoline-containing siderophore 
mycobactins 
Rv2393 Che1 Possibly involved in inserting FE2+ into 
sirohydrochlorin to produce siroheme 
Rv2401 Conserved hypothetical 
protein 
Unknown 
Rv2177c, 
Rv2424c 
Possible transposase Required for the transposition of an insertion 
element 
Rv2431c PE25 Unknown 
Rv2464c Possible DNA 
glycosylase 
Hydrolyses DNA 
Rv2517c Conserved hypothetical 
protein 
Unknown 
Rv2609c Probable conserved 
membrane protein 
Unknown 
Rv2766c Probable short-chain 
type 
dehydrogenase/reductase 
Function unknown, possibly involved in cellular 
metabolism 
Rv2793c truB Formation of pseudouridine at position 55 in the 
psi GC loop of transfer RNAS 
Rv2956 Conserved hypothetical 
protein 
Unknown 
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Rv3013 Conserved hypothetical 
protein 
Unknown 
Rv3020c esxS Unknown 
Rv3033 Unknown protein Unknown 
Rv3145 nuoA Involved in aerobic|anaerobic respiration 
Rv3169 Conserved hypothetical 
protein 
Unknown 
Rv3256c Conserved hypothetical 
protein 
Unknown 
Rv3261 fbiA Required for coenzyme F420 production 
Rv3304 Conserved hypothetical 
protein 
Unknown 
Rv3315c cdd This enzyme scavenge exogenous and endogenous 
cytidine and 2'-deoxycytidine for UMP synthesis 
Rv3565 aspB Thought to be involved in glutamate biosynthesis 
Rv3643 Conserved hypothetical 
protein 
Unknown 
Rv3677c Possible hydrolase Unknown; probably involved in cellular 
metabolism 
Rv3690 Probable conserved 
membrane protein 
Unknown 
Rv3691 Conserved hypothetical 
protein 
Unknown 
Rv3695 Possible conserved 
membrane protein 
Unknown 
Rv3764c TcrY Sensor part of a two component regulatory system 
Rv3769 Conserved hypothetical 
protein 
Unknown 
Rv3908 MutT4 Unknown 
Rv3492c Conserved hypothetical 
Mce associated protein 
Unknown 
Rv3539 PPE63 Unknown 
Rv0868c moaD2 Involved in molybdenum cofactor biosynthesis 
Rv0924c mntH Responsible for the translocation of the divalent 
metal across the membrane 
Rv0467 icl Involved in glyoxylate bypass 
Rv3251c RubA Involved in the hydrocarbon hydroxylating system 
Rv1165 typA Unknown; probably interacts with the ribosomes in 
a GTP dependent manner 
Appendix 4.3 Genes with significantly more transposon inserts present in the control 
libraries compared to INH libraries. These genes have a potential role in INH sensitivity.  
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5.1 PPDA Responses During Cattle Challenge  
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Appendix 5.1 IFN-γ release from whole blood harvested from vaccinated and naïve calves 
when stimulated with PPDA. A high response at week 0 suggests previous exposure to 
environmental mycobacteria. Black data sets are BCG vaccinated animals. 
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5.2 Lymph Node Selected Transposon Library Quality Control 
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Appendix 5.2 qPCR optimisation of PCR conditions for preparation of transposon containing 
DNA isolated from cattle lymph nodes for sequencing library preparation & Agilent 
bioanalyzer analysis of lymph node recovered libraries. 29 cycles was the selected number of 
optimal DNA amplification to reduce the production of artefacts. 777R was shown to have 
reduced maximum amplification quantities which may reflect the low number of reads 
obtained from this sample.  Bioanalyzer profiling revealed no DNA of unexpected sizes was 
present in the lymph node DNA preparation.  
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5.3 Lymph Node Selected Transposon Library Unique TA Mutants 
Sample 
Counted 
mutants 
No. % 
772L 15763 0.2133 
772R 15917 0.2154 
774L 16315 0.2208 
774R 5715 0.0773 
777L 2630 0.0356 
777R 2398 0.0324 
Control 46298 0.6263 
773L 11560 0.1564 
773R 13079 0.1769 
778L 15166 0.2052 
778R 20011 0.2707 
804L 19760 0.2673 
804R 15360 0.2078 
Appendix 5.3 Lymph node recovered libraries unique TA site mutants quantified as 
percentage of total TA dinucleotide number present in the BCG genome. Coverage in some 
animals is low, potentially due to the variable protection offered by BCG vaccination.  
 
 
 
 
 
 
 
 
 
 
 
